

PACE

Pharmaceutical Assistance Contract for the Elderly

ANNUAL REPORT TO THE PENNSYLVANIA GENERAL ASSEMBLY



JANUARY 1 - DECEMBER 31, 2003

PRESENTED BY

PENNSYLVANIA
DEPARTMENT OF
AGING

EDWARD G. RENDELL
GOVERNOR

NORA DOWD EISENHOWER
SECRETARY OF AGING

PHARMACEUTICAL ASSISTANCE CONTRACT FOR THE ELDERLY

ANNUAL REPORT TO THE PENNSYLVANIA GENERAL ASSEMBLY

JANUARY 1 - DECEMBER 31, 2003

For the Pennsylvania Department of Aging

Director

Secretary

Operations Chief

Compliance Chief

Administrative Assistant

Enrollment and Applications Chief

Administrative Assistant

Research and Evaluation Chief

Program Analyst

Program Analyst

Thomas M. Snedden

Linda Mulhollan

Rose M. Paulus

Gretchen L. Beard

Marian Kowatch

Darlene L. Shughart

Barbara Butler

Theresa V. Brown

Antonino G. Vetrano

Richard P. Gorski

Pennsylvania Department of Aging

The PACE Program

Forum Place Building

555 Walnut Street

5th Floor

Harrisburg, PA 17101-1919

717-787-7313

For FIRST HEALTH

Vice President, PACE Operations

Director, PACE Operations

Pharmacy Research Scientist

Programmer/Analyst

Business Services Manager

Reporting Specialist/Documentalist

Research Specialist

James A. Mikula

Bradley I. Kohler

Debra A. Heller, Ph.D.

Beth A. Schlaline

Donald G. Smith

Brad MacDonald

Kristine E. Pringle

FIRST HEALTH

4000 Crums Mill Road

Suite 301

Harrisburg, PA 17112

April 2004

Any questions or comments pertaining to information within this report may be addressed to the Pennsylvania Department of Aging at the address given above.

TABLE OF CONTENTS

Executive Summary.....	1-3
History	5
Administration.....	6
PACE On-Line Claims Adjudication System	6-7
Overview of Drug Utilization Review Systems	7-8
Section 1 – Program Research Highlights	9-14
Section 2 – Financial Data by Date of Service	15-32
Table 2.1A Historical Claim and Expenditure Data for PACE Enrolled..... and Participating Cardholders by Semi-Annual Period Based On Date of Service January 1991 - December 2003	17
Table 2.1B Historical Claim and Expenditure Data for PACENET Enrolled	18
and Participating Cardholders by Semi-Annual Period Based On Date of Service July 1996 - December 2003	
Figure 2.1 PACE and PACENET Claim Distribution by Amount Paid per Claim	19
January - December 2003	
Figure 2.2 Distribution of PACE Annual Benefit	20
January - December 2003	
Figure 2.3 Distribution of PACENET Annual Benefit.....	21
January - December 2003	
Table 2.2 PACE and PACENET Expenditures and Recoveries.....	22
January - December 2003	
Figure 2.4 PACE and PACENET Enrollment, Claims, and	23
Claims Expenditures by Calendar Year 1988-2003	
Figure 2.5A PACE Total Enrolled and Participating Cardholders	24
By Month January 1997 – January 2004	
Figure 2.5B PACENET Total Enrolled and Participating Cardholders	25
By Month January 1997 – January 2004	

Figure 2.6A	Average Prescriptions per Participating PACE Cardholder.....26 By Month January 1997 – January 2004
Figure 2.6B	Average Prescriptions per Participating PACENET Cardholder27 By Month January 1997 – January 2004
Figure 2.7A	PACE Average State Share per Claim28 By Month January 1997 – January 2004
Figure 2.7B	PACENET Average State Share per Copaid Claim.....29 By Month January 1997 – January 2004
Figure 2.8A	Total PACE Expenditure by Month.....30 January 1997 – January 2004
Figure 2.8B	Total PACENET Expenditure by Month.....31 January 1997 – January 2004
Figure 2.9	PACE Average Wholesale Price (AWP) and32 Average Manufacturer's Price (AMP) by Quarter January 1997 – September 2003
Section 3 – Program Data by Date of Payment	33-50
Table 3.1	PACE and PACENET Claims and Expenditures Paid by Fiscal Year 35-36 July 1984 - December 2003
Table 3.2A	PACE High Expenditure and High Volume Claims 37-39 January - December 2003
Table 3.2B	PACENET High Expenditure and High Volume Claims..... 40-42 January - December 2003
Table 3.3	Annual Change in PACE Expenditure and Utilization for 43-46 High Expenditure Therapeutic Classes 2002 - 2003
Table 3.4	PACE and PACENET Number and Percent of 47-48 Expenditures and Claims by Manufacturer January - December 2003
Table 3.5	Manufacturers' Rebate Cash Receipts by Quarter49 Billed and by Fiscal Year Received January 1991 - December 2003

Section 4 – Cardholder Utilization Data	51-62
Table 4.1	PACE and PACENET Cardholder Enrollments by Quarter..... 53-54 July 1984 – December 2003
Table 4.2A	PACE Cardholder Enrollment, Participation, Utilization,..... 55-56 and Expenditures by Demographic Characteristics January - December 2003
Table 4.2B	PACENET Cardholder Enrollment, Participation, Utilization, 57-58 and Expenditures by Demographic Characteristics January - December 2003
Figure 4.1	Percent of Enrolled PACE Cardholders by Income.....59 and Marital Status January - December 2003
Table 4.3	Other Prescription Insurance Coverage of PACE and60 PACENET Enrolled Cardholders January - December 2003
Figure 4.2	PACE Generic Utilization Rates by Quarter61 December 1988 - December 2003
Section 5 – County Data.....	63-70
Table 5.1	Number and Percent of PACE and PACENET Cardholders..... 65-67 and Number of Providers by County January - December 2003
Figure 5.1	PACE and PACENET Cardholder, Claim, and Provider68 Information by County Type January - December 2003
Figure 5.2	Percent of Elderly Enrolled in PACE and PACENET by County69 January - December 2003
Section 6 - Provider Data	71-82
Table 6.1	PACE Claims and Expenditures by Provider Type.....73 January - December 2003
Table 6.2	PACE Claims Volume by Product and Provider Type.....74 January - December 2003
Table 6.3	PACE Expenditures by Product and Provider Type75 January - December 2003

Table 6.4	Average State Share per PACE Claim by Product.....76 and Provider Type January - December 2003	
Table 6.5	PACENET Claims and Expenditures by Provider Type77 January - December 2003	
Table 6.6	PACENET Claims Volume by Phase of Coverage,.....78 Product Type, and Provider Type January - December 2003	
Table 6.7	PACENET Expenditures by Phase of Coverage, 79-80 Product Type, and Provider Type January - December 2003	
Table 6.8	Average Cardholder and State Share Cost per PACENET81 Claim by Phase of Coverage, Product Type, and Provider Type January - December 2003	
Section 7 - Therapeutic Class Data and Drug Utilization Review Data		83-94
Table 7.1A	Number and Percent of PACE Claims, State Share Expenditures,..... 85-86 and Cardholders with Claims by Therapeutic Class January – December 2003	
Table 7.1B	Number and Percent of PACENET Claims, State Share..... 87-88 Expenditures, and Cardholders with Claims by Therapeutic Class January – December 2003	
Figure 7.1	Percent of PACE State Share Expenditures by Therapeutic Class.....89 January - December 2003	
Figure 7.2	Timeline of ProDUR Implementation90	
Figure 7.3	Number and Percent of PACE and PACENET Claims 91-92 with a Prospective Review Message by Therapeutic Class January - December 2003	
Table 7.2	Number of Cases in the Surveillance Utilization Review System93 January - December 2003	
Section 8 – The PACE PhRMA Program		95-98
Figure 8.1	PACE PhRMA Referral Program Flowchart.....98	
Appendix A - The PACE/PACENET Medical Exception Process.....		99
Appendix B - American Hospital Formulary Service (AHFS) Classifications		100
Appendix C - PACE Prospective Drug Utilization Review Criteria		101-115

EXECUTIVE SUMMARY

For the past twenty years, the PACE Program has provided life sustaining medication to over one million older Pennsylvanians in need of assistance. As a leader in State Pharmacy Assistance Programs, the Pennsylvania Department of Aging prepares this annual report for research and informational purposes.

This executive summary highlights descriptive statistics that delineate key Program elements. The Program encourages report readers to conduct a deeper review of the pages that follow for additional details on Program operations, expenditures, and benefits to older persons.

The annual report presents an administrative overview of the PACE/PACENET Programs within the Pennsylvania Department of Aging followed by eight sections of information about the pharmaceutical utilization of older Pennsylvanians, including:

- collaborative research efforts,
- financial information,
- program measures,
- utilization parameters,
- data stratified by county,
- provider statistics,
- therapeutic drug utilization review results, and
- a report on pharmaceutical manufacturer assistance referrals.

ENROLLMENT, UTILIZATION, and EXPENDITURES

Prescription drug benefits comprise 98.4% of the Program's total gross expenses while administrative costs are 1.6%. Mandated manufacturer rebates reduced 2003 gross expenses by 16.0% (Table 2.2, page 22). Analysis of historical trends of the three drivers of PACE/PACENET expenditures - enrollment, utilization, and cost per claim based on the semi-annual periods by date of service - reveals several findings:

PACE (Table 2.1A, page 17): The combination of the following three factors resulted in an overall 7.8% increase in total PACE expenditures for 2003.

- *Slowing Decline in the Rate of Enrollment:* PACE enrollment continued to decline but only slightly (-1.2% from 209,737 in 2002 to 207,144 in 2003). The rate of decline has lessened considerably since 1999 (-7.2% from 1998 to 1999) due to the impact of the moratorium that excludes Social Security cost-of-living increases as part of cardholder income and smaller increases in Social Security income.
- *Moderating Upward Utilization Trend:* Claims per PACE cardholder rose by 3.0% from the last half of 2002 to the last half of 2003 (from 22.0 to 22.6 claims per six months). This rise in utilization has moderated considerably from the double-digit trend seen in 1999 (10.8%).
- *Continuing Increase in Cost Per Claim:* Average costs per PACE claim increased by 7.0% (from \$44.20 to \$47.30 per claim for the six-month period, July – December), significantly contributing to rising overall program costs. The benefit per enrolled PACE cardholder for the last six months of 2003 exceeded \$1,000 for the first time, reaching \$1,069. Though a significant change of 10.2% from the same period one year ago, it is the lowest increase since 1997.

PACENET (Table 2.1B, page 18): A different combination of similar factors resulted in an overall 29.9% increase in PACENET expenditures for 2003.

- *Growing Enrollment:* PACENET enrollment continues to grow steadily, with an increase of 11.1% from 2002 (36,146 total enrolled) to 2003 (40,148 total enrolled).
- *Moderating Upward Utilization Trend:* Total claims (deductible and copaid) per PACENET cardholder rose by 5.8% from the last half of 2002 to the last half of 2003 (from 17.0 to 18.0 claims per six months).
- *Continuing Increase in Cost Per Claim:* The average cost per PACENET claim climbed steadily, with an 8.8% increase over the previous year (from \$32.71 to \$35.60 per claim for the six-month period, July – December). The total benefit per enrolled PACENET cardholder increased by 15.1% from \$555 in the last six months of 2002 to \$639 in the last six months of 2003, putting the PACENET benefit at 60% of the PACE benefit value.

MAGNITUDE OF NEED (Figure 2.2, page 20)

The magnitude of enrollee need for assistance is profound. A close examination of the distribution of the PACE annual benefit reveals that nearly 31% of PACE enrollees (68,500) received prescription coverage valued between \$2,000 and \$5,000. An additional 16,300 older persons, 7.4% of enrollees, utilized \$5,000 or more in benefits.

DEPTH AND BREADTH OF THE BENEFIT (Table 5.1 page 68 and Figure 5.2, page 69)

The Program reaches across all Commonwealth counties. Cardholders and pharmacy providers in large and small counties are well represented. Statewide, 2,808 pharmacies received the benefit of increased business, reliable payments, stable customer base, and rapid Program response. The proportion of elderly enrolled in PACE and PACENET ranges from 7.2% in Chester County to 25.8% in Schuylkill County.

MEDICATIONS USED (Tables 7.1A and 7.1B, pages 85-88)

The medications used reflect the chronic disease burden experienced by many elderly. On average, participants used between four and five different medications each month. Over 80% of PACE enrollees utilized one or more cardiovascular drugs, accounting for approximately one-third of all claims and expenditures. Other high volume classes include anti-infective agents, medications for pain, and gastrointestinal agents.

ENSURING SAFE MEDICATION USE (Figures 7.2 and 7.3, pages 90-92)

Since 1992, PACE has maintained an exemplary prospective drug utilization review (ProDUR) program. ProDUR assists the Program, physicians, and pharmacists in attaining the common goal of ensuring safe and effective use of medications by this special population – older Pennsylvanians. Prior to dispensing medications, the review checks for safety issues related to dosage, duplicative therapy, drug interactions, and other potential problems. Approximately 1% of all claims received a prospective review message. The Program's medical exception process relies upon communication with physicians regarding individual patient needs.

STATEWIDE SURVEY (Program Research Highlights, page 11)

In 2003, the Program repeated the statewide survey of older Pennsylvanians. A report to be released in 2004 will document the extent of prescription coverage offered through private and public plans and reveals how changing trends in coverage, out-of-pocket costs, total drug costs, and health status impact older adults. Survey statistics show that one out of four respondents reported having no prescription drug coverage assistance and that 19% of respondents failed to

fill a prescription at least once in the prior year because of the cost. The survey also collected information on older persons' information seeking behaviors with regard to health insurance.

CONSUMER PHARMACEUTICAL ASSISTANCE (*PhRMA Referral Program, page 97*)

During 2003, the Program enhanced its referral system for persons 55 years of age or older who are in need of pharmaceutical assistance but ineligible for PACE/PACENET benefits. This effort, which responded to 3,444 inquiries over three years, facilitated contact between Area Agency on Aging offices and the patient assistance programs offered by pharmaceutical manufacturers. Despite complex applications, lengthy waits for approval, and limited amounts of medication granted with each approval, the collaboration led to successful referrals. At the beginning of 2004, 14% (482) of inquirers were receiving medication assistance through the program. Another 279 persons were over the income limits set by drug manufacturers. Nearly 2,000 more patients were referred to other forms of coverage, including PACE and PACENET.

FREQUENTLY REQUESTED PROGRAM STATISTICS

The table below provides frequently requested Program information and lists references within the report for additional details.

2003 PACE AND PACENET SUMMARY			
	PACE	PACENET	REFER TO:
DEMOGRAPHIC DATA			
Total enrolled for 2003	220,794	46,880	Tables 4.3, A and B
% Participating	88.9%	80.8%	Tables 4.3, A and B
Avg. age for enrolled	79.3 yrs.	78.3 yrs.	Tables 4.3, A and B
Female, avg. age	79.8 yrs.	78.6 yrs.	
Male, avg. age	77.2 yrs.	77.4 yrs.	
% Female	80.7%	74.6%	Tables 4.3, A and B
% Own residence	49.7%	59.2%	Tables 4.3, A and B
% Rent	27.8%	22.9%	Tables 4.3, A and B
% Married	13.1%	28.1%	Tables 4.3, A and B
Avg. Income	\$11,257	\$16,174	Tables 4.3, A and B
% Cardholders in urban counties	42.1%	38.0%	Table 5.1
% Cardholders in rural counties	12.4%	13.2%	Table 5.1
BENEFIT DATA			
Avg. state share per enrolled cardholder	\$1,946	\$1,009	Tables 4.3, A and B
Avg. state share per participant	\$2,189	\$1,249	Tables 4.3, A and B
Avg. state share per copaid claim	\$46.52	\$44.05	Figure 2.1
2003 % increase in state share per claim	7.0%	6.5%	Figure 2.1, 2003 and 2004
Avg. cardholder share per claim	\$6.00	\$20.82	Table 6.5
Avg. claims per participant	47.1	36.1	Tables 4.3, A and B
UTILIZATION DATA (by date of payment)			
Total claims	9,200,996	1,349,534	Tables 6.1 and 6.6
Avg. claims per cardholder	41.7	28.8	Tables 5.1, 6.1 and 6.6
Avg. deductible claims per cardholder	-	6.7	Table 6.6
Avg. copaid claims per cardholder	-	22.1	Table 6.6
Generic utilization rate	47.1%	48.1%	Tables 6.2 and 6.6
PAYMENT DATA			
Total Program payout	\$429.94 M	\$47.30 M	Table 3.1
Avg. weekly program payout	\$8.27 M	\$0.91 M	Table 3.1
Avg. annual program payout per pharmacy	\$153,113	\$16,845	Tables 3.1 and 5.1
% Program payout to chain pharmacies	53.8%	52.6%	Tables 6.1 and 6.5

PENNSYLVANIA PHARMACEUTICAL ASSISTANCE CONTRACT FOR THE ELDERLY

History

The Pharmaceutical Assistance Contract for the Elderly (PACE) Program began on July 1, 1984. Its purpose as stated in Act 1996-134 (P.L. 342, No. 36) (72 P.S. Section 3761-501-3761-522) is to establish a program of limited pharmaceutical assistance for qualified state residents. The legislation of 1996 expanded the PACE Program eligibility requirements and also created a new Program, PACENET (Pharmaceutical Assistance Contract for the Elderly Needs Enhancement Tier). In July 2001, Act 2001-77, the Pennsylvania Master Tobacco Settlement, increased PACENET income eligibility by \$1,000. Recognizing that the nominal increases in Social Security income were making enrollees ineligible for PACE, the legislature also created a limited PACE moratorium, effective January 1, 2001 until December 31, 2002, which permitted enrollees to remain in benefit even though their incomes exceeded the eligibility limits. Late in 2002, Act 2002-149 extended the moratorium for the PACE enrollment and expanded it to the PACENET enrollment as well. This moratorium expired on December 31, 2003 with the passage of the PACE/PACENET Expansion Bill, Act 37 of 2003.

PACE/PACENET beneficiaries consist of qualified Pennsylvania residents 65 years of age and older who meet certain income eligibility requirements. Applicants may not receive prescription benefits from the Pennsylvania Medical Assistance Program. To be eligible for PACE, the combined income for married applicants must not exceed \$17,700 and the annual income for single applicants must not exceed \$14,500 during the calendar year prior to application. The PACENET Program began on November 21, 1996, and enables additional older Pennsylvanians to enjoy pharmaceutical benefits through the proceeds from the Pennsylvania Lottery. PACENET participants must meet the same age and residency requirements as PACE enrollees. PACENET income ranges are between \$17,700 and \$31,500 for married couples and \$14,500 to \$23,500 for single persons. A PACENET enrollee is responsible for a \$40 cumulative monthly deductible before the Program begins reimbursing for prescriptions.

When approved for participation in PACE or PACENET, the applicant is sent an identification card. To receive Program benefits, the cardholder presents the card to the pharmacist or another dispensing provider when filling a prescription. As of July 1, 1991, the PACE cardholder provided a \$6.00 copayment for each generic prescription. Beginning in 2004, the copayment changed to \$6.00 for each generic prescription and \$9.00 for each brand prescription. The PACENET cardholder pays an \$8.00 copayment for generic medications and a \$15.00 copayment for brand name medications. The PACENET copayment remains the same in 2004. However, Act 37 requires both programs to adjust the copayments in future years to reflect increasing drug prices over time. Before filling a prescription for a cardholder, the provider submits a claim to the Program. Act 37 added the cost containment provision of reimbursing under the Federal Upper Limits for generics and increased the provider's dispensing fee by \$0.50. The 2003 data in this report do not fall under these new provisions. Effective January 1, 2004, the Commonwealth reimburses the providers for the average wholesale price of the medication minus 10%, plus a \$4.00 dispensing fee, or the Federal Upper Limits for a multisource product, or their usual and customary charge, whichever is less, minus the copayment. A reimbursement limit of thirty days' supply or 100 units (tablets or capsules), whichever is less, applies to any given claim. The Program guarantees reimbursement to the provider within 21 days, paying interest on any unpaid balance after 21 days.

Six types of providers dispense PACE/PACENET-funded prescriptions to cardholders. The majority of PACE/PACENET providers are either independent pharmacies or chain pharmacies. Other provider types include institutional pharmacies, nursing home pharmacies, mail order pharmacies, and dispensing physicians. All providers may offer mail prescription services if they are enrolled as a mail order pharmacy and if they follow specialized Program requirements pertaining to record keeping and cardholder verification procedures.

PACE covers all medications that require a prescription in the Commonwealth, as well as insulin, insulin syringes and insulin needles, unless a manufacturer does not participate in the Manufacturers' Rebate Program. PACE does not cover experimental medications, medications for hairloss or wrinkles, or any medication that can be purchased without a prescription. With appropriate documentation, PACE covers Drug Efficacy Study Implementation (DESI) medications. PACE requires generic substitution of brand multi-source products when an approved, Food and Drug Administration (FDA) A-rated generic is available. At the time of dispensing, a cardholder may encounter a prospective drug utilization review edit; PACE will not reimburse the prescription unless the pharmacist or physician documents the medical necessity for it. The Department of Aging recognizes the possibility of exceptional circumstances in connection with the application of therapeutic criteria and reimbursement edits. Appendix A contains a description of the PACE/PACENET medical exception process.

Administration

The Pennsylvania Department of Aging administers the PACE/PACENET Program. A contractor directly responsible to the Department assists in conducting many of the day-to-day operations.

Four primary operation responsibilities of the Program are to process applications, reimburse providers for prescriptions, protect enrollees from adverse drug events, and obtain the most cost-efficient reimbursement possible for the Program. Administrative responsibilities include monitoring and evaluating operations and ensuring that the mandates of the Act and Program regulations are met. Activities in these areas include conducting audits of not only the providers, but also of the cardholders and the contracting agency. Staff routinely review medication utilization profiles of the cardholders and dispensing practices of the providers and physicians. The Department also evaluates the procedures used to implement the Program, identifies any trends which may be relevant for future administration, and carefully scrutinizes all expenditures.

The Program serves as the fiscal agent for the General Assistance Program, the Special Pharmaceutical Assistance Program (both in the Department of Public Welfare), and the Chronic Renal Disease Program (Department of Health) for the collection of rebates from pharmaceutical manufacturers.

PACE On-Line Claims Adjudication System

In 1991, PACE implemented the PACE On-Line Claims Adjudication System (POCAS) to better serve the needs of providers and cardholders, as well as offering the Program a wider array of policy options in the future. POCAS furnishes several benefits to providers including: improved reimbursement timing; immediate on-line claims adjudication, fifteen hours per day, seven days a

week; cardholder eligibility verification; claim edit messages; and seven days a week access to the POCAS hotline for prompt problem solving.

In January 1996, the POCAS system began accepting claims for the Chronic Renal Disease Program funded through the Department of Health. Since February 1997, providers for the Special Pharmaceutical Benefits Program within the Department of Public Welfare have utilized the on-line system. Beginning in October 1998, prescription claims for the Cystic Fibrosis Program, the Spina Bifida Program, and Metabolic Conditions Program (all within the Department of Health) have been processed through POCAS. All of the services provided through the POCAS System will be extended to these Programs, their providers and their cardholders.

Overview of Drug Utilization Review Systems

Prospective Drug Utilization Review System (ProDUR)

To enhance the effectiveness of the retrospective drug utilization review process, the Department of Aging instituted Prospective Drug Utilization Review (ProDUR) in the PACE Program in 1992. This innovation serves both the physician and the pharmacist by reducing the incidence of miscalculation among cardholders. Through the on-line claims processing system, PACE provides prospective review of prescriptions before the pharmacist dispenses the medication to the cardholder. The review checks for potentially dangerous drug interactions, duplicative therapies, over-utilization, and underutilization.

The Program recognizes the possibility of medical exceptions in connection with the application of therapeutic criteria. A medical exception may be granted when the cardholder's physician requests an exception on the basis of the diagnosis, anticipated therapeutic outcomes, and the expected length of exception therapy (see Appendix A). The Department of Aging continues to support the policy that the reimbursement of medications must be medically justifiable and within the guidelines of recommended prescribing practices. ProDUR assists the Program, physicians, and pharmacists in attaining the common goal of ensuring safe and effective use of medications by older people.

The steps in the development and selection of ProDUR criteria reflect the Program's desire to provide accurate and beneficial information. PACE staff and consultants initiate the process with an analysis of the Program's experience within the retrospective environment. This yields an ample source of data for evaluating specific criteria elements. The utilization data assist in measuring the potential impact of moving an element from retrospective to prospective review. The original criteria and therapeutic standards developed by the University of Maryland and the Philadelphia College of Pharmacy and Science served as the foundation for therapeutic retrospective review and influenced the structure of ProDUR.

Criteria development continues with an extensive review and comment period. This period begins when a Technical Advisory Committee, convened by the Secretary of Aging, evaluates the criteria elements in conjunction with the retrospective utilization analyses, the prevailing community practice, and the medical literature. The Committee consists of noted health care professionals with experience in geriatrics, pharmacology, and pharmacokinetics. The Committee prepares recommendations for consideration by the Secretary.

The Secretary then invites professional medical societies to comment on the proposed criteria. The Committee discusses all responses received on the criteria elements. The process depends upon open communication, which permits professional societies, drug manufacturers,

advocates for older persons, health care professionals, and the media to freely and critically examine the ProDUR effort.

Early in 1992, PACE implemented the ProDUR review of triazolam (Halcion) based upon the reformulated indications and dosing guidelines disseminated in November 1991 by the manufacturer. Over the years, PACE extended ProDUR to other therapeutic classes. Criteria now encompass many therapeutic classes as indicated in Appendix C. Updated ProDUR criteria are available upon request from the PACE Program.

Surveillance Utilization Review System (SURS)

The Program's primary objectives for SURS are to identify and investigate potential misutilization and deficiencies in the level and quality of care. Through its computerized review system, PACE monitors medication utilization for potential fraud and abuse by cardholders, providers and prescribers. Requests for case reviews can also originate from the public, providers, or state agencies.

The computerized Surveillance Utilization Review System (SURS) detects and reports potential fraud, abuse, and underutilization within PACE by examining claims history. SURS generates profiles that detail utilization patterns that exceed PACE-specific utilization criteria. SURS computes averages, standard deviations, frequency distributions, trends and comparisons by time periods. After the initial SURS review, if it still appears as if a violation of Program policy or regulation exists, or if the physician has failed to respond to the SURS inquiries, the reviewer will refer the case to the PACE Compliance Unit for further investigation and/or restriction.

Some of the products that receive regular review within the SURS system include inhalers, barbiturates, opiates, skeletal muscle relaxants, sedatives, hypnotics and benzodiazepines.

SECTION 1

**PROGRAM
RESEARCH
HIGHLIGHTS**

HIGHLIGHTS OF CURRENT PACE/PACENET COLLABORATIVE RESEARCH AND EVALUATION PROJECTS (APRIL 2004)

The PACE/PACENET Program engages in a variety of outcomes research endeavors, usually in collaboration with university research centers and medical schools, that address many topics in the field of pharmacy. The history of research collaboration extends back into the mid-1980s. These highlights represent efforts of a current nature between the Program and institutions that resulted in noteworthy products or achieved a significant milestone. Several of these are multi-year projects and they will continue into the future. Updates on past and present research are available by contacting the Program.

UNDERSTANDING THE NATURE OF PRESCRIPTION DRUG COVERAGE FOR OLDER PENNSYLVANIANS (Pennsylvania State University, Center for Survey Research, Institute of State and Regional Affairs)

The PACE/PACENET Program provides limited prescription coverage for qualified older Pennsylvanians of low to moderate income. The ability to assess the prescription coverage of older Pennsylvanians is critical to program planning and forecasting. In order to examine more closely the needs of Pennsylvania's sixty-five and older population with regard to health insurance coverage in general, and more specifically, prescription drug coverage, the Program contracted with Penn State Harrisburg's Center for Survey Research to conduct a statewide survey of older Pennsylvanians. That first study, conducted in 2001, provided the Program with critical baseline measures of the extent and nature of both health and prescription drug coverage for this particular population. In 2003, the Program supported a follow-up study to explore the current needs of Pennsylvania's seniors along the same dimensions as those in found in the 2001 survey. The Center utilized the same methodology, namely, a statewide, telephone survey of Pennsylvanians, age 65 and older, using random-digit dialing and a Computer-Assisted Telephone Interviewing System. A total of 1,481 interviews were completed during the summer of 2003 with a response rate of 29%. The questionnaire consisted of approximately 50 questions, and the average length of time for an interview was about 20 minutes. *The survey results show that 25% of the respondents reported having no assistance with prescription drug costs. Prescription drug coverage varies by region of the state with persons in Allegheny County and the Southwest region having the highest percentages of coverage. About 19% of the respondents reported that they failed to fill a prescription at least once in the last year due to costs. Analysis of the data also provided useful information about the self-reported health status of older Pennsylvanians and who they call when seeking information about health insurance issues. New questions in the 2003 survey revealed that 35% of seniors have access to the Internet. When asked about purchasing drugs from a Canadian pharmacy, 3% of the respondents said they did so and nearly all said they did to save money. The survey asked seniors if they had lost employer sponsored health insurance coverage in the last year; 5% said they had lost that coverage.* The final report, to be released in May 2004, includes many other results by prescription drug coverage and by health insurance coverage.

SELF-REPORTED MEDICATIONS IN LOW-INCOME OLDER ADULTS (Pennsylvania State University)

In 1998 and 1999, The Pennsylvania State University recruited participants for a large scale, clinical trial on cognitive training from the enrollment files of the PACE Program. In addition to the cognitive training trial, PACE Program recruits participated in a medication brown bag review. Researchers at the Pennsylvania State University examined the congruence of self-reported medication with the PACE Program's pharmacy prescription records. Results of the prescription

drug review were published in April 2004. The researchers obtained pharmacy records and self-reported medications from 294 participants. *Congruence between self-report and pharmacy records was generally high. Perfect agreement between self-reports and pharmacy records varied from 49% for major drug classes to 81% for specific cardiovascular and central nervous system drugs. Poorer health was consistently related to poorer self-report of medications. Self-report was most likely to be congruent with the computerized pharmacy data for medications prescribed for more serious conditions, for more specific therapeutic classes and for healthier individuals.*

PACE ENROLLMENT APPLICATION HEALTH AND WELL-BEING SURVEY (Pennsylvania State University, Department of Biobehavioral Health, First Health Services Corporation)

Understanding the health status and behaviors of cardholders in the Pharmaceutical Assistance Contract for the Elderly (PACE) Program is an integral component of the Department of Aging's program of research and evaluation. The application packet for the PACE/PACENET Program includes a two-page survey entitled "Survey on Health and Well-Being". The survey addresses issues such as self-rated health, self-reported medical conditions, specific women's health questions, alcohol and tobacco use, falls and pain. The survey provides an overall picture of the health conditions and problems experienced by the population. The combination of existing administrative data comprised of prescription drug claims, hospitalization records and vital statistics, with the information collected from enrollees leads to a more complete understanding of the PACE/PACENET population. A new report, entitled PACE/PACENET Survey on Health and Well-Being 2000-2001, will provide an overview of the Program's history of survey research that has assessed important areas of cardholders' lives: self-reported health status, quality of life, attitudes and health-related behavior. The report, to be released in the spring of 2004 focuses on the 2000 and 2001 surveys. The surveys had an overall response rate of over 70%. *Just under half of respondents (43.9%) reported physical health as fair or poor, and only 2.1% reported it as excellent. About 75% of the survey respondents said that their ability to think clearly and remember things was excellent, very good or good. The most commonly reported medical condition was arthritis (61.4%), followed by high blood pressure (60.4%) and high cholesterol (36.7%). Results obtained by linking survey responses with prescription claim records indicated that many cardholders might not understand the therapeutic use for the drugs they are prescribed. For cardholders enrolled in the PACE Program, 93.3% said that the Program had improved their quality of life either extremely or quite a bit. For PACENET members, 57.1% said the same. The results for the question about not filling or delaying a prescription due to out-of-pocket costs were quite different when analyzed by coverage status in the previous 90 days. About 20% of cardholders without prescription program enrollment in the previous 90 days admitted that they skipped or delayed a prescription due to cost, while about 10% of the PACENET enrolled and just 3% of the PACE enrolled indicated the same.* The initial findings in this report present a challenging set of concerns for the Program to consider as it moves forward with its research and evaluation agenda and its goal of providing safe and effective pharmaceutical assistance to older Pennsylvanians.

IMPROVING PATIENT SAFETY BY REDUCING MEDICATION ERRORS (University of Pennsylvania, School of Medicine)

The primary aim of this project is to identify predisposing factors for hospitalizations due to errors in medication use among a large, representative cohort of community-dwelling elderly patients initiated or maintained on warfarin, phenytoin, and digoxin—drugs with a narrow therapeutic index. Medication errors that result in dose-related adverse events can occur anywhere along the medication use process. The specific causes of and solutions for medication errors are likely to

differ across drugs with different properties. Error prevention strategies might include programs that improve therapeutic drug dosing and monitoring (phenytoin), improve patient drug adherence (warfarin), or reduce physician gaps in knowledge about the risks and benefits of drugs (digoxin). The design of these interventions requires information on the underlying causes of errors for both new and chronic users of these specific agents. *The primary hypothesis is that uncoordinated medical and pharmaceutical care, inadequate delivery of new medication instructions, visual and cognitive impairment and psychosocial barriers are predisposing factors for medication errors resulting in hospitalization. The secondary aims of this study are (1) to develop a prediction rule to identify elderly outpatients at high risk for hospitalization due to errors in drug use, and (2) to estimate the costs associated with hospitalization due to these errors.* This prospective cohort study, funded in mid-2001, began to enroll PACE/PACENET cardholders from across the state in the spring of 2002. At the time of enrollment, study participants will complete a detailed baseline interview to identify key psychosocial, behavioral, and clinical predictors. Enrollment ended in May 2003. Outcomes will be identified over a two-year follow-up period by regular phone contact with cohort members using a screening instrument to identify hospitalizations. Researchers will review medical records and clinical findings along with admission drug or anticoagulation levels to identify hospitalizations that are likely due to medication errors. Analyses will focus on the identification of risk factors and development of a prediction rule to identify subjects at high risk of hospitalization due to medication errors.

OSTEOPOROSIS AND MEDICATION USE (Division of Pharmacoepidemiology and Pharmacoconomics of the Brigham and Women's Hospital and Harvard Medical School)

Little is known about patterns of osteoporosis medication use and what factors might affect prescribing patterns. This collaboration examined patterns of osteoporosis treatment in Pennsylvania's elderly population, and developed interventions when deficits in care were discovered in the first phase of the research. During the first phase, the researchers defined the patterns of use of medications that have been shown to prevent and/or treat osteoporosis in groups of PACE enrollees who are at increased risk of osteoporosis, specifically patients who had undergone a procedure and/or received a diagnosis of hip or wrist fracture during 1995-1999. *The study concluded that while there has been an increase in the use of medicine for the treatment of osteoporosis overtime, there was still under-treatment that needed to be addressed. The next phase of the research, begun in 2002, entailed the development and pilot testing of osteoporosis fracture prevention behavior-change programs, The Healthy Bones Project, targeting both patients and physicians.* Researchers identified 23,500 high-risk patients from 28 high-population density counties seen by 823 physicians. Physicians and their patients were randomized into four treatment assignment groups: Group A, physician and patient control; Group B, physician intervention and patient control; Group C, physician control and patient intervention; and Group D, physician and patient intervention. Patients in Groups C and D who did not opt-out received two mailings that had been developed and tested during year 1. Physicians in Groups B and D who agreed to see an educator received 15-30 minute one-on-one educational sessions with trained nurses and pharmacists in the fall of 2003. The materials included diagnostic and treatment algorithms for osteoporosis, fracture prevention material, patient vignettes, and a Harvard Medical School CME post-test. The primary endpoint for this study is a comparison of the effects of the patient and physician intervention efforts on the prescribing patterns for osteoporosis therapy. Data for this outcome will be collected through PACE claims data. The study will assess the differences in patient knowledge, attitudes and behavior through a survey in the spring of 2004. Researchers will also examine Medicare claims data to detect any differences in fracture rates.

SECTION 2

**FINANCIAL
DATA
BY DATE OF
SERVICE**

TABLE 2.1A
HISTORICAL CLAIM AND EXPENDITURE DATA FOR PACE ENROLLED AND PARTICIPATING CARDHOLDERS
BY SEMI-ANNUAL PERIOD BASED ON DATE OF SERVICE
JANUARY 1991 - DECEMBER 2003

<u>SEMI-ANNUAL PERIOD</u>	<u>ENROLLED CARDHOLDERS</u>	<u>PARTICIPATING CARDHOLDERS</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER ENROLLED CARDHOLDER</u>	<u>CLAIMS PER PARTICIPATING CARDHOLDER</u>	<u>TOTAL EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>	<u>EXPENDITURES PER PARTICIPATING CARDHOLDER</u>	<u>AVERAGE STATE SHARE PER CLAIM</u>
JAN-JUN 1991	405,358	337,684	5,280,376	13.03	15.64	\$116,074,618	\$286.35	\$343.74	\$21.98
JUL-DEC 1991	394,055	324,574	4,677,159	11.87	14.41	\$109,871,650	\$278.82	\$338.51	\$23.49
JAN-JUN 1992	399,721	326,469	4,656,986	11.65	14.26	\$116,082,506	\$290.41	\$355.57	\$24.93
JUL-DEC 1992	385,103	313,430	4,602,261	11.95	14.68	\$117,081,602	\$304.03	\$373.55	\$25.44
JAN-JUN 1993	376,916	310,438	4,402,171	11.68	14.18	\$113,068,754	\$299.98	\$364.22	\$25.68
JUL-DEC 1993	357,777	296,802	4,456,223	12.46	15.01	\$116,164,381	\$324.68	\$391.39	\$26.07
JAN-JUN 1994	354,819	293,462	4,320,159	12.18	14.72	\$115,413,542	\$325.27	\$393.28	\$26.72
JUL-DEC 1994	340,607	281,465	4,404,257	12.93	15.65	\$119,100,741	\$349.67	\$423.15	\$27.04
JAN-JUN 1995	331,965	277,461	4,383,968	13.21	15.80	\$121,147,211	\$364.94	\$436.63	\$27.63
JUL-DEC 1995	317,719	263,576	4,347,335	13.68	16.49	\$122,158,872	\$384.49	\$463.47	\$28.10
JAN-JUN 1996	306,062	253,283	4,244,190	13.87	16.76	\$120,868,654	\$394.92	\$477.21	\$28.48
JUL-DEC 1996	292,755	238,963	4,204,461	14.36	17.59	\$120,429,840	\$411.37	\$503.97	\$28.64
JAN-JUN 1997	286,126	236,157	4,286,478	14.98	18.15	\$116,732,847	\$407.98	\$494.30	\$27.23
JUL-DEC 1997	276,180	226,806	4,358,892	15.78	19.22	\$123,482,056	\$447.11	\$544.44	\$28.33
JAN-JUN 1998	267,225	222,465	4,235,619	15.85	19.04	\$126,872,548	\$474.78	\$570.30	\$29.95
JUL-DEC 1998	257,009	213,694	4,331,390	16.85	20.27	\$137,146,444	\$533.63	\$641.79	\$31.66
JAN-JUN 1999	246,467	208,992	4,316,588	17.51	20.65	\$142,412,978	\$577.82	\$681.43	\$32.99
JUL-DEC 1999	238,388	200,921	4,450,893	18.67	22.15	\$153,596,648	\$644.31	\$764.46	\$34.51
JAN-JUN 2000	237,017	202,683	4,449,102	18.77	21.95	\$160,615,339	\$677.65	\$792.45	\$36.10
JUL-DEC 2000	230,752	197,777	4,530,829	19.64	22.91	\$169,886,476	\$736.23	\$858.98	\$37.50
JAN-JUN 2001	225,325	197,082	4,558,339	20.23	23.13	\$178,650,979	\$792.86	\$906.48	\$39.19
JUL-DEC 2001	218,576	190,540	4,590,216	21.00	24.09	\$187,820,534	\$859.29	\$985.73	\$40.92
JAN-JUN 2002	216,719	190,131	4,558,000	21.03	23.97	\$194,788,889	\$898.81	\$1,024.50	\$42.74
JUL-DEC 2002	209,737	183,318	4,605,906	21.96	25.13	\$203,591,448	\$970.70	\$1,110.59	\$44.20
JAN-JUN 2003	209,761	182,654	4,552,662	21.70	24.93	\$208,103,630	\$992.10	\$1,139.33	\$45.71
JUL-DEC 2003	207,144	180,460	4,683,173	22.61	25.95	\$221,512,877	\$1,069.37	\$1,227.49	\$47.30

SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY.

NOTES: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS.
 ENROLLED CARDHOLDERS ARE THOSE ENROLLED FOR ANY PORTION OF THE REPORTED PERIOD.

TABLE 2.1B
HISTORICAL CLAIM AND EXPENDITURE DATA FOR PACENET ENROLLED AND PARTICIPATING CARDHOLDERS
BY SEMI-ANNUAL PERIOD BASED ON DATE OF SERVICE
JULY 1996 - DECEMBER 2003


<u>SEMI-ANNUAL PERIOD</u>	<u>ENROLLED CARDHOLDERS</u>	<u>PARTICIPATING CARDHOLDERS</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER ENROLLED CARDHOLDER</u>	<u>CLAIMS PER PARTICIPATING CARDHOLDER</u>	<u>TOTAL EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>	<u>EXPENDITURES PER PARTICIPATING CARDHOLDER</u>	<u>AVERAGE STATE SHARE PER CLAIM</u>
JUL-DEC 1996	1,523	740	2,331	1.53	3.15	\$823	\$0.54	\$1.11	\$0.35
JAN-JUN 1997	9,063	6,369	75,721	8.35	11.89	\$592,426	\$65.37	\$93.02	\$7.82
JUL-DEC 1997	12,523	9,007	149,187	11.91	16.56	\$2,676,259	\$213.71	\$297.13	\$17.94
JAN-JUN 1998	18,053	12,683	175,085	9.70	13.80	\$2,909,397	\$161.16	\$229.39	\$16.62
JUL-DEC 1998	18,673	13,804	232,846	12.47	16.87	\$4,738,127	\$253.74	\$343.24	\$20.35
JAN-JUN 1999	22,272	16,649	263,010	11.81	15.80	\$5,519,395	\$247.82	\$331.52	\$20.99
JUL-DEC 1999	22,187	16,885	309,280	13.94	18.32	\$7,416,866	\$334.29	\$439.26	\$23.98
JAN-JUN 2000	25,739	19,762	339,481	13.19	17.18	\$8,371,658	\$325.25	\$423.62	\$24.66
JUL-DEC 2000	25,446	19,630	381,074	14.98	19.41	\$10,193,859	\$400.61	\$519.30	\$26.75
JAN-JUN 2001	29,522	22,146	412,077	13.96	18.61	\$11,255,086	\$381.24	\$508.22	\$27.31
JUL-DEC 2001	29,278	23,284	477,954	16.32	20.53	\$13,849,683	\$473.04	\$594.82	\$28.98
JAN-JUN 2002	35,508	27,594	540,878	15.23	19.60	\$16,333,097	\$459.98	\$591.91	\$30.20
JUL-DEC 2002	36,146	28,611	613,528	16.97	21.44	\$20,069,086	\$555.22	\$701.45	\$32.71
JAN-JUN 2003	39,263	31,011	644,800	16.42	20.79	\$21,627,367	\$550.83	\$697.41	\$33.54
JUL-DEC 2003	40,148	31,869	720,687	17.95	22.61	\$25,653,456	\$638.97	\$804.97	\$35.60

SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY.

NOTES: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF SERVICE. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.
 ENROLLED CARDHOLDERS ARE THOSE ENROLLED FOR ANY PORTION OF THE REPORTED PERIOD.
 PARTICIPATING CARDHOLDERS ARE CARDHOLDERS WITH ONE OR MORE APPROVED CLAIMS DURING THE REPORTED PERIOD.

FIGURE 2.1
PACE AND PACENET CLAIM DISTRIBUTION BY AMOUNT PAID PER CLAIM
JANUARY - DECEMBER 2003
(PACE N = 9,235,835; PACENET N=1,051,982)


PERCENT OF CLAIMS



SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET DEDUCTIBLE CLAIMS


FIGURE 2.2
DISTRIBUTION OF PACE ANNUAL BENEFIT
JANUARY - DECEMBER 2003
N = 220,794



SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS

FIGURE 2.3
DISTRIBUTION OF PACENET ANNUAL BENEFIT
JANUARY - DECEMBER 2003
N = 46,880



SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE PACENET ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACE CLAIMS


**TABLE 2.2
PACE AND PACENET EXPENDITURES AND RECOVERIES
JANUARY - DECEMBER 2003**

EXPENDITURES	JAN - JUN 2003	JUL - DEC 2003	CY 2003 TOTAL	% OF GROSS EXPENSES
CLAIMS:				
EXPENDITURES	\$ 229,144,352	\$ 227,098,953	\$ 456,243,305	
ADJUSTMENTS	(9,989)	13,670,749	13,660,760	
GROSS CLAIMS SUBTOTAL	\$ 229,134,364	\$ 240,769,702	\$ 469,904,066	98.44%
FHS CONTRACT:				
START-UP	\$ -	\$ -	\$ -	
OPERATIONS	2,867,702	3,662,721	6,530,423	
MISCELLANEOUS	-	-	-	
SPECIAL CLAIMS	1,645	1,620	3,265	
GROSS CONTRACT SUBTOTAL	\$ 2,869,347	\$ 3,664,340	\$ 6,533,688	1.37%
PDA ADMINISTRATION:				
PERSONNEL	\$ 372,510	\$ 384,253	\$ 756,763	
OPERATIONS	-	-	-	
FIXED ASSETS	-	-	-	
GROSS PDA ADMIN. SUBTOTAL	\$ 372,510	\$ 384,253	\$ 756,763	0.16%
MISCELLANEOUS:				
MEDICAL ADVISOR	\$ 7,434	\$ 3,350	\$ 10,784	
REFUND OF OVERPAYMENTS	-	-	-	
ATTY GENERAL FEES	-	-	-	
HEALTH MANAGEMENT SYSTEMS	-	121,772	\$ 121,772	
GROSS MISC. SUBTOTAL	\$ 7,434	\$ 125,122	\$ 132,556	0.03%
GROSS EXPENDITURES	\$ 232,383,654	\$ 244,943,417	\$ 477,327,072	
RECOVERIES:				
MANUFACTURER REBATES	\$ 28,644,773	\$ 44,136,787	\$ 72,781,560	% OF GROSS REDUCED
INCOME VERIFICATION AND REVENUE MATCH	52,167	228,834	281,001	
ATTY GENERAL COLLECTIONS	37,707	19,965	57,672	
MISCELLANEOUS	94,736	48,804	143,541	
THIRD-PARTY REIMBURSEMENTS	828,275	2,610,627	3,438,902	
COMBINED RECOVERIES	\$ 29,657,659	\$ 47,045,017	\$ 76,702,676	16.07%
NET EXPENSES				
GROSS EXPENDITURES	\$ 232,383,654	\$ 244,943,417	477,327,072	
COMBINED RECOVERIES	(29,657,659)	(47,045,017)	(76,702,676)	
	\$ 202,725,995	\$ 197,898,401	\$ 400,624,396	

NOTES: TABLE USES PDA ACCRUAL BASIS APPROACH.
ADJUSTMENTS INCLUDE CLAIMS PAID FROM PRIOR FISCAL YEARS.

**FIGURE 2.4
PACE AND PACENET ENROLLMENT, CLAIMS, AND CLAIMS EXPENDITURES
BY CALENDAR YEAR
1988-2003**

- - - ENROLLMENT
 - - - CLAIMS
 — GROSS EXPENDITURES
 - - - NET EXPENDITURES AFTER RECOVERIES




Source: PACE Biannual Reports, 1988-1995; PACE Annual Reports, 1996-2003

Notes: Enrollment figures represent the number of enrolled cardholders at the end of each reported calendar year.


Notes: Recoveries include third party payments, manufacturers' rebate, and restitutions.

FIGURE 2.5A
PACE TOTAL ENROLLED AND PARTICIPATING CARDHOLDERS BY MONTH
JANUARY 1997 - JANUARY 2004




SOURCE: END-OF-MONTH PACE ENROLLED TAKEN FROM MR-0-01A REPORT, PARTICIPATING TAKEN FROM CLAIMS HISTORY BASED ON DATE OF SERVICE.

**FIGURE 2.5B
 PACENET TOTAL ENROLLED AND PARTICIPATING CARDHOLDERS BY MONTH
 JANUARY 1997 - JANUARY 2004**



SOURCE: END-OF-MONTH PACE ENROLLED TAKEN FROM MR-0-01A REPORT, PARTICIPATING TAKEN FROM CLAIMS HISTORY BASED ON DATE OF SERVICE.


FIGURE 2.6A
AVERAGE PRESCRIPTIONS PER PARTICIPATING PACE CARDHOLDER BY MONTH
JANUARY 1997 - JANUARY 2004
(TOTAL INCREASE OVER 84 MONTHS = 32.8%)



SOURCE: PACE CLAIMS HISTORY (INCLUDES PACE PAID, ORIGINAL CLAIMS; EXCLUDES PACENET CLAIMS).

NOTE: PARTICIPATING CARDHOLDERS INCLUDE THOSE WITH ONE OR MORE CLAIMS IN A GIVEN MONTH, BASED ON DATE OF SERVICE.


FIGURE 2.6B
AVERAGE PRESCRIPTIONS PER PARTICIPATING PACENET CARDHOLDER BY MONTH
JANUARY 1997 - JANUARY 2004
(TOTAL INCREASE OVER 84 MONTHS = 20.1%)



SOURCE: PACENET CLAIMS HISTORY (INCLUDES PACENET PAID, ORIGINAL CLAIMS; EXCLUDES PACE CLAIMS).


NOTE: PARTICIPATING CARDHOLDERS INCLUDE THOSE WITH ONE OR MORE CLAIMS IN A GIVEN MONTH, BASED ON DATE OF SERVICE.

FIGURE 2.7A
PACE AVERAGE STATE SHARE PER CLAIM BY MONTH
JANUARY 1997-JANUARY 2004
(TOTAL INCREASE OVER 84 MONTHS = 65.3%)




SOURCE: PACE CLAIMS HISTORY
 NOTE: INCLUDES PAID, ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACENET CLAIMS.

FIGURE 2.7B
PACENET AVERAGE STATE SHARE PER COPAID CLAIM BY MONTH
JANUARY 1997-JANUARY 2004
(TOTAL INCREASE OVER 84 MONTHS = 34.9%)




SOURCE: PACENET CLAIMS HISTORY
 NOTE: INCLUDES ONLY PACENET COPAID, ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACENET DEDUCTIBLE AND PACE CLAIMS.

FIGURE 2.8A
TOTAL PACE EXPENDITURE BY MONTH
JANUARY 1997-JANUARY 2004
(TOTAL INCREASE OVER 84 MONTHS = 78.1%)



SOURCE: PACE CLAIMS HISTORY
 NOTE: INCLUDES PAID, ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACENET CLAIMS.


**FIGURE 2.8B
TOTAL PACENET EXPENDITURE BY MONTH
JANUARY 1997-JANUARY 2004**



SOURCE: PACENET CLAIMS HISTORY

NOTE: INCLUDES PACENET PAID, ORIGINAL CLAIMS BASED ON DATE OF SERVICE; EXCLUDES PACE CLAIMS.

FIGURE 2.9
PACE AVERAGE WHOLESALE PRICE (AWP) AND AVERAGE MANUFACTURER'S PRICE (AMP) *
BY QUARTER
JANUARY 1997 - SEPTEMBER 2003



* DATA INCLUDE CLAIMS FOR NDC'S FOR WHICH REBATE AMP DATA ARE AVAILABLE FOR ANY QUARTER IN 1997-2003.
 SOURCE: PACE CLAIMS HISTORY AND MANUFACTURERS' REBATE HISTORY.

SECTION 3

**PROGRAM DATA
BY DATE OF
PAYMENT**

TABLE 3.1
PACE AND PACENET CLAIMS AND EXPENDITURES PAID BY FISCAL YEAR
JULY 1984 - DECEMBER 2003

SEMI-ANNUAL PERIOD	NUMBER OF WEEKS	PACE			PACENET		
		NUMBER OF PROCESSED CLAIMS	EXPENDITURES	AVERAGE STATE SHARE PER PROCESSED CLAIM *	NUMBER OF PROCESSED CLAIMS	EXPENDITURES	AVERAGE STATE SHARE PER PROCESSED CLAIM **
JUL-DEC 1984	26	2,101,419	\$20,714,685	\$9.86			
JAN-JUN 1985	26	3,475,440	\$36,579,102	\$10.53			
FIRST YEAR TOTAL		5,576,859	\$57,293,787	\$10.27			
JUL-DEC 1985	26	4,372,468	\$50,616,334	\$11.58			
JAN-JUN 1986	26	4,966,536	\$61,368,193	\$12.36			
SECOND YEAR TOTAL		9,339,004	\$111,984,527	\$11.99			
JUL-DEC 1986	26	5,237,141	\$68,786,114	\$13.13			
JAN-JUN 1987	26	5,257,747	\$72,761,148	\$13.84			
THIRD YEAR TOTAL		10,494,888	\$141,547,262	\$13.49			
JUL-DEC 1987	27	5,515,827	\$80,237,477	\$14.55			
JAN-JUN 1988	25	5,440,743	\$84,469,697	\$15.53			
FOURTH YEAR TOTAL		10,956,570	\$164,707,174	\$15.03			
JUL-DEC 1988	27	6,055,327	\$99,192,197	\$16.38			
JAN-JUN 1989	26	5,937,088	\$103,781,619	\$17.48			
FIFTH YEAR TOTAL		11,992,415	\$202,973,816	\$16.93			
JUL-DEC 1989	26	5,709,497	\$106,600,899	\$18.67			
JAN-JUN 1990	26	5,544,295	\$110,848,137	\$19.99			
SIXTH YEAR TOTAL		11,253,792	\$217,449,036	\$19.32			
JUL-DEC 1990	26	5,352,797	\$112,293,188	\$20.98			
JAN-JUN 1991	26	5,453,044	\$117,814,625	\$21.61			
SEVENTH YEAR TOTAL		10,805,841	\$230,107,813	\$21.29			
JUL-DEC 1991	26	5,073,452	\$115,304,410	\$22.73			
JAN-JUN 1992	26	4,816,750	\$115,596,910	\$24.00			
EIGHTH YEAR TOTAL		9,890,202	\$230,901,320	\$23.35			
JUL-DEC 1992	26	4,724,142	\$115,980,339	\$24.55			
JAN-JUN 1993	26	4,403,096	\$108,876,491	\$24.73			
NINTH YEAR TOTAL		9,127,238	\$224,856,830	\$24.64			
JUL-DEC 1993	26	4,729,097	\$118,778,523	\$25.12			
JAN-JUN 1994	26	4,341,896	\$111,401,456	\$25.66			
TENTH YEAR TOTAL		9,070,993	\$230,179,979	\$25.38			
JUL-DEC 1994	26	4,721,702	\$122,294,905	\$25.90			
JAN-JUN 1995	27	4,228,653	\$111,136,630	\$26.28			
ELEVENTH YEAR TOTAL		8,950,355	\$233,431,535	\$26.08			
JUL-DEC 1995	26	4,895,160	\$131,701,547	\$26.90			
JAN-JUN 1996	26	4,443,096	\$121,066,818	\$27.25			
TWELFTH YEAR TOTAL		9,338,256	\$252,768,365	\$27.07			
JUL-DEC 1996	26	4,334,551	\$119,612,179	\$27.60	540	\$23	\$0.04
JAN-JUN 1997	26	4,523,225	\$116,697,725	\$25.80	74,647	\$586,350	\$7.85
THIRTEENTH YEAR TOTAL		8,857,776	\$236,309,904	\$26.68	75,187	\$586,373	\$7.80
JUL-DEC 1997	26	4,546,360	\$121,880,844	\$26.81	150,263	\$2,680,675	\$17.84
JAN-JUN 1998	26	4,497,031	\$126,776,785	\$28.19	171,797	\$2,860,833	\$16.65
FOURTEENTH YEAR TOTAL		9,043,391	\$248,657,629	\$27.50	322,060	\$5,541,508	\$17.21
JUL-DEC 1998	26	4,504,394	\$134,229,706	\$29.80	233,277	\$4,737,561	\$20.31

TABLE 3.1
PACE AND PACENET CLAIMS AND EXPENDITURES PAID BY FISCAL YEAR
JULY 1984 - DECEMBER 2003

SEMI-ANNUAL PERIOD	NUMBER OF WEEKS	PACE		AVERAGE STATE SHARE PER PROCESSED CLAIM *	NUMBER OF PROCESSED CLAIMS	PACENET		AVERAGE STATE SHARE PER PROCESSED CLAIM **
		NUMBER OF PROCESSED CLAIMS	EXPENDITURES			EXPENDITURES		
JAN-JUN 1999	26	4,220,448	\$139,246,165	\$32.99	256,109	\$5,410,383	\$21.13	
FIFTEENTH YEAR TOTAL		8,724,842	\$273,475,871	\$31.34	489,386	\$10,147,944	\$20.74	
JUL-DEC 1999	26	4,456,680	\$153,781,999	\$34.51	310,165	\$7,421,422	\$23.93	
JAN-JUN 2000	26	4,453,977	\$160,846,800	\$36.11	339,250	\$8,389,295	\$24.73	
SIXTEENTH YEAR TOTAL		8,910,657	\$314,628,799	\$35.31	649,415	\$15,810,717	\$24.35	
JUL-DEC 2000	26	4,538,814	\$170,118,213	\$37.48	382,379	\$10,200,170	\$26.68	
JAN-JUN 2001	26	4,536,651	\$177,830,053	\$39.20	420,529	\$11,319,858	\$26.92	
SEVENTEENTH YEAR TOTAL		9,075,465	\$347,948,266	\$38.34	802,908	\$21,520,028	\$26.80	
JUL-DEC 2001	26	4,635,934	\$189,489,307	\$40.87	480,559	\$13,924,106	\$28.97	
JAN-JUN 2002	26	4,554,962	\$194,745,251	\$42.75	542,321	\$16,348,022	\$30.14	
EIGHTEENTH YEAR TOTAL		9,190,896	\$384,234,558	\$41.81	1,022,880	\$30,272,128	\$29.59	
JUL-DEC 2002	26	4,615,282	\$203,947,092	\$44.19	615,169	\$20,100,929	\$32.68	
JAN-JUN 2003	26	4,554,809	\$208,208,623	\$45.71	644,320	\$21,608,906	\$33.54	
NINETEENTH YEAR TOTAL		9,170,091	\$412,155,715	\$44.95	1,259,489	\$41,709,835	\$33.12	
JUL-DEC 2003	26	4,688,095	\$221,734,037	\$47.30	722,537	\$25,698,628	\$35.57	
TWENTIETH YEAR-TO-DATE TOTAL		4,688,095	\$221,734,037	\$47.30	722,537	\$25,698,628	\$35.57	
CUMULATIVE TOTAL		184,457,626	\$4,737,346,261	\$25.68	5,343,862	\$151,287,161	\$28.31	

* The State Share is the amount paid by the PACE Program for each claim. The State Share per processed claim does not reflect rebates from manufacturers, recoupments from insurance carriers, or audit disallowances received from providers and enrollees. The number of claims includes all original, debit, credit and void claims. Some claims, therefore, do not have a payment associated with them. The State Share per original, paid claim would be higher than the values shown on this table.

Reimbursement formulas for PACE:

July 1, 1984 - June 1985: The lesser of either the Average Wholesale Price (AWP) plus a \$2.50 dispensing fee or the Usual and Customary Charge (U&C), then subtracting a \$4.00 cardholder payment.

July 1, 1984 - June 1991: The lesser of either the Average Wholesale Price (AWP) plus a \$2.75 dispensing fee or the Usual and Customary Charge (U&C), then subtracting a \$4.00 cardholder payment.

July 1, 1991 - November 21, 1996: Same as above with copayment increased to \$6.00.

November 22, 1996 - December 31, 2003: The lesser of either the AWP minus 10% plus a \$3.50 dispensing fee, or the U&C, then subtracting a \$6.00 copayment.

January 1, 2004 - Present: The lesser of either AWP minus 10% plus a \$4.00 dispensing fee, or the U&C, or the Federal Upper Limit for a generic product plus a \$4.00 dispensing fee, then subtracting a copayment of \$6.00 for generics and \$9.00 for brand products. The copayment can be adjusted annually.

** The State Share is the amount paid by the PACENET Program for each claim in the copayment phase. The State Share per processed claim does not reflect rebates from manufacturers, recoupments from insurance carriers, or audit disallowances received from providers and enrollees. The number of processed claims includes claims in the copay and deductible phases. Therefore, the State Share per copay phase claim would be higher than the values shown on this table.

Reimbursement formulas for PACENET:

November 22, 1996 - December 31, 2003: The lesser of either AWP minus 10% plus a \$3.50 dispensing fee, or the U&C, then subtracting a copayment of \$8.00 for generics and \$15 for brand products.

January 1, 2004 - Present: The lesser of either AWP minus 10% plus a \$4.00 dispensing fee, or the U&C, or the Federal Upper Limit for a generic product plus a \$4.00 dispensing fee, then subtracting a copayment of \$8.00 for generics and \$15.00 for brand products. The copayment can be adjusted annually.

SOURCE: PDA/MRW200-01 & MRM730-01

**TABLE 3.2A
PACE HIGH EXPENDITURE AND HIGH VOLUME CLAIMS
JANUARY - DECEMBER 2003**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDI- TURES</u>	<u>RANK BY EXPENDI- TURE</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>	<u>RANK BY VOLUME</u>	<u>EXCLUSIVITY/ PATENT EXPIRATION</u>	<u>PRODUCT DESCRIPTION</u>
ER SQUIBB AND SONS, INC.	PLAVIX	75 MG	\$13,874,577.99	3.25	1	134,754	1.46	2	07/03	ANTIPLATELET AGENT
MERCK AND COMPANY	ZOCOR	20 MG	\$10,850,175.72	2.54	2	92,587	1.01	6	12/05	LIPID-LOWERING AGENT
TAP PHARMACEUTICALS	PREVACID	30 MG	\$10,236,318.95	2.40	3	84,857	0.92	7	05/09	GASTROINTESTINAL AGENT
PHARMACIA CORP	CELEBREX	200 MG	\$8,843,648.80	2.07	4	95,271	1.04	5	11/13	ANTI-INFLAMMATORY/ANALGESIC
KREMERS URBAN SCHWARZ	OMEPRAZOLE	20 MG	\$8,286,928.32	1.94	5	72,748	0.79	12	?	GASTROINTESTINAL AGENT
PFIZER, INC.	LIPITOR	10 MG	\$8,075,582.19	1.89	6	135,150	1.47	1	01/13	LIPID-LOWERING AGENT
ASTRA ZENECA	NEXIUM	40 MG	\$7,816,494.90	1.83	7	67,354	0.73	14	04/05	GASTROINTESTINAL AGENT
MERCK AND COMPANY	FOSAMAX	70 MG	\$7,389,492.30	1.73	8	128,663	1.40	3	08/07	OSTEOPOROSIS TREATMENT
PFIZER, INC.	LIPITOR	20 MG	\$6,944,410.24	1.63	9	74,216	0.81	9	09/09	LIPID-LOWERING AGENT
WYETH PHARMACEUTICALS	PROTONIX	40 MG	\$6,766,485.94	1.59	10	74,366	0.81	8	06/10	GASTROINTESTINAL AGENT
MERCK AND COMPANY	ZOCOR	40 MG	\$5,601,707.05	1.31	11	47,674	0.52	19	12/05	LIPID-LOWERING AGENT
PFIZER, INC.	NORVASC	5 MG	\$5,114,598.59	1.20	12	127,401	1.38	4	07/06	CALCIUM CHANNEL BLOCKER
PFIZER, INC.	NORVASC	10 MG	\$4,133,693.75	0.97	13	73,823	0.80	10	07/06	CALCIUM CHANNEL BLOCKER
PFIZER, INC.	ARICEPT	10 MG	\$3,846,992.34	0.90	14	30,707	0.33	46	11/10	ALZHEIMER'S DISEASE TREATMENT
MERCK AND COMPANY	VIOXX	25 MG	\$3,761,222.32	0.88	15	50,916	0.55	18	06/13	ANTI-INFLAMMATORY/ANALGESIC
ER SQUIBB AND SONS, INC.	PRAVACHOL	40 MG	\$3,603,345.75	0.84	16	30,639	0.33	47	10/05	LIPID-LOWERING AGENT
PFIZER, INC.	ZOLOFT	50 MG	\$3,306,124.64	0.77	17	45,461	0.49	24	12/05	ANTIDEPRESSANT
PFIZER, INC.	ARICEPT	5 MG	\$2,876,314.38	0.67	18	22,220	0.24	81	11/10	ALZHEIMER'S DISEASE TREATMENT
PFIZER, INC.	ACIPHEX	20 MG	\$2,840,819.18	0.67	19	25,024	0.27	67	04/09	GASTROINTESTINAL AGENT
PFIZER, INC.	LIPITOR	40 MG	\$2,752,396.01	0.65	20	28,406	0.31	53	09/09	LIPID-LOWERING AGENT
ELI LILLY AND COMPANY	EVISTA	60 MG	\$2,731,597.44	0.64	21	42,199	0.46	26	04/03	OSTEOPOROSIS TREATMENT
TAKEDA PHARMACEUTICALS	ACTOS	30 MG	\$2,640,769.73	0.62	22	19,466	0.21	94	01/11	DIABETES TREATMENT
PHARMACIA CORP.	DETROL LA	4 MG	\$2,575,964.39	0.60	23	33,472	0.36	38	03/12	OVERACTIVE BLADDER TREATMENT
ER SQUIBB AND SONS, INC.	PRAVACHOL	20 MG	\$2,550,705.71	0.60	24	32,648	0.35	40	10/05	LIPID-LOWERING AGENT
PHARMACIA CORP.	XALATAN	5 %	\$2,528,256.76	0.59	25	56,720	0.62	15	07/06	GLAUCOMA TREATMENT
GLAXOSMITHKLINE	ADVAIR DISKUS 250/50	250/50 MCG	\$2,427,820.31	0.57	26	19,251	0.21	97	11/03	RESPIRATORY AGENT
TAP PHARMACEUTICALS	PREVACID	15 MG	\$2,377,416.58	0.56	27	18,827	0.20	100	06/08	GASTROINTESTINAL AGENT
MERCK AND COMPANY	ZOCOR	10 MG	\$2,377,370.50	0.56	28	35,712	0.39	34	12/05	LIPID-LOWERING AGENT
ORTHO BIOTECH	PROCRIT	40000 U	\$2,218,175.06	0.52	29	1,539	0.02	902	?	HEMATOPOIETIC AGENT
TAKEDA PHARMACEUTICALS	ACTOS	45 MG	\$2,188,683.98	0.51	30	14,844	0.16	131	01/11	DIABETES TREATMENT

**TABLE 3.2A
PACE HIGH EXPENDITURE AND HIGH VOLUME CLAIMS
JANUARY - DECEMBER 2003**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDI- TURES</u>	<u>RANK BY EXPENDI- TURE</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>	<u>RANK BY VOLUME</u>	<u>EXCLUSIVITY/ PATENT EXPIRATION</u>	<u>PRODUCT DESCRIPTION</u>
MERCK AND COMPANY	SINGULAIR	10 MG	\$2,159,455.04	0.51	31	29,209	0.32	51	02/12	RESPIRATORY AGENT
PFIZER, INC.	NEURONTIN	300 MG	\$2,121,653.17	0.50	32	25,589	0.28	62	05/08	ANTICONVULSANT
NOVARTIS PHARMACEUTICAL	MIACALCIN	200 IU	\$2,033,799.16	0.48	33	32,706	0.36	39	?	CALCITONIN REPLACEMENT
MERCK AND COMPANY	COZAAR	50 MG	\$2,024,620.22	0.47	34	41,953	0.46	27	08/09	ANGIOTENSIN II INHIBITOR
BOEHRINGER INGELHEIM	COMBIVENT	103-18MCG	\$2,019,337.30	0.47	35	39,658	0.43	29	06/15	RESPIRATORY AGENT
PROCTER & GAMBLE	ACTONEL	35 MG	\$2,000,835.80	0.47	36	35,147	0.38	35	12/13	OSTEOPOROSIS TREATMENT
ELI LILLY AND COMPANY	ZYPREXA	2.5 MG	\$1,952,431.83	0.46	37	12,844	0.14	151	04/11	ANTIPSYCHOTIC AGENT
GLAXOSMITHKLINE	AVANDIA	4 MG	\$1,851,679.52	0.43	38	21,949	0.24	82	08/08	DIABETES TREATMENT
FOREST PHARMACEUTICALS	CELEXA	20 MG	\$1,827,662.35	0.43	39	29,562	0.32	48	07/03	ANTIDEPRESSANT
GLAXOSMITHKLINE	PAXIL	20 MG	\$1,819,925.73	0.43	40	24,897	0.27	68	12/06	ANTIDEPRESSANT
GLAXOSMITHKLINE	AVANDIA	8 MG	\$1,784,089.27	0.42	41	13,627	0.15	141	08/08	DIABETES TREATMENT
PHARMACIA CORP	BEXTRA	10 MG	\$1,733,133.49	0.41	42	20,765	0.23	90	02/15	ANTI-INFLAMMATORY/ANALGESIC
NOVARTIS PHARMACEUTICALS	LOTREL	5 MG	\$1,602,453.65	0.38	43	24,867	0.27	69	08/03	COMBINATION ACE INHIBITOR/CCB
ELI LILLY AND COMPANY	ZYPREXA	5 MG	\$1,539,466.99	0.36	44	8,840	0.10	227	04/11	ANTIPSYCHOTIC AGENT
AMGEN/IMMUNEX	ENBREL	25 MG	\$1,537,963.60	0.36	45	1,350	0.01	970	?	ARTHRITIS TREATMENT
BOEHRINGER INGELHEIM	FLOMAX	0.4 MG	\$1,478,833.04	0.35	46	25,989	0.28	58	10/09	FOR PROSTATE HYPERPLASIA
NOVARTIS PHARMACEUTICAL	DIOVAN	80 MG	\$1,458,876.35	0.34	47	33,880	0.37	36	03/12	ANGIOTENSIN II INHIBITOR
ALLERGAN, INC.	ALPHAGAN P	0.15 %	\$1,399,319.36	0.33	48	31,806	0.35	42	05/12	GLAUCOMA TREATMENT
WARRICK PHARMACEUTICALS	ISOSORBIDE MONONITRATE	60 MG	\$1,388,026.65	0.33	49	44,694	0.49	25	?	ANTI-ANGINAL AGENT
WARRICK PHARMACEUTICALS	ISOSORBIDE MONONITRATE	30 MG	\$1,323,366.33	0.31	50	47,272	0.51	20	?	ANTI-ANGINAL AGENT
ASTRA ZENECA	TOPROL XL	50 MG	\$1,317,686.12	0.31	51	67,879	0.74	13	05/07	BETA BLOCKER
ASTRA ZENECA	TOPROL XL	100 MG	\$1,208,802.63	0.28	60	39,115	0.43	30	05/07	BETA BLOCKER
PFIZER, INC.	GLUCOTROL XL	10 MG	\$1,009,495.20	0.24	76	31,618	0.34	43	09/03	DIABETES TREATMENT
UPSHER-SMITH LABORATORIES	KLOR-CON M20	20 MEQ	\$811,476.44	0.19	100	47,121	0.51	21	?	POTASSIUM REPLACEMENT
WARRICK PHARMACEUTICALS	POTASSIUM CHLORIDE	20 MEQ	\$532,011.62	0.12	145	32,290	0.35	41	?	POTASSIUM REPLACEMENT
MYLAN PHARMACEUTICALS, INC.	METOPROLOL TARTRATE	50 MG	\$499,697.44	0.12	157	46,994	0.51	22	?	BETA BLOCKER
TEVA PHARMACEUTICAL	METOPROLOL TARTRATE	50 MG	\$496,830.47	0.12	158	54,326	0.59	17	?	BETA BLOCKER
CARACO PHARMACEUTICAL	METOPROLOL TARTRATE	50 MG	\$472,689.29	0.11	163	33,476	0.36	37	?	BETA BLOCKER
SANDOZ PHARMACEUTICALS	ATENOLOL	50 MG	\$419,445.15	0.10	183	38,058	0.41	32	?	BETA BLOCKER
SANDOZ PHARMACEUTICALS	ATENOLOL	25 MG	\$415,044.87	0.10	186	39,772	0.43	28	?	BETA BLOCKER

**TABLE 3.2A
PACE HIGH EXPENDITURE AND HIGH VOLUME CLAIMS
JANUARY - DECEMBER 2003**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDI- TURES</u>	<u>RANK BY EXPENDI- TURE</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>	<u>RANK BY VOLUME</u>	<u>EXCLUSIVITY/ PATENT EXPIRATION</u>	<u>PRODUCT DESCRIPTION</u>
ETHEX CORPORATION	POTASSIUM CHLORIDE	10 MEQ	\$291,240.23	0.07	249	29,231	0.32	49	?	POTASSIUM REPLACEMENT
UPSHER-SMITH LABORATORIES	KLOR-CON 10	10 MEQ	\$284,773.98	0.07	256	31,071	0.34	45	?	POTASSIUM REPLACEMENT
ABBOTT LABORATORIES	SYNTHROID	0.05 MG	\$239,432.91	0.06	315	29,217	0.32	50	?	SYNTHETIC THYROID AGENT
MYLAN PHARMACEUTICALS, INC.	FUROSEMIDE	40 MG	\$196,691.11	0.05	368	73,533	0.80	11	?	LOOP DIURETIC
BERTEK PHARMACEUTICALS, INC.	DIGITEK	0.125 MG	\$126,878.51	0.03	483	54,567	0.59	16	?	CARDIAC GLYCOSIDE
GLAXOSMITHKLINE	LANOXIN	0.125 MG	\$101,479.23	0.02	571	46,026	0.50	23	?	CARDIAC GLYCOSIDE
SANDOZ PHARMACEUTICALS, INC.	FUROSEMIDE	40 MG	\$79,812.60	0.02	678	38,125	0.41	31	?	LOOP DIURETIC
MYLAN PHARMACEUTICALS, INC.	FUROSEMIDE	20 MG	\$66,879.64	0.02	759	37,234	0.40	33	?	LOOP DIURETIC
IVAX PHARMACEUTICALS	HYDROCHLOROTHIAZIDE	25 MG	\$1,404.84	0.00	4,179	31,191	0.34	44	?	THIAZIDE DIURETIC
	TOTAL 69 PRODUCTS		\$195,166,790.95	45.75		3,064,363	33.30			
	TOTAL ALL PRODUCTS		\$426,604,301.27	100.00		9,200,996	100.00			

NOTES: PATENT AND EXCLUSIVITY EXPIRATION INFORMATION TAKEN FROM USPDI APPROVED DRUG PRODUCTS AND LEGAL REQUIREMENTS, VOLUME III, 23RD EDITION (2003).
DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT FOR PACE ONLY, EXCLUDING PACENET.

SOURCE: PDA/EOM CLAIMS HX

**TABLE 3.2B
PACENET HIGH EXPENDITURE AND HIGH VOLUME CLAIMS
JANUARY - DECEMBER 2003**

MANUFACTURER	PRODUCT	STRENGTH	CARDHOLDER EXPENDITURES	STATE SHARE EXPENDITURES	TOTAL EXPENDITURES	RANK BY		% OF CLAIMS	% OF TOTAL	RANK BY VOLUME
						% OF TOTAL	EXPEN- TURES			
ER SQUIBB AND SONS, INC.	PLAVIX	75 MG	\$765,899.31	\$1,738,881.06	\$2,504,780.37	3.36	1	22,208	1.65	1
MERCK AND COMPANY	ZOCOR	20 MG	\$487,686.02	\$1,213,835.83	\$1,701,521.85	2.28	2	13,358	0.99	5
TAP PHARMACEUTICALS	PREVACID	30 MG	\$361,863.81	\$1,078,684.07	\$1,440,547.88	1.93	3	11,040	0.82	7
KREMERS URBAN SCHWARZ PHARMACIA CORP	OMEPRAZOLE CELEBREX	20 MG 200 MG	\$276,182.27 \$351,573.17	\$841,973.64 \$820,301.71	\$1,118,155.91 \$1,171,874.88	1.50 1.57	4 5	9,105 11,722	0.67 0.87	13 6
ASTRA ZENECA	NEXIUM	40 MG	\$301,372.02	\$785,096.16	\$1,086,468.18	1.46	6	8,639	0.64	14
MERCK AND COMPANY	FOSAMAX	70 MG	\$557,351.05	\$753,606.18	\$1,310,957.23	1.76	7	19,650	1.46	2
PFIZER, INC.	LIPITOR	10 MG	\$534,409.74	\$751,281.74	\$1,285,691.48	1.72	8	18,942	1.40	3
WYETH PHARMACEUTICALS	PROTONIX	40 MG	\$329,119.67	\$742,380.60	\$1,071,500.27	1.44	9	10,678	0.79	8
PFIZER, INC.	LIPITOR	20 MG	\$331,972.97	\$708,709.36	\$1,040,682.33	1.40	10	10,142	0.75	9
MERCK AND COMPANY	ZOCOR	40 MG	\$261,794.01	\$639,976.50	\$901,770.51	1.21	11	7,114	0.53	18
PFIZER, INC.	ARICEPT	10 MG	\$208,449.73	\$540,904.61	\$749,354.34	1.00	12	5,509	0.41	28
PFIZER, INC.	NORVASC	5 MG	\$440,276.98	\$444,382.85	\$884,659.83	1.19	13	18,332	1.36	4
ER SQUIBB AND SONS INC.	PRAVACHOL	40 MG	\$156,868.56	\$401,987.95	\$558,856.51	0.75	14	4,379	0.32	48
ORTHO BIOTECH	PROCRIT	40000 U	\$51,608.64	\$384,969.78	\$436,578.42	0.59	15	274	0.02	819
PFIZER, INC.	NORVASC	10 MG	\$261,591.38	\$382,038.63	\$643,630.01	0.86	16	10,121	0.75	10
PFIZER, INC.	ZOLOFT	50 MG	\$183,346.49	\$357,069.47	\$540,415.96	0.72	17	6,808	0.50	23
TAKEDA PHARMACEUTICALS	ACTOS	30 MG	\$109,263.54	\$343,111.73	\$452,375.27	0.61	18	3,082	0.23	83
MERCK AND COMPANY	VIOXX	25 MG	\$188,419.37	\$336,733.40	\$525,152.77	0.70	19	6,350	0.47	25
PFIZER, INC.	LIPITOR	40 MG	\$144,961.14	\$319,840.08	\$464,801.22	0.62	20	4,428	0.33	46
PFIZER, INC.	ARICEPT	5 MG	\$133,223.99	\$317,817.79	\$451,041.78	0.60	21	3,235	0.24	72
GLAXOSMITHKLINE	ADVAIR DISKUS 250/50	250/50 MCG	\$106,780.85	\$303,949.60	\$410,730.45	0.55	22	2,969	0.22	87
ELI LILLY AND COMPANY	ZYPREXA	2.5 MG	\$70,064.87	\$274,520.85	\$344,585.72	0.46	23	2,071	0.15	131
PFIZER, INC.	ACIPHEX	20 MG	\$96,042.38	\$268,920.23	\$364,962.61	0.49	24	2,977	0.22	86
PHARMACIA CORP.	DETROL LA	4 MG	\$138,078.91	\$266,779.06	\$404,857.97	0.54	25	4,657	0.35	42
PFIZER, INC.	NEURONTIN	300 MG	\$120,324.96	\$261,247.68	\$381,572.64	0.51	26	4,171	0.31	51
ELI LILLY AND COMPANY	EVISTA	60 MG	\$169,759.06	\$254,737.85	\$424,496.91	0.57	27	5,747	0.43	27
TAKEDA PHARMACEUTICALS	ACTOS	45 MG	\$71,856.08	\$253,816.46	\$325,672.54	0.44	28	2,054	0.15	134
MERCK AND COMPANY	ZOCOR	10 MG	\$161,054.58	\$243,079.83	\$404,134.41	0.54	29	5,414	0.40	29
ER SQUIBB AND SONS INC.	PRAVACHOL	20 MG	\$132,249.93	\$236,705.39	\$368,955.32	0.49	30	4,254	0.32	50

**TABLE 3.2B
PACENET HIGH EXPENDITURE AND HIGH VOLUME CLAIMS
JANUARY - DECEMBER 2003**

MANUFACTURER	PRODUCT	STRENGTH	CARDHOLDER EXPENDITURES	STATE SHARE EXPENDITURES	TOTAL EXPENDITURES	RANK BY		% OF CLAIMS	% OF TOTAL	RANK BY VOLUME
						% OF TOTAL	EXPEN- TURES			
MERCK AND COMPANY	SINGULAIR	10 MG	\$111,853.36	\$228,120.09	\$339,973.45	0.46	31	4,075	0.30	55
PHARMACIA CORP.	XALATAN	5 %	\$205,870.84	\$219,489.49	\$425,360.33	0.57	32	8,026	0.59	15
ELI LILLY AND COMPANY	ZYPREXA	5 MG	\$54,997.40	\$215,743.95	\$270,741.35	0.36	33	1,413	0.10	212
FOREST PHARMACEUTICALS	CELEXA	20 MG	\$127,326.96	\$211,156.12	\$338,483.08	0.45	34	4,752	0.35	40
GLAXOSMITHKLINE	AVANDIA	8 MG	\$67,600.28	\$206,938.69	\$274,538.97	0.37	35	1,930	0.14	144
MERCK AND COMPANY	COZAAR	50 MG	\$150,566.65	\$200,735.12	\$351,301.77	0.47	36	6,099	0.45	26
TAP PHARMACEUTICALS	PREVACID	15 MG	\$66,872.46	\$199,839.60	\$266,712.06	0.36	37	2,069	0.15	132
GLAXOSMITHKLINE	AVANDIA	4 MG	\$94,065.75	\$198,285.89	\$292,351.64	0.39	38	3,149	0.23	76
GLAXOSMITHKLINE	PAXIL	20 MG	\$111,884.61	\$196,792.93	\$308,677.54	0.41	39	3,787	0.28	56
NOVARTIS PHARMACEUTICAL	MIACALCIN	200 IU	\$128,337.10	\$195,625.16	\$323,962.26	0.43	40	4,555	0.34	43
AMGEN/IMMUNEX	ENBREL	25 MG	\$20,150.62	\$193,843.91	\$213,994.53	0.29	41	180	0.01	1,064
PROCTER & GAMBLE	ACTONEL	35 MG	\$145,715.28	\$193,144.51	\$338,859.79	0.45	42	5,138	0.38	33
BOEHRINGER INGELHEIM	FLOMAX	0.4 MG	\$137,367.47	\$186,384.93	\$323,752.40	0.43	43	5,011	0.37	36
BOEHRINGER INGELHEIM	COMBIVENT	103-18MCG	\$133,180.39	\$185,176.38	\$318,356.77	0.43	44	5,366	0.40	30
WARRICK PHARMACEUTICALS	ISOSORBIDE MONONITRATE	60 MG	\$94,761.59	\$173,677.76	\$268,439.35	0.36	45	7,014	0.52	20
PHARMACIA CORP	BEXTRA	10 MG	\$78,144.00	\$172,269.08	\$250,413.08	0.34	46	2,755	0.20	96
GLAXOSMITHKLINE	ADVAIR DISKUS 500/50	500/50 MCG	\$43,437.73	\$167,288.39	\$210,726.12	0.28	47	1,123	0.08	269
NOVARTIS PHARMACEUTICAL	LOTREL	5 MG	\$123,681.11	\$164,899.69	\$288,580.80	0.39	48	3,782	0.28	57
NOVARTIS PHARMACEUTICAL	GLEEVEC	100 MG	\$9,034.41	\$155,645.82	\$164,680.23	0.22	49	93	0.01	1,532
MERCK AND COMPANY	PROSCAR	5 MG	\$90,877.87	\$149,601.83	\$240,479.70	0.32	50	3,101	0.23	81
WARRICK PHARMACEUTICALS	ISOSORBIDE MONONITRATE	30 MG	\$92,848.91	\$146,130.35	\$238,979.26	0.32	52	6,998	0.52	21
ALLERGAN INC.	ALPHAGAN P	0.15 %	\$122,040.51	\$136,530.23	\$258,570.74	0.35	56	5,000	0.37	37
NOVARTIS PHARMACEUTICAL	DIOVAN	80 MG	\$112,946.86	\$116,210.26	\$229,157.12	0.31	70	4,503	0.33	44
ASTRA ZENECA	TOPROL XL	100 MG	\$135,140.98	\$112,302.80	\$247,443.78	0.33	75	6,452	0.48	24
ELI LILLY AND COMPANY	HUMULIN N	100 U	\$98,126.95	\$110,944.43	\$209,071.38	0.28	76	4,425	0.33	47
PFIZER, INC.	GLUCOTROL XL	10 MG	\$106,314.50	\$91,246.15	\$197,560.65	0.26	98	5,047	0.37	35
UPSHER-SMITH LABORATORIES	KLOR-CON M20	20 MEQ	\$80,147.55	\$87,501.35	\$167,648.90	0.22	100	6,932	0.51	22
ASTRA ZENECA	TOPROL XL	50 MG	\$187,325.77	\$82,978.87	\$270,304.64	0.36	109	9,989	0.74	12
WARRICK PHARMACEUTICALS	POTASSIUM CHLORIDE	20 MEQ	\$60,720.30	\$64,922.05	\$125,642.35	0.17	137	5,151	0.38	32
MYLAN PHARMACEUTICALS, INC.	METOPROLOL TARTRATE	50 MG	\$76,593.44	\$53,311.56	\$129,905.00	0.17	158	7,566	0.56	17

**TABLE 3.2B
PACENET HIGH EXPENDITURE AND HIGH VOLUME CLAIMS
JANUARY - DECEMBER 2003**

<u>MANUFACTURER</u>	<u>PRODUCT</u>	<u>STRENGTH</u>	<u>CARDHOLDER EXPENDITURES</u>	<u>STATE SHARE EXPENDITURES</u>	<u>TOTAL EXPENDITURES</u>	<u>% OF TOTAL</u>	<u>RANK BY EXPEN- TURES</u>	<u>CLAIMS</u>	<u>% OF TOTAL</u>	<u>RANK BY VOLUME</u>
CARACO PHARMACEUTICAL	METOPROLOL TARTRATE	50 MG	\$52,785.49	\$48,835.29	\$101,620.78	0.14	181	4,857	0.36	38
TEVA PHARMACEUTICAL	METOPROLOL TARTRATE	50 MG	\$79,421.42	\$45,147.22	\$124,568.64	0.17	192	7,896	0.59	16
BARR LABORATORIES INC.	WARFARIN SODIUM	5 MG	\$53,903.86	\$42,450.55	\$96,354.41	0.13	202	4,483	0.33	45
SANDOZ PHARMACEUTICALS	ATENOLOL	50 MG	\$54,096.80	\$38,052.11	\$92,148.91	0.12	227	5,186	0.38	31
SANDOZ PHARMACEUTICALS	ATENOLOL	25 MG	\$49,578.24	\$31,975.28	\$81,553.52	0.11	257	4,757	0.35	39
UPSHER-SMITH LABORATORIES	KLOR-CON 10	10 MEQ	\$49,662.25	\$28,183.05	\$77,845.30	0.10	282	5,052	0.37	34
ETHEX CORPORATION	POTASSIUM CHLORIDE	10 MEQ	\$43,844.10	\$27,761.97	\$71,606.07	0.10	290	4,291	0.32	49
MYLAN PHARMACEUTICALS, INC.	FUROSEMIDE	40 MG	\$84,098.95	\$9,753.47	\$93,852.42	0.13	637	9,990	0.74	11
BERTEK PHARMACEUTICALS INC.	DIGITEK	0.125 MG	\$59,286.69	\$3,099.93	\$62,386.62	0.08	1,241	7,057	0.52	19
MYLAN PHARMACEUTICALS, INC.	FUROSEMIDE	20 MG	\$38,892.95	\$2,488.66	\$41,381.61	0.06	1,386	4,724	0.35	41
	TOTAL 70 PRODUCTS		\$11,136,947.88	\$21,361,825.01	\$32,498,772.89	43.58		433,204	32.10	
	TOTAL ALL PRODUCTS		\$28,094,515.64	\$46,473,618.47	\$74,568,134.11	100.00		1,349,534	100.00	

NOTE: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF PAYMENT. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.
SOURCE: PDA CLAIMS HX

TABLE 3.3
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES
2002-2003

MANUFACTURER	PRODUCT	STRENGTH	2003									2002						PERCENT CHANGE: 2002-2003				
			EXPENDITURE		CLAIMS		COST PER CLAIM			EXPENDITURE		CLAIMS		COST PER CLAIM		EXPENDITURE	CHANGE	CLAIMS	COST PER CLAIM	USERS		
			%	%	%	%	%	%	%	%	%	%	%	%								
ANTI-INFECTIVE AGENTS																						
MCNEIL	LEVAQUIN (LEVOFLOXACIN)	500 MG	\$1,155,519	10.8	15,701	6.3	\$73.60	11,738	12.6	\$1,135,651	11.1	16,572	6.5	\$68.53	12,300	12.9	1.7	-5.3	7.4	-4.6		
PFIZER	ZITHROMAX (AZITHROMYCIN)	250 MG	\$970,982	9.0	25,752	10.4	\$37.71	19,697	21.2	\$937,517	9.1	25,884	10.2	\$36.22	19,933	20.8	3.6	-0.5	4.1	-1.2		
BAYER	CIPRO (CIPROFLOXACIN)	500 MG	\$777,452	7.2	9,865	4.0	\$78.81	7,471	8.0	\$1,137,549	11.1	15,775	6.2	\$72.11	11,252	11.8	-31.7	-37.5	9.3	-33.6		
BAYER	AVELOX (MOXIFLOXACIN)	400 MG	\$416,384	3.9	6,062	2.4	\$68.69	4,861	5.2	\$258,884	2.5	4,007	1.6	\$64.61	3,288	3.4	60.8	51.3	6.3	47.8		
MCNEIL	LEVAQUIN (LEVOFLOXACIN)	250 MG	\$390,314	3.6	7,088	2.9	\$55.07	5,646	6.1	\$367,679	3.6	7,294	2.9	\$50.41	5,824	6.1	6.2	-2.8	9.2	-3.1		
	ALL OTHER		\$7,027,172	65.4	183,172	74.0	\$38.36	74,710	80.5	\$6,420,591	62.6	183,949	72.6	\$34.90	76,410	79.8	9.4	-0.4	9.9	-2.2		
	TOTAL		\$10,737,822	100.0	247,640	100.0	\$43.36	92,840	100.0	\$10,257,870	100.0	253,481	100.0	\$40.47	95,715	100.0	4.7	-2.3	7.1	-3.0		
AUTONOMIC DRUGS																						
PFIZER	ARICEPT (DONEPEZIL)	10 MG	\$3,846,992	23.5	30,707	11.7	\$125.28	4,704	10.0	\$3,266,938	21.3	27,377	10.2	\$119.33	4,204	8.8	17.8	12.2	5.0	11.9		
PFIZER	ARICEPT (DONEPEZIL)	5 MG	\$2,876,314	17.6	22,220	8.5	\$129.45	4,781	10.1	\$2,858,718	18.7	22,971	8.6	\$124.45	4,743	9.9	0.6	-3.3	4.0	0.8		
BOEHRINGER INGELHEIM	COMBIVENT (ALBUTEROL/ IPRATROPIUM)	103/18 MCG	\$2,019,337	12.3	39,658	15.1	\$50.92	8,990	19.0	\$1,686,546	11.0	37,814	14.1	\$44.60	8,482	17.8	19.7	4.9	14.2	6.0		
GLAXOSMITHKLINE	SEREVENT (SALMETEROL)	1 MCG	\$629,692	3.8	8,816	3.4	\$71.43	2,754	5.8	\$1,203,930	7.9	18,145	6.8	\$66.35	4,234	8.9	-47.7	-51.4	7.6	-35.0		
BOEHRINGER INGELHEIM	ATROVENT (IPRATROPIUM)	0.018 MG	\$588,947	3.6	12,017	4.6	\$49.01	2,404	5.1	\$634,696	4.1	14,452	5.4	\$43.92	2,942	6.2	-7.2	-16.8	11.6	-18.3		
	ALL OTHER		\$6,402,029	39.1	149,047	56.8	\$42.95	34,333	72.7	\$5,656,065	37.0	146,838	54.9	\$38.52	34,240	71.8	13.2	1.5	11.5	0.3		
	TOTAL		\$16,363,402	100.0	262,472	100.0	\$62.34	47,222	100.0	\$15,306,893	100.0	267,597	100.0	\$57.20	47,671	100.0	6.9	-1.9	9.0	-0.9		
BLOOD FORMATION AND COAGULATION AGENTS																						
ER SQUIBB	PLAVIX (CLOPIDOGREL)	75 MG	\$13,874,578	52.3	134,754	36.0	\$102.96	18,686	39.4	\$10,928,942	48.1	113,480	31.7	\$96.31	16,700	36.0	27.0	18.7	6.9	11.9		
ORTHO BIOTECH	PROCRIT (EPOETIN ALFA)	40000 U	\$2,218,175	8.4	1,539	0.4	\$1,441.31	385	0.8	\$1,948,913	8.6	1,336	0.4	\$1,458.77	376	0.8	13.8	15.2	-1.2	2.4		
BOEHRINGER INGELHEIM	AGGRENOX (ASA/DIPYRIDAMOLE)	5 MG	\$940,121	3.5	10,071	2.7	\$93.35	1,520	3.2	\$713,468	3.1	8,666	2.4	\$82.33	1,429	3.1	31.8	16.2	13.4	6.4		
OTSUKA AMERICA	PLETAL (CILOSTAZOL)	100 MG	\$926,476	3.5	10,865	2.9	\$85.27	1,816	3.8	\$785,631	3.5	9,454	2.6	\$83.10	1,795	3.9	17.9	14.9	2.6	1.2		
ORTHO BIOTECH	PROCRIT (EPOETIN ALFA)	20000 U	\$869,188	3.3	1,077	0.3	\$807.05	269	0.6	\$755,560	3.3	861	0.2	\$877.54	242	0.5	15.0	25.1	-8.0	11.2		
	ALL OTHER		\$7,673,246	28.9	214,081	57.3	\$35.84	28,538	60.2	\$7,578,765	33.4	223,950	62.6	\$33.84	29,936	64.5	1.2	-4.4	5.9	-4.7		
	TOTAL		\$26,522,083	100.0	373,924	100.0	\$70.93	47,414	100.0	\$22,711,278	100.0	357,747	100.0	\$63.48	46,405	100.0	16.8	4.5	11.7	2.2		
CARDIAC DRUGS																						
PFIZER	NORVASC (AMLODIPINE)	5 MG	\$5,114,599	7.2	127,401	5.9	\$40.15	17,710	12.0	\$4,995,796	7.4	128,409	6.0	\$38.91	18,001	12.0	2.4	-0.8	3.2	-1.6		
PFIZER	NORVASC (AMLODIPINE)	10 MG	\$4,133,694	5.8	73,823	3.4	\$55.99	10,084	6.8	\$3,838,553	5.7	68,592	3.2	\$55.96	9,293	6.2	7.7	7.6	0.1	8.5		
MERCK	COZAAR (LOSARTAN)	50 MG	\$2,024,620	2.9	41,953	1.9	\$48.26	5,832	3.9	\$2,114,066	3.1	45,111	2.1	\$46.86	6,271	4.2	-4.2	-7.0	3.0	-7.0		
NOVARTIS	LOTREL (AMLODIPINE/BENAZEPRIL)	5 MG	\$1,602,454	2.3	24,867	1.1	\$64.44	3,307	2.2	\$1,452,845	2.2	24,018	1.1	\$60.49	3,181	2.1	10.3	3.5	6.5	4.0		
NOVARTIS	DIOVAN (VALSARTAN)	80 MG	\$1,458,876	2.1	33,880	1.6	\$43.06	5,313	3.6	\$1,147,223	1.7	29,713	1.4	\$38.61	4,827	3.2	27.2	14.0	11.5	10.1		
	ALL OTHER		\$56,523,100	79.8	1,866,392	86.1	\$30.28	138,919	93.8	\$53,904,363	79.9	1,849,735	86.2	\$29.14	140,175	93.8	4.9	0.9	3.9	-0.9		
	TOTAL		\$70,857,342	100.0	2,168,316	100.0	\$32.68	148,029	100.0	\$67,452,846	100.0	2,145,578	100.0	\$31.44	149,501	100.0	5.0	1.1	3.9	-1.0		
LIPID-LOWERING AGENTS																						
MERCK	ZOCOR (SIMVASTATIN)	20 MG	\$10,850,176	21.0	92,587	15.0	\$117.19	12,319	16.9	\$9,982,515	22.1	89,613	15.8	\$111.40	12,526	18.4	8.7	3.3	5.2	-1.7		
PFIZER	LIPITOR (ATORVASTATIN)	10 MG	\$8,075,582	15.6	135,150	21.9	\$59.75	18,292	25.2	\$7,631,206	16.9	132,353	23.3	\$57.66	18,410	27.1	5.8	2.1	3.6	-0.6		
PFIZER	LIPITOR (ATORVASTATIN)	20 MG	\$6,944,410	13.4	74,216	12.0	\$93.57	10,483	14.4	\$5,977,225	13.3	67,867	12.0	\$88.07	9,739	14.3	16.2	9.4	6.2	7.6		
MERCK	ZOCOR (SIMVASTATIN)	40 MG	\$5,601,707	10.8	47,674	7.7	\$117.50	6,885	9.5	\$4,596,968	10.2	41,040	7.2	\$112.01	6,002	8.8	21.9	16.2	4.9	14.7		
ER SQUIBB	PRAVACHOL (PRAVASTATIN)	40 MG	\$3,603,346	7.0	30,639	5.0	\$117.61	4,505	6.2	\$2,913,039	6.5	25,959	4.6	\$112.22	3,798	5.6	23.7	18.0	4.8	18.6		
	ALL OTHER		\$16,570,528	32.1	236,405	38.3	\$70.09	30,585	42.1	\$13,985,048	31.0	210,907	37.1	\$66.31	27,538	40.5	18.5	12.1	5.7	11.1		
	TOTAL		\$51,645,748	100.0	616,671	100.0	\$83.75	72,712	100.0	\$45,086,001	100.0	567,739	100.0	\$79.41	67,913	100.0	14.5	8.6	5.5	7.1		

TABLE 3.3
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES
2002-2003

MANUFACTURER	PRODUCT	STRENGTH	2003							2002						PERCENT CHANGE: 2002-2003						
			EXPENDITURE	%	CLAIMS	%	COST PER		EXPENDITURE	%	CLAIMS	%	COST PER CLAIM	USERS	%	EXPENDITURE	%	CHANGE	%	CHANGE	%	
							CLAIM	USERS														CLAIM
COX-2 INHIBITOR ANTI-INFLAMMATORY DRUGS																						
PHARMACIA	CELEBREX (CELECOXIB)	200 MG	\$8,843,649	50.1	95,271	45.4	\$92.83	16,867	45.0	\$8,904,309	52.8	101,119	47.9	\$88.06	18,641	47.5	-0.7	-5.8	5.4	-9.5		
MERCK	VIOXX (ROFECOXIB)	25 MG	\$3,761,222	21.3	50,916	24.2	\$73.87	10,220	27.3	\$4,037,606	24.0	57,462	27.2	\$70.27	12,256	31.2	-6.8	-11.4	5.1	-16.6		
PHARMACIA	BEXTRA (VALDECOXIB)	10 MG	\$1,733,133	9.8	20,765	9.9	\$83.46	5,607	15.0	\$748,142	4.4	9,317	4.4	\$80.30	3,522	9.0	131.7	122.9	3.9	59.2		
PHARMACIA	CELEBREX (CELECOXIB)	100 MG	\$1,071,133	6.1	15,319	7.3	\$69.92	2,956	7.9	\$1,385,281	8.2	20,736	9.8	\$66.81	4,211	10.7	-22.7	-26.1	4.7	-29.8		
MERCK	VIOXX (ROFECOXIB)	12.5 MG	\$1,043,962	5.9	13,389	6.4	\$77.97	3,154	8.4	\$1,157,568	6.9	15,370	7.3	\$75.31	3,756	9.6	0.0	0.0	0.0	0.0		
	ALL OTHER		\$1,210,865	6.9	14,306	6.8	\$84.64	3,822	10.2	\$623,431	3.7	7,263	3.4	\$85.84	2,549	6.5	94.2	97.0	-1.4	49.9		
	TOTAL		\$17,663,964	100.0	209,966	100.0	\$84.13	37,504	100.0	\$16,856,338	100.0	211,267	100.0	\$79.79	39,254	100.0	4.8	-0.6	5.4	-4.5		
OTHER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS																						
BOEHRINGER INGELHEIM	MOBIC (MELOXICAM)	7.5 MG	\$680,269	20.2	8,601	11.9	\$79.09	1,986	10.3	\$610,381	16.3	8,758	10.8	\$69.69	2,146	10.0	11.4	-1.8	13.5	-7.5		
PHARMACIA	ARTHROTEC (DICLOFENAC/MISOPROSTOL)	75 MG	\$289,879	8.6	3,391	4.7	\$85.48	671	3.5	\$318,503	8.5	3,869	4.8	\$82.32	806	3.8	-9.0	-12.4	3.8	-16.7		
TEVA	NABUMETONE	500 MG	\$197,757	5.9	3,143	4.3	\$62.92	708	3.7	\$299,894	8.0	4,724	5.8	\$63.48	1,133	5.3	-34.1	-33.5	-0.9	-37.5		
PHARMACIA	ARTHROTEC (DICLOFENAC/MISOPROSTOL)	50 MG	\$170,700	5.1	1,918	2.6	\$89.00	436	2.3	\$195,949	5.2	2,326	2.9	\$84.24	551	2.6	-12.9	-17.5	5.6	-20.9		
BOEHRINGER INGELHEIM	MOBIC (MELOXICAM)	15 MG	\$136,832	4.1	1,717	2.4	\$79.69	378	2.0	\$70,658	1.9	1,148	1.4	\$61.55	260	1.2	93.7	49.6	29.5	45.4		
	ALL OTHER		\$1,899,254	56.3	53,644	74.1	\$35.40	15,963	82.6	\$2,249,109	60.1	60,592	74.4	\$37.12	17,568	82.2	-15.6	-11.5	-4.6	-9.1		
	TOTAL		\$3,374,692	100.0	72,414	100.0	\$46.60	19,324	100.0	\$3,744,493	100.0	81,417	100.0	\$45.99	21,378	100.0	-9.9	-11.1	1.3	-9.6		
OPIATE AGONIST ANALGESICS																						
JANSSEN	DURAGESIC (FENTANYL)	50 MCG	\$1,001,419	9.9	5,147	2.1	\$194.56	1,650	3.0	\$787,936	8.8	4,483	1.8	\$175.76	1,500	2.7	27.1	14.8	10.7	10.0		
JANSSEN	DURAGESIC (FENTANYL)	100 MCG	\$994,557	9.9	2,180	0.9	\$456.22	447	0.8	\$708,639	7.9	1,706	0.7	\$415.38	338	0.6	40.3	27.8	9.8	32.2		
JANSSEN	DURAGESIC (FENTANYL)	25 MCG	\$857,123	8.5	7,968	3.3	\$107.57	2,966	5.4	\$694,274	7.8	7,087	2.9	\$97.96	2,755	5.0	23.5	12.4	9.8	7.7		
PURDUE PHARMA	OXYCONTIN (OXYCODONE)	20 MG	\$836,889	8.3	6,075	2.5	\$137.76	1,433	2.6	\$804,130	9.0	6,107	2.5	\$131.67	1,445	2.6	4.1	-0.5	4.6	-0.8		
JANSSEN	DURAGESIC (FENTANYL)	75 MCG	\$637,550	6.3	1,988	0.8	\$320.70	592	1.1	\$475,220	5.3	1,616	0.7	\$294.07	502	0.9	34.2	23.0	9.1	17.9		
	ALL OTHER		\$5,759,171	57.1	221,027	90.4	\$26.06	53,759	98.3	\$5,469,883	61.2	222,490	91.4	\$24.58	54,159	98.4	5.3	-0.7	6.0	-0.7		
	TOTAL		\$10,086,709	100.0	244,385	100.0	\$41.27	54,689	100.0	\$8,940,081	100.0	243,489	100.0	\$36.72	55,026	100.0	12.8	0.4	12.4	-0.6		
ANTIDEPRESSANTS																						
PFIZER	ZOLOFT (SERTRALINE)	50 MG	\$3,306,125	16.3	45,461	13.0	\$72.72	7,499	16.4	\$3,133,517	16.6	45,270	13.4	\$69.22	7,622	16.9	5.5	0.4	5.1	-1.6		
FOREST	CELEXA (CITALOPRAM)	20 MG	\$1,827,662	9.0	29,562	8.4	\$61.82	4,702	10.3	\$1,939,468	10.3	33,018	9.8	\$58.74	6,324	14.0	-5.8	-10.5	5.3	-25.6		
GLAXOSMITHKLINE	PAXIL (PAROXETINE)	20 MG	\$1,819,926	9.0	24,897	7.1	\$73.10	4,295	9.4	\$2,452,339	13.0	34,416	10.2	\$71.26	5,692	12.6	-25.8	-27.7	2.6	-24.5		
PFIZER	ZOLOFT (SERTRALINE)	100 MG	\$1,206,269	6.0	16,368	4.7	\$73.70	2,472	5.4	\$1,071,643	5.7	15,019	4.5	\$71.35	2,321	5.1	12.6	9.0	3.3	6.5		
GLAXOSMITHKLINE	PAXIL (PAROXETINE)	10 MG	\$944,780	4.7	13,620	3.9	\$69.37	2,508	5.5	\$1,278,267	6.8	19,063	5.7	\$67.05	3,629	8.0	-26.1	-28.6	3.4	-30.9		
	ALL OTHER		\$11,139,800	55.0	220,023	62.9	\$50.63	33,927	74.4	\$8,983,735	47.6	190,318	56.5	\$47.20	28,016	62.1	24.0	15.6	7.3	21.1		
	TOTAL		\$20,244,562	100.0	349,931	100.0	\$57.85	45,614	100.0	\$18,858,969	100.0	337,104	100.0	\$55.94	45,117	100.0	7.3	3.8	3.4	1.1		
ANTIPSYCHOTICS																						
ELI LILLY	ZYPREXA (OLANZAPINE)	2.5 MG	\$1,952,432	22.9	12,844	19.4	\$152.01	2,755	28.7	\$1,783,473	23.6	11,966	18.6	\$149.05	2,797	29.0	9.5	7.3	2.0	-1.5		
ELI LILLY	ZYPREXA (OLANZAPINE)	5 MG	\$1,539,467	18.1	8,840	13.4	\$174.15	1,892	19.7	\$1,348,716	17.9	7,957	12.4	\$169.50	1,814	18.8	14.1	11.1	2.7	4.3		
JANSSEN	RISPERDAL (RISPERIDONE)	0.5 MG	\$803,116	9.4	7,373	11.2	\$108.93	1,617	16.8	\$804,088	10.6	8,022	12.5	\$100.24	1,824	18.9	-0.1	-8.1	8.7	-11.3		
ELI LILLY	ZYPREXA (OLANZAPINE)	10 MG	\$697,355	8.2	2,561	3.9	\$272.30	522	5.4	\$653,950	8.7	2,430	3.8	\$269.12	504	5.2	6.6	5.4	1.2	3.6		
JANSSEN	RISPERDAL (RISPERIDONE)	1 MG	\$528,409	6.2	4,847	7.3	\$109.02	968	10.1	\$552,837	7.3	5,695	8.9	\$97.07	1,164	12.1	-4.4	-14.9	12.3	-16.8		
	ALL OTHER		\$2,990,045	35.1	29,593	44.8	\$101.04	4,760	49.6	\$2,407,123	31.9	28,210	43.9	\$85.33	4,622	48.0	24.2	4.9	18.4	3.0		
	TOTAL		\$8,510,824	100.0	66,058	100.0	\$128.84	9,606	100.0	\$7,550,187	100.0	64,280	100.0	\$117.46	9,637	100.0	12.7	2.8	9.7	-0.3		

**TABLE 3.3
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES
2002-2003**

MANUFACTURER	PRODUCT	STRENGTH	2003						2002						PERCENT CHANGE: 2002-2003					
			EXPENDITURE	%	CLAIMS	%	COST PER CLAIM	USERS	%	EXPENDITURE	%	CLAIMS	%	COST PER CLAIM	USERS	%	EXPENDITURE	%	CLAIMS	%
ANXIOLYTICS, SEDATIVES, AND HYPNOTICS																				
SANOVI-SYNTHELABO	AMBIEN (ZOLPIDEM)	5 MG	\$1,288,550	13.6	24,351	8.3	\$52.92	6,279	13.2	\$459,027	4.9	9,058	3.0	\$50.68	3,240	6.5	180.7	168.8	4.4	93.8
SANOVI-SYNTHELABO	AMBIEN (ZOLPIDEM)	5 MG	\$1,211,058	12.7	18,492	6.3	\$65.49	3,230	6.8	\$428,186	4.6	6,975	2.3	\$61.39	2,150	4.3	182.8	165.1	6.7	50.2
WATSON	LORAZEPAM	0.5 MG	\$469,431	4.9	18,154	6.2	\$25.86	4,456	9.4	\$211,965	2.3	8,506	2.8	\$24.92	2,891	5.8	121.5	113.4	3.8	54.1
MYLAN	LORAZEPAM	0.5 MG	\$382,129	4.0	16,220	5.5	\$23.56	3,802	8.0	\$561,248	6.0	22,728	7.5	\$24.69	5,961	12.0	-31.9	-28.6	-4.6	-36.2
RANBAXY	LORAZEPAM	0.5 MG	\$365,435	3.8	14,991	5.1	\$24.38	3,767	7.9	\$159,188	1.7	6,386	2.1	\$24.93	2,205	4.4	0.0	0.0	0.0	0.0
	ALL OTHER		\$5,787,961	60.9	200,306	68.5	\$28.90	35,258	74.0	\$7,586,464	80.7	250,115	82.3	\$30.33	43,989	88.5	-23.7	-19.9	-4.7	-19.8
	TOTAL		\$9,504,563	100.0	292,514	100.0	\$32.49	47,656	100.0	\$9,406,078	100.0	303,768	100.0	\$30.96	49,691	100.0	1.0	-3.7	4.9	-4.1
EYE, EAR, NOSE AND THROAT PREPARATIONS																				
PHARMACIA	XALATAN (LATANOPROST)	0.005 %	\$2,528,257	23.2	56,720	19.2	\$44.57	9,113	18.4	\$2,643,939	25.3	61,261	19.8	\$43.16	9,653	18.7	-4.4	-7.4	3.3	-5.6
ALLERGAN	ALPHAGAN P (BRIMONIDINE)	0.15 %	\$1,399,319	12.8	31,806	10.8	\$44.00	5,224	10.5	\$809,839	7.7	19,955	6.5	\$40.58	4,622	9.0	72.8	59.4	8.4	13.0
GLAXOSMITHKLINE	FLONASE (FLUTICASONE)	0.05 MG	\$812,293	7.4	15,161	5.1	\$53.58	5,352	10.8	\$712,663	6.8	14,009	4.5	\$50.87	5,068	9.8	14.0	8.2	5.3	5.6
MERCK	COSOPT OCUMETER (DORZOLAMIDE/TIMOLOL)	2%-5%	\$804,175	7.4	20,726	7.0	\$38.80	3,141	6.3	\$751,179	7.2	19,777	6.4	\$37.98	2,984	5.8	7.1	4.8	2.2	5.3
ALLERGAN	LUMIGAN (BIMATOPIROST)	2.5 %	\$666,799	6.1	12,982	4.4	\$51.36	2,565	5.2	\$563,633	5.4	9,581	3.1	\$58.83	2,234	4.3	18.3	35.5	-12.7	14.8
	ALL OTHER		\$4,704,368	43.1	157,334	53.4	\$29.90	39,168	79.1	\$4,979,937	47.6	184,573	59.7	\$26.98	43,024	83.3	-5.5	-14.8	10.8	-9.0
	TOTAL		\$10,915,212	100.0	294,729	100.0	\$37.03	49,531	100.0	\$10,461,190	100.0	309,156	100.0	\$33.84	51,633	100.0	4.3	-4.7	9.4	-4.1
PROTON PUMP INHIBITOR ANTI-ULCER AGENTS																				
TAP	PREVACID (LANSOPRAZOLE)	30 MG	\$10,236,319	24.4	84,857	22.9	\$120.63	13,061	24.7	\$9,692,856	25.1	84,655	25.1	\$114.50	13,913	28.0	5.6	0.2	5.4	-6.1
KREMERS URBAN	OMEPRAZOLE	20 MG	\$8,286,928	19.8	72,748	19.6	\$113.91	12,092	22.9	\$10,551	0.0	92	0.0	\$114.68	92	0.2	78,442.4	78,973.9	-0.7	13,043.5
ASTRA ZENECA	NEXIUM (ESOMEPRAZOLE)	40 MG	\$7,816,495	18.6	67,354	18.2	\$116.05	11,501	21.8	\$4,358,064	11.3	39,562	11.7	\$110.16	8,122	16.4	79.4	70.2	5.3	41.6
WYETH	PROTONIX (PANTOPRAZOLE)	40 MG	\$6,766,486	16.1	74,366	20.0	\$90.99	14,351	27.1	\$3,798,442	9.8	45,250	13.4	\$83.94	10,063	20.3	78.1	64.3	8.4	42.6
PFIZER	ACIPHEX (RABEPRAZOLE)	20 MG	\$2,840,819	6.8	25,024	6.7	\$113.52	4,065	7.7	\$2,346,681	6.1	22,034	6.5	\$106.50	3,887	7.8	21.1	13.6	6.6	4.6
	ALL OTHER		\$5,989,125	14.3	46,711	12.6	\$128.22	11,586	21.9	\$18,396,410	47.7	145,378	43.1	\$126.54	20,836	42.0	-67.4	-67.9	1.3	-44.4
	TOTAL		\$41,936,173	100.0	371,060	100.0	\$113.02	52,872	100.0	\$38,603,005	100.0	336,971	100.0	\$114.56	49,660	100.0	8.6	10.1	-1.3	6.5
OTHER ANTI-ULCER AGENTS																				
PROCTER & GAMBLE	ASACOL (MESALAMINE)	400 MG	\$631,089	10.8	7,722	6.6	\$81.73	819	4.1	\$561,135	8.5	7,479	5.6	\$75.03	810	3.6	12.5	3.2	8.9	1.1
TEVA	FAMOTIDINE	5 MG	\$569,111	9.7	11,858	10.2	\$47.99	2,272	11.4	\$625,474	9.4	11,616	8.8	\$53.85	2,535	11.2	-9.0	2.1	-10.9	-10.4
PAR	FAMOTIDINE	20 MG	\$461,317	7.9	10,152	8.7	\$45.44	2,068	10.3	\$528,252	8.0	10,581	8.0	\$49.92	2,351	10.4	-12.7	-4.1	-9.0	-12.0
PAR	RANITIDINE	150 MG	\$460,106	7.9	11,734	10.1	\$39.21	2,420	12.1	\$349,490	5.3	8,637	6.5	\$40.46	2,139	9.4	31.7	35.9	-3.1	13.1
APOTEX	RANITIDINE	150 MG	\$343,030	5.9	9,183	7.9	\$37.35	2,070	10.4	\$279,216	4.2	6,929	5.2	\$40.30	1,717	7.6	22.9	32.5	-7.3	20.6
	ALL OTHER		\$3,375,578	57.8	66,062	56.6	\$51.10	13,093	65.5	\$4,293,271	64.7	87,403	65.9	\$49.12	17,122	75.5	-21.4	-24.4	4.0	-23.5
	TOTAL		\$5,840,232	100.0	116,711	100.0	\$50.04	20,000	100.0	\$6,636,837	100.0	132,645	100.0	\$50.03	22,675	100.0	-12.0	-12.0	0.0	-11.8
ANTIDIABETIC AGENTS																				
TAKEDA	ACTOS (PIOGLITAZONE)	30 MG	\$2,640,770	10.0	19,466	3.7	\$135.66	2,849	6.7	\$2,382,683	9.8	18,529	3.5	\$128.59	2,934	6.9	10.8	5.1	5.5	-2.9
TAKEDA	ACTOS (PIOGLITAZONE)	45 MG	\$2,188,684	8.3	14,844	2.8	\$147.45	2,012	4.8	\$1,989,030	8.2	14,098	2.7	\$141.09	1,973	4.6	10.0	5.3	4.5	2.0
GLAXOSMITHKLINE	AVANDIA (ROSIGLITAZONE)	4 MG	\$1,851,680	7.0	21,949	4.1	\$84.36	3,278	7.7	\$1,803,551	7.4	22,272	4.2	\$80.98	3,452	8.1	2.7	-1.5	4.2	-5.0
GLAXOSMITHKLINE	AVANDIA (ROSIGLITAZONE)	8 MG	\$1,784,089	6.8	13,627	2.6	\$130.92	1,909	4.5	\$1,552,243	6.4	12,455	2.4	\$124.63	1,837	4.3	14.9	9.4	5.1	3.9
TAKEDA	ACTOS (PIOGLITAZONE)	15 MG	\$1,029,752	3.9	12,054	2.3	\$85.43	1,987	4.7	\$983,983	4.0	11,908	2.3	\$82.63	2,028	4.8	4.7	1.2	3.4	-2.0
	ALL OTHER		\$16,891,024	64.0	448,809	84.6	\$37.64	40,673	96.1	\$15,627,616	64.2	445,798	84.9	\$35.06	40,927	96.3	8.1	0.7	7.4	-0.6
	TOTAL		\$26,385,999	100.0	530,749	100.0	\$49.71	42,334	100.0	\$24,339,107	100.0	525,060	100.0	\$46.35	42,487	100.0	8.4	1.1	7.2	-0.4

45

TABLE 3.3
ANNUAL CHANGE IN PACE EXPENDITURE AND UTILIZATION FOR HIGH EXPENDITURE THERAPEUTIC CLASSES
2002-2003

MANUFACTURER	PRODUCT	STRENGTH	2003							2002							PERCENT CHANGE: 2002-2003			
			EXPENDITURE	%	CLAIMS	%	COST PER CLAIM	USERS	%	EXPENDITURE	%	CLAIMS	%	COST PER CLAIM	USERS	%	EXPENDITURE	%	CLAIMS	%
OTHER HORMONES AND SYNTHETIC AGENTS																				
GLAXOSMITHKLINE	ADVAIR DISKUS 250/50 (FLUTICASONE/SALMETEROL)	250 MG/50 MG	\$2,427,820	19.2	19,251	3.6	\$126.11	4,719	7.0	\$1,523,656	13.5	12,882	2.3	\$118.28	3,266	4.7	59.3	49.4	6.6	44.5
GLAXOSMITHKLINE	ADVAIR DISKUS 500/50 (FLUTICASONE/SALMETEROL)	500 MG/50 MG	\$1,250,349	9.9	7,153	1.3	\$174.80	1,653	2.5	\$797,944	7.1	4,923	0.9	\$162.08	1,206	1.7	56.7	45.3	7.8	37.1
GLAXOSMITHKLINE	ADVAIR DISKUS 100/50 (FLUTICASONE/SALMETEROL)	100 MG/50 MG	\$1,232,662	9.7	12,413	2.3	\$99.30	3,221	4.8	\$838,728	7.4	8,978	1.6	\$93.42	2,536	3.7	47.0	38.3	6.3	27.0
GLAXOSMITHKLINE	FLOVENT (FLUTICASONE)	0.11 MG	\$789,209	6.2	12,023	2.2	\$65.64	2,854	4.2	\$835,635	7.4	13,392	2.4	\$62.40	3,345	4.8	-5.6	-10.2	5.2	-14.7
GLAXOSMITHKLINE	FLOVENT (FLUTICASONE)	0.22 MG	\$704,547	5.6	6,712	1.2	\$104.97	1,496	2.2	\$775,593	6.9	7,736	1.4	\$100.26	1,846	2.7	-9.2	-13.2	4.7	-19.0
	ALL OTHER		\$6,238,957	49.3	481,950	89.3	\$12.95	61,406	91.4	\$6,542,329	57.8	516,042	91.5	\$12.68	64,254	92.9	-4.6	-6.6	2.1	-4.4
	TOTAL		\$12,643,545	100.0	539,502	100.0	\$23.44	67,174	100.0	\$11,315,426	100.0	564,176	100.0	\$20.06	69,141	100.0	11.7	-4.4	16.8	-2.8
OSTEOPOROSIS DRUGS																				
MERCK	FOSAMAX (ALENDRONATE)	70 MG	\$7,389,492	46.6	128,663	48.4	\$57.43	16,603	47.8	\$6,437,681	45.6	118,107	47.4	\$54.51	16,370	48.5	14.8	8.9	5.4	1.4
ELI LILLY	EVISTA (RALOXIFENE)	60 MG	\$2,731,597	17.2	42,199	15.9	\$64.73	5,395	15.5	\$2,477,469	17.6	40,823	16.4	\$60.69	5,414	16.0	10.3	3.4	6.7	-0.4
NOVARTIS	MIACALCIN (CALCITONIN)	200 IU	\$2,033,799	12.8	32,706	12.3	\$62.18	6,710	19.3	\$2,092,687	14.8	36,895	14.8	\$56.72	7,613	22.6	-2.8	-11.4	9.6	-11.9
PROCTER & GAMBLE	ACTONEL (RISEDRONATE)	35 MG	\$2,000,836	12.6	35,147	13.2	\$56.93	6,141	17.7	\$355,530	2.5	6,509	2.6	\$54.62	2,387	7.1	462.8	440.0	4.2	157.3
MERCK	FOSAMAX (ALENDRONATE)	10 MG	\$637,589	4.0	10,340	3.9	\$61.66	1,498	4.3	\$1,111,872	7.9	19,110	7.7	\$58.18	3,173	9.4	-42.7	-45.9	6.0	-52.8
	ALL OTHER		\$1,065,750	6.7	16,875	6.3	\$63.16	2,637	7.6	\$1,632,643	11.6	27,747	11.1	\$58.84	4,491	13.3	-34.7	-39.2	7.3	-41.3
	TOTAL		\$15,859,063	100.0	265,930	100.0	\$59.64	34,714	100.0	\$14,107,882	100.0	249,191	100.0	\$56.61	33,736	100.0	12.4	6.7	5.3	2.9
ALL OTHER DRUGS																				
PHARMACIA	DETROL LA (TOLTERODINE)	4 MG	\$2,575,964	3.8	33,472	1.5	\$76.96	6,091	3.9	\$1,992,003	3.1	26,607	1.2	\$74.87	5,252	3.3	29.3	25.8	2.8	16.0
MERCK	SINGULAIR (MONTELUKAST)	10 MG	\$2,159,455	3.2	29,209	1.3	\$73.93	4,358	2.8	\$1,774,900	2.7	25,200	1.1	\$70.43	3,688	2.3	21.7	15.9	5.0	18.2
PFIZER	NEURONTIN (GABAPENTIN)	300 MG	\$2,121,653	3.1	25,589	1.2	\$82.91	5,075	3.2	\$1,693,397	2.6	21,594	1.0	\$78.42	4,399	2.7	25.3	18.5	5.7	15.4
AMGEN/IMMUNEX	ENBREL (ETANERCEPT)	25 MG	\$1,537,964	2.3	1,350	0.1	\$1,139.23	173	0.1	\$1,360,621	2.1	1,252	0.1	\$1,086.76	147	0.1	13.0	7.8	4.8	17.7
BOEHRINGER INGELHEIM	FLOMAX (TAMSULOSIN)	0.4 MG	\$1,478,833	2.2	25,989	1.2	\$56.90	4,029	2.6	\$1,185,141	1.8	22,819	1.0	\$51.94	3,742	2.3	24.8	13.9	9.6	7.7
	ALL OTHER		\$57,638,497	85.4	2,062,415	94.7	\$27.95	155,041	98.7	\$56,581,383	87.6	2,096,785	95.6	\$26.98	159,285	98.9	1.9	-1.6	3.6	-2.7
	TOTAL		\$67,512,366	100.0	2,178,024	100.0	\$31.00	157,004	100.0	\$64,587,446	100.0	2,194,257	100.0	\$29.43	160,984	100.0	4.5	-0.7	5.3	-2.5
TOTAL (ALL CATEGORIES)			\$426,604,301	100.0	9,200,996	100.0	\$46.37	196,769	100.0	\$396,221,928	100.0	9,144,923	100.0	\$43.33	202,537	100.0	7.7	0.6	7.0	-2.8

DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT FOR PACE ONLY, EXCLUDING PACENET.

TABLE 3.4
PACE AND PACENET NUMBER AND PERCENT OF EXPENDITURES AND CLAIMS BY MANUFACTURER
JANUARY - DECEMBER 2003

LABELER CODE	MANUFACTURER	RANK BY EXPENDITURE	EXPENDITURE	% OF ALL EXPENDITURES	CLAIMS	% OF ALL CLAIMS
00006	MERCK AND COMPANY	1	\$47,674,641.93	10.08	669,749	6.35
00071	PFIZER, INC.	2	\$27,405,594.52	5.79	431,395	4.09
00378	MYLAN PHARMACEUTICALS, INC.	3	\$18,724,056.51	3.96	910,822	8.63
00093	TEVA PHARMACEUTICAL (LEMMON)	4	\$18,281,067.41	3.86	624,266	5.92
00186	ASTRA ZENECA PHARMACEUTICALS	5	\$17,759,719.95	3.75	311,720	2.95
63653	ER SQUIBB AND SONS, INC.	6	\$15,613,459.05	3.30	156,962	1.49
00025	PHARMACIA CORP.	7	\$15,228,206.91	3.22	185,972	1.76
00069	PFIZER, INC.	8	\$14,183,938.31	3.00	324,995	3.08
00300	TAP PHARMACEUTICALS	9	\$14,137,805.72	2.99	117,920	1.12
00078	NOVARTIS PHARMACEUTICAL CORP.	10	\$14,044,536.60	2.97	223,003	2.11
00002	ELI LILLY AND COMPANY	11	\$12,710,844.96	2.69	153,532	1.46
00173	GLAXOSMITHKLINE	12	\$11,438,434.22	2.42	195,837	1.86
62856	PFIZER, INC.	13	\$10,691,768.53	2.26	89,672	0.85
62175	KREMERS URBAN SCHWARZ PHARMA	14	\$10,154,396.99	2.15	113,739	1.08
00008	WYETH PHARMACEUTICALS	15	\$9,978,228.41	2.11	116,647	1.11
00029	GLAXOSMITHKLINE	16	\$8,950,962.71	1.89	115,174	1.09
50458	JANSSEN PHARMACEUTICALS, INC.	17	\$7,992,513.36	1.69	55,337	0.52
00597	BOEHRINGER INGELHEIM PHARMACEUTICALS	18	\$7,763,359.11	1.64	135,879	1.29
00003	ER SQUIBB AND SONS, INC.	19	\$7,684,975.85	1.62	94,132	0.89
00049	PFIZER, INC.	20	\$7,672,441.64	1.62	166,271	1.58
00781	SANDOZ PHARMACEUTICALS, INC.	21	\$7,127,748.26	1.51	404,078	3.83
64764	TAKEDA PHARMACEUTICALS AMERICA, INC.	22	\$6,564,429.15	1.39	53,114	0.50
00009	PHARMACIA CORP.	23	\$5,898,617.49	1.25	77,460	0.73
00591	WATSON PHARMA, INC.	24	\$5,235,613.66	1.11	254,836	2.42
00087	BRISTOL-MYERS SQUIBB COMPANY	25	\$5,217,355.38	1.10	118,490	1.12
49884	PAR PHARMACEUTICAL INC.	26	\$4,985,937.37	1.05	163,542	1.55
59930	WARRICK PHARMACEUTICALS	27	\$4,707,254.06	1.00	192,363	1.82
00456	FOREST PHARMACEUTICALS, INC.	28	\$4,632,310.52	0.98	111,396	1.06
00310	ASTRA ZENECA PHARMACEUTICALS	29	\$4,574,358.10	0.97	39,535	0.37
00074	ABBOTT LABORATORIES	30	\$4,461,316.52	0.94	198,652	1.88

TABLE 3.4
PACE AND PACENET NUMBER AND PERCENT OF EXPENDITURES AND CLAIMS BY MANUFACTURER
JANUARY - DECEMBER 2003

<u>LABELER CODE</u>	<u>MANUFACTURER</u>	<u>RANK BY EXPENDITURE</u>	<u>EXPENDITURE</u>	<u>% OF ALL EXPENDITURES</u>	<u>CLAIMS</u>	<u>% OF ALL CLAIMS</u>
59676	ORTHO BIOTECH	31	\$4,353,507.38	0.92	4,941	0.05
00555	BARR LABORATORIES, INC.	32	\$4,312,869.65	0.91	186,890	1.77
00088	AVENTIS PHARMACEUTICALS	33	\$4,082,941.47	0.86	64,350	0.61
00149	PROCTER & GAMBLE PHARMACEUTICALS, INC.	34	\$4,014,660.18	0.85	71,469	0.68
00007	GLAXOSMITHKLINE	35	\$4,003,897.89	0.85	49,632	0.47
00083	NOVARTIS PHARMACEUTICALS CORP.	36	\$3,967,787.45	0.84	84,426	0.80
00172	IVAX PHARMACEUTICALS	37	\$3,792,538.16	0.80	224,221	2.13
00228	ALPHARMA/PUREPAC	38	\$3,216,229.83	0.68	113,801	1.08
00045	MCNEIL PHARMACEUTICAL	39	\$2,945,608.77	0.62	43,940	0.42
00085	SCHERING CORPORATION	40	\$2,932,643.80	0.62	48,949	0.46
00013	PHARMACIA CORP.	41	\$2,905,684.80	0.61	66,241	0.63
00023	ALLERGAN INC.	42	\$2,854,895.37	0.60	63,409	0.60
17314	ALZA PHARMACEUTICAL	43	\$2,823,974.33	0.60	34,708	0.33
00024	SANOFI-SYNTHELABO, INC.	44	\$2,818,323.14	0.60	49,918	0.47
00185	EON LABS	45	\$2,646,395.97	0.56	72,837	0.69
59011	PURDUE PHARMA L.P.	46	\$2,514,380.85	0.53	17,771	0.17
61570	MONARCH PHARMACEUTICALS	47	\$2,396,276.70	0.51	56,309	0.53
63304	RANBAXY PHARMACEUTICALS	48	\$2,272,607.35	0.48	78,869	0.75
62037	ANDRX PHARMACEUTICALS, INC.	49	\$2,213,004.35	0.47	59,576	0.56
00026	BAYER CORPORATION, PHARM. DIVISION	50	\$2,181,183.17	0.46	33,907	0.32
			\$414,745,303.81	87.67	8,232,654	78.03

SOURCE: PDA CLAIMS HX

NOTES: DATA INC.LUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT

MANUFACTURER DATA SUMMARIZED BY FIRST FIVE DIGITS OF THE ELEVEN-DIGIT NATIONAL DRUG CODE, i.e., LABELER CODE

**TABLE 3.5
MANUFACTURERS' REBATE CASH RECEIPTS
BY QUARTER BILLED AND BY FISCAL YEAR RECEIVED
JANUARY 1991 - DECEMBER 2003**

QUARTER	FISCAL YEAR												YEAR TO-DATE 03-04	TOTAL
	91-92 RECEIPTS	92-93 RECEIPTS	93-94 RECEIPTS	94-95 RECEIPTS	95-96 RECEIPTS	96-97 RECEIPTS	97-98 RECEIPTS	98-99 RECEIPTS	99-00 RECEIPTS	00-01 RECEIPTS	01-02 RECEIPTS	02-03 RECEIPTS		
JAN-MAR 1991	\$4,324,394	\$8,971	\$84,430	(\$12,717)	\$0	\$0	\$0	\$2,392	(\$0)	\$11,682	(\$18,999)	(\$6,213)	\$11	\$4,393,951
APR-JUN 1991	\$5,369,587	\$12,325	\$82,415	(\$19,532)	\$0	\$0	\$0	\$1,025	\$11,358	\$30,612	\$43,050	(\$1,531)	\$7	\$5,529,317
JUL-SEP 1991	\$6,631,796	\$16,059	\$90,856	(\$51,399)	\$0	\$0	\$0	\$109,081	\$46,999	\$249	(\$13,137)	(\$2,018)	(\$1,484)	\$6,827,002
OCT-DEC 1991	\$5,942,488	\$32,321	\$99,885	(\$80,855)	\$0	\$0	\$0	(\$851)	\$1,274	\$29,028	(\$17,268)	(\$4,940)	(\$572)	\$6,000,511
JAN-MAR 1992	\$5,235,137	\$829,852	\$172,465	(\$95,775)	\$1,004	\$0	\$0	\$111,486	\$53,193	\$1,137	\$22,874	\$29,723	\$756	\$6,361,853
APR-JUN 1992	\$0	\$7,006,889	\$285,825	(\$60,721)	\$534	\$0	\$0	\$125,062	\$346,674	\$398	\$79,182	\$5,365	(\$403)	\$7,788,805
JUL-SEP 1992	\$0	\$7,079,003	\$94,696	(\$83,590)	\$464	\$0	\$0	\$46,120	\$65,813	\$182	\$183,405	(\$12,389)	\$3,717	\$7,377,420
OCT-DEC 1992	\$0	\$7,497,808	\$975,249	(\$14,901)	\$478	\$0	\$55	\$114,050	\$1,267	\$525	\$9,548	\$12,272	\$148	\$8,596,500
JAN-MAR 1993	\$0	\$6,218,258	\$2,034,280	(\$47,762)	\$288	\$0	\$0	\$34,940	\$149	\$5,012	(\$31,131)	\$298,924	(\$45)	\$8,512,913
APR-JUN 1993	\$0	\$0	\$7,782,191	\$16,536	\$277	\$0	\$19,274	\$130,858	\$986	\$169	(\$39,518)	\$7,737	\$452	\$7,918,962
JUL-SEP 1993	\$0	\$0	\$7,587,897	\$110,561	\$353	\$0	\$0	(\$2,079)	\$187	\$2,255	(\$25,317)	\$90,470	\$307	\$7,764,633
OCT-DEC 1993	\$0	\$0	\$7,664,556	\$160,370	\$263	\$0	\$155	(\$5,144)	\$1,555	\$489	(\$24,055)	\$4,859	\$4,948	\$7,807,996
JAN-MAR 1994	\$0	\$0	\$5,471,410	\$1,449,919	\$213	\$0	(\$26)	\$13,585	(\$964)	\$410	\$15,745	(\$89)	\$218	\$6,950,421
APR-JUN 1994	\$0	\$0	\$0	\$7,699,352	\$225	\$0	\$75	\$10,229	(\$6,843)	\$276	(\$30,317)	\$527	\$2,084	\$7,675,607
JUL-SEP 1994	\$0	\$0	\$0	\$8,036,879	\$779	\$0	\$16,030	(\$4,271)	(\$7,401)	\$533	(\$28,512)	\$15,482	\$665	\$8,030,184
OCT-DEC 1994	\$0	\$0	\$0	\$7,993,747	\$8,265	\$0	\$10,268	\$13,993	\$1,021	\$225	(\$9,929)	(\$8,542)	\$902	\$8,009,950
JAN-MAR 1995	\$0	\$0	\$0	\$7,382,094	\$932,029	\$0	\$11,804	(\$15,320)	(\$1,354)	\$114	\$35,762	(\$32,018)	\$112	\$8,313,223
APR-JUN 1995	\$0	\$0	\$0	\$0	\$8,322,779	\$1,987	\$9,429	\$27,159	\$3,522	\$368	(\$53,039)	(\$44,407)	\$18,632	\$8,286,430
JUL-SEP 1995	\$0	\$0	\$0	\$0	\$7,993,338	\$67,026	(\$350)	\$6,388	\$7,013	\$233	\$56,908	(\$12,621)	\$46,248	\$8,164,184
OCT-DEC 1995	\$0	\$0	\$0	\$0	\$7,649,418	\$183,312	\$14,395	\$13,304	\$2,106	\$234	\$1,094	(\$11,279)	\$25,901	\$7,878,484
JAN-MAR 1996	\$0	\$0	\$0	\$0	\$5,821,513	\$2,626,379	\$291	\$36,802	\$17,083	\$91	(\$36,095)	\$800	\$43,080	\$8,509,944
APR-JUN 1996	\$0	\$0	\$0	\$0	\$0	\$7,527,637	(\$656)	\$14,153	(\$25,125)	(\$8,703)	(\$38,497)	(\$3,683)	(\$1,201)	\$7,463,924
JUL-SEP 1996	\$0	\$0	\$0	\$0	\$0	\$7,613,882	\$89	\$12,152	\$12,120	(\$3,270)	(\$52,841)	(\$40,879)	\$1,278	\$7,542,531
OCT-DEC 1996	\$0	\$0	\$0	\$0	\$0	\$7,681,732	\$75,477	\$15,934	(\$40,794)	(\$9,169)	(\$62,031)	\$293	\$1,508	\$7,662,950
JAN-MAR 1997	\$0	\$0	\$0	\$0	\$0	\$868,074	\$8,018,098	\$128,258	(\$1,849)	(\$229)	\$30,734	\$1,784	\$2,368	\$9,047,238
APR-JUN 1997	\$0	\$0	\$0	\$0	\$0	\$0	\$9,171,090	\$120,303	\$12,959	\$94,749	(\$21,113)	\$80,104	\$2,076	\$9,460,167
JUL-SEP 1997	\$0	\$0	\$0	\$0	\$0	\$0	\$9,675,141	\$60,132	\$18,536	\$94,608	\$14,027	(\$9,043)	\$10,831	\$9,864,231
OCT-DEC 1997	\$0	\$0	\$0	\$0	\$0	\$0	\$10,244,315	\$54,403	(\$6,797)	\$107,450	\$7,410	(\$7,857)	\$15,052	\$10,413,976
JAN-MAR 1998	\$0	\$0	\$0	\$0	\$0	\$0	\$9,526,971	\$1,053,017	\$435,746	\$26,792	\$136,638	(\$7,449)	\$7,670	\$11,179,385
APR-JUN 1998	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$11,094,589	\$910,370	\$23,357	\$191,819	\$521	(\$11,722)	\$12,208,934
JUL-SEP 1998	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$11,153,380	\$1,030,933	\$30,427	\$116,555	\$24,704	(\$1,479)	\$12,354,520
OCT-DEC 1998	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$11,763,310	\$1,235,255	\$16,086	\$117,070	\$13,636	(\$3,640)	\$13,141,716
JAN-MAR 1999	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$8,765,506	\$4,244,691	\$353,858	\$32,543	(\$21,584)	(\$6,415)	\$13,368,600
APR-JUN 1999	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,715,085	\$63,722	(\$295,190)	\$27,517	(\$14,738)	\$12,496,397
JUL-SEP 1999	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,382,637	\$191,084	\$202,452	(\$44,852)	(\$15,330)	\$12,715,992
OCT-DEC 1999	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,926,889	\$488,664	\$81,137	(\$127,365)	\$132,252	\$13,501,577
JAN-MAR 2000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$7,924,800	\$5,324,979	\$486,367	(\$229,072)	(\$107,416)	\$13,399,657
APR-JUN 2000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$14,508,638	\$3,103,715	(\$459,782)	(\$70,737)	\$17,081,834
JUL-SEP 2000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$13,462,608	\$144,681	(\$112,875)	(\$84,454)	\$13,409,960
OCT-DEC 2000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$13,899,384	\$2,630	\$354,138	(\$188,328)	\$14,067,824
JAN-MAR 2001	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,126,291	\$2,720,271	\$230,133	(\$132,992)	\$14,943,702
APR-JUN 2001	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$12,532,229	\$115,002	\$12,666,741	\$15,823,873
JUL-SEP 2001	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$15,801,482	\$64,542	(\$42,150)	\$15,823,873
OCT-DEC 2001	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$14,759,173	\$879,004	(\$199,040)	\$15,439,136
JAN-MAR 2002	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$10,339,259	\$6,722,006	(\$159,590)	\$16,901,675
APR-JUN 2002	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$18,103,859	\$44,341	\$18,148,199
JUL-SEP 2002	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$18,496,229	\$145,249	\$18,641,477
OCT-DEC 2002	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$17,508,607	\$624,960	\$18,133,567
JAN-MAR 2003	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$5,050,874	\$13,415,934	\$18,466,808
APR-JUN 2003	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$18,878,539	\$18,878,539
JUL-SEP 2003	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$16,805,768	\$16,805,768
TOTAL	\$27,503,402	\$28,701,486	\$32,426,155	\$32,382,209	\$30,732,220	\$26,570,030	\$46,791,924	\$45,003,946	\$54,319,094	\$60,875,546	\$60,470,770	\$66,938,621	\$49,213,787	\$561,929,191

SOURCE: PDA CHECK RECEIPTS AS REPORTED ON STATE STATUS REPORT FOR WEEK ENDING JANUARY 2, 2004.

SECTION 4

**CARDHOLDER
UTILIZATION
DATA**

**TABLE 4.1
PACE AND PACENET CARDHOLDER ENROLLMENTS BY QUARTER**

PACE

		JULY 1984 - JUNE 1988		
	<u>QUARTER</u>	<u>NEWLY ENROLLED *</u>	<u>% OF NEWLY ENROLLED</u>	<u>CUMULATIVE ENROLLMENTS</u>
FIRST	JUL-SEP 1984	273,001	100.0	273,001
PROGRAM	OCT-DEC 1984	23,561	7.9	296,562
YEAR	JAN-MAR 1985	20,941	6.6	317,503
	APR-JUN 1985	69,436	17.9	386,939
SECOND	JUL-SEP 1985	38,750	10.0	389,177
PROGRAM	OCT-DEC 1985	20,522	5.0	409,699
YEAR	JAN-MAR 1986	18,770	4.4	428,469
	APR-JUN 1986	17,367	3.9	445,836
THIRD	JUL-SEP 1986	23,595	5.6	420,776
PROGRAM	OCT-DEC 1986	14,982	3.4	435,758
YEAR	JAN-MAR 1987	18,130	4.0	453,888
	APR-JUN 1987	18,853	4.0	472,741
FOURTH	JUL-SEP 1987	26,133	5.9	439,967
PROGRAM	OCT-DEC 1987	10,432	2.3	450,399
YEAR	JAN-MAR 1988	13,429	2.9	463,828
	APR-JUN 1988	13,944	2.9	477,772

PACE

		JULY 1988 - JUNE 1996		
	<u>QUARTER</u>	<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER**</u>
FIFTH	JUL-SEP 1988	15,990	3.6	443,518
PROGRAM	OCT-DEC 1988	26,069	5.7	454,428
YEAR	JAN-MAR 1989	41,866	9.1	460,232
	APR-JUN 1989	57,406	12.7	451,547
SIXTH	JUL-SEP 1989	9,847	2.2	438,834
PROGRAM	OCT-DEC 1989	17,787	4.2	426,822
YEAR	JAN-MAR 1990	30,278	7.1	424,120
	APR-JUN 1990	40,169	9.8	408,493
SEVENTH	JUL-SEP 1990	6,714	1.7	394,821
PROGRAM	OCT-DEC 1990	26,742	6.9	384,854
YEAR	JAN-MAR 1991	37,239	9.7	383,792
	APR-JUN 1991	46,020	12.4	371,592
EIGHTH	JUL-SEP 1991	8,657	2.3	370,654
PROGRAM	OCT-DEC 1991	17,529	4.7	373,365
YEAR	JAN-MAR 1992	31,581	8.4	375,697
	APR-JUN 1992	44,986	12.2	369,919
NINTH	JUL-SEP 1992	7,115	2.0	355,319
PROGRAM	OCT-DEC 1992	13,436	3.9	347,371
YEAR	JAN-MAR 1993	29,556	8.4	353,309
	APR-JUN 1993	41,397	12.1	341,361
TENTH	JUL-SEP 1993	6,658	2.0	334,757
PROGRAM	OCT-DEC 1993	11,519	3.5	331,338
YEAR	JAN-MAR 1994	20,162	6.2	324,160
	APR-JUN 1994	33,967	10.4	325,090
ELEVENTH	JUL-SEP 1994	7,091	2.3	312,413
PROGRAM	OCT-DEC 1994	11,167	3.6	307,231
YEAR	JAN-MAR 1995	22,732	7.3	311,450
	APR-JUN 1995	31,995	10.5	304,153
TWELFTH	JUL-SEP 1995	5,382	1.8	298,732
PROGRAM	OCT-DEC 1995	8,278	2.9	289,919
YEAR	JAN-MAR 1996	16,146	5.6	290,460
	APR-JUN 1996	22,518	8.1	279,397

**TABLE 4.1
PACE AND PACENET CARDHOLDER ENROLLMENTS BY QUARTER
JULY 1996 - DECEMBER 2003**

		<u>PACE</u>			<u>PACENET</u>		
<u>QUARTER</u>		<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER**</u>	<u>CUMULATIVE NEWLY ENROLLED</u>	<u>% OF NEWLY ENROLLED</u>	<u>ENROLLMENT AT END OF QUARTER</u>
THIRTEENTH	JUL-SEP 1996	4,127	1.5	267,049			
PROGRAM	OCT-DEC 1996	9,332	3.6	260,678	1,523	100.0	1,523
YEAR	JAN-MAR 1997	23,797	8.6	275,607	5,771	100.0	5,771
	APR-JUN 1997	30,602	11.6	264,414	9,088	100.0	9,088
FOURTEENTH	JUL-SEP 1997	4,536	1.8	257,291	1,949	17.7	11,037
PROGRAM	OCT-DEC 1997	8,694	3.5	250,671	3,801	29.5	12,889
YEAR	JAN-MAR 1998	16,693	6.6	251,915	5,710	48.5	11,771
	APR-JUN 1998	22,838	9.3	245,553	7,419	53.8	13,802
FIFTEENTH	JUL-SEP 1998	4,375	1.8	237,753	879	5.8	15,213
PROGRAM	OCT-DEC 1998	8,042	3.5	230,722	1,504	9.4	15,964
YEAR	JAN-MAR 1999	14,744	6.4	231,049	3,216	19.9	16,164
	APR-JUN 1999	20,672	9.1	227,041	4,722	27.2	17,372
SIXTEENTH	JUL-SEP 1999	4,086	1.8	221,535	761	4.2	18,195
PROGRAM	OCT-DEC 1999	7,981	3.7	217,103	1,510	8.1	18,655
YEAR	JAN-MAR 2000	18,146	8.2	220,896	4,169	21.6	19,298
	APR-JUN 2000	25,583	11.8	217,140	6,125	30.1	20,375
SEVENTEENTH	JUL-SEP 2000	5,061	2.4	213,041	1,032	4.9	21,223
PROGRAM	OCT-DEC 2000	10,283	4.9	208,227	2,034	9.3	21,781
YEAR	JAN-MAR 2001	19,041	9.1	208,299	4,610	20.8	22,167
	APR-JUN 2001	24,932	12.0	207,193	6,603	28.9	22,875
EIGHTEENTH	JUL-SEP 2001	3,877	1.9	204,839	1,710	6.9	24,929
PROGRAM	OCT-DEC 2001	7,907	4.0	199,898	3,132	12.1	25,873
YEAR	JAN-MAR 2002	16,319	8.2	199,719	6,931	23.3	29,692
	APR-JUN 2002	22,742	11.4	198,629	9,938	32.7	30,346
NINETEENTH	JUL-SEP 2002	3,490	1.8	191,935	1,378	4.6	29,980
PROGRAM	OCT-DEC 2002	6,925	3.7	188,566	2,476	8.2	30,356
YEAR	JAN-MAR 2003	13,384	7.0	190,697	5,516	17.5	31,464
	APR-JUN 2003	21,287	10.9	194,961	9,654	29.7	32,520
TWENTIETH	JUL-SEP 2003	4,467	2.4	187,914	2,299	6.8	33,855
PROGRAM	OCT-DEC 2003	8,106	4.4	185,143	3,737	10.9	34,314
YEAR							

* THE NEWLY ENROLLED NUMBER IS CALCULATED AS A TOTAL FOR THE QUARTER.

** ENROLLMENT AT END OF QUARTER REPRESENTS THE ENROLLMENT REPORTED ON THE LAST DAY OF THE QUARTER (I.E., 185,143 PACE CARDHOLDERS AND 34,314 PACENET CARDHOLDERS ON THE FILE ON DECEMBER 31, 2003).

SOURCE: PDA/MR-0-01A/CARDHOLDER FILE

TABLE 4.2A
PACE CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES
BY DEMOGRAPHIC CHARACTERISTICS
JANUARY - DECEMBER 2003

	<u>TOTAL ENROLLED CARDHOLDERS</u>	<u>TOTAL PARTICIPATING CARDHOLDERS</u>	<u>TOTAL CLAIMS</u>	<u>PERCENT OF TOTAL CLAIMS</u>	<u>CLAIMS PER PARTICIPATING CARDHOLDER</u>	<u>TOTAL EXPENDITURES</u>	<u>STATE SHARE PER PARTICIPATING CARDHOLDER</u>	<u>PERCENT OF ALL EXPENDITURES</u>
TOTAL	220,794	196,243	9,235,835	100.0	47.1	\$429,616,507	\$2,189.21	100.0
SEX								
FEMALE	178,245	161,002	7,781,345	84.3	48.3	\$360,239,460	\$2,237.48	83.9
MALE	42,549	35,241	1,454,490	15.7	41.3	\$69,377,047	\$1,968.65	16.1
AGE								
65-69 YEARS	28,788	24,946	995,955	10.8	39.9	\$49,481,134	\$1,983.53	11.5
70-74 YEARS	39,117	35,036	1,645,233	17.8	47.0	\$80,558,029	\$2,299.29	18.8
75-79 YEARS	50,691	45,844	2,237,554	24.2	48.8	\$105,531,741	\$2,301.97	24.6
80-84 YEARS	49,618	44,767	2,208,526	23.9	49.3	\$101,088,111	\$2,258.09	23.5
85 YEARS OR OVER	52,580	45,650	2,148,567	23.3	47.1	\$92,957,491	\$2,036.31	21.6
RESIDENCE TYPE								
OWN	109,817	98,741	4,418,643	47.8	44.7	\$203,765,325	\$2,063.63	47.4
RENT	61,456	55,266	2,653,620	28.7	48.0	\$122,956,842	\$2,224.82	28.6
NURSING HOME/ PERSONAL CARE HOME	10,171	8,523	504,394	5.5	59.2	\$24,829,641	\$2,913.25	5.8
LIVE WITH RELATIVE	20,825	19,230	982,890	10.6	51.1	\$45,973,056	\$2,390.69	10.7
OTHER	14,498	12,531	619,538	6.7	49.4	\$29,516,530	\$2,355.48	6.9
MISSING	4,027	1,952	56,750	0.6	29.1	\$2,575,113	\$1,319.22	0.6
MARITAL STATUS								
SINGLE OR WIDOWED	172,090	153,257	7,354,625	79.6	48.0	\$339,128,848	\$2,212.81	78.9
MARRIED	28,876	25,380	1,092,091	11.8	43.0	\$52,170,586	\$2,055.58	12.1
DIVORCED	14,941	13,326	596,455	6.5	44.8	\$29,049,142	\$2,179.88	6.8
MARRIED, LIVING SEPARATELY	4,887	4,280	192,664	2.1	45.0	\$9,267,932	\$2,165.40	2.2

TABLE 4.2A
PACE CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES
BY DEMOGRAPHIC CHARACTERISTICS
JANUARY - DECEMBER 2003

	<u>TOTAL ENROLLED CARDHOLDERS</u>	<u>TOTAL PARTICIPATING CARDHOLDERS</u>	<u>TOTAL CLAIMS</u>	<u>PERCENT OF TOTAL CLAIMS</u>	<u>CLAIMS PER PARTICIPATING CARDHOLDER</u>	<u>TOTAL EXPENDITURES</u>	<u>STATE SHARE PER PARTICIPATING CARDHOLDER</u>	<u>PERCENT OF ALL EXPENDITURES</u>
ETHNIC ORIGIN								
WHITE	196,797	176,824	8,508,135	92.1	48.1	\$395,857,006	\$2,238.71	92.1
AFRICAN-AMERICAN	16,956	14,888	576,200	6.2	38.7	\$26,516,248	\$1,781.05	6.2
AMERICAN INDIAN	190	171	7,797	0.1	45.6	\$382,860	\$2,238.95	0.1
HISPANIC	1,505	1,334	49,323	0.5	37.0	\$2,354,398	\$1,764.92	0.5
ASIAN	612	524	16,516	0.2	31.5	\$836,168	\$1,595.74	0.2
OTHER	403	352	13,400	0.1	38.1	\$663,708	\$1,885.53	0.2
MISSING	4,331	2,150	64,464	0.7	30.0	\$3,006,118	\$1,398.19	0.7
INCOME - SINGLE								
\$0-\$2,999	1,539	1,157	49,665	0.5	42.9	\$2,408,497	\$2,081.67	0.6
\$3,000-\$5,999	8,687	7,473	344,138	3.7	46.1	\$16,380,277	\$2,191.93	3.8
\$6,000-\$8,999	34,853	29,766	1,334,329	14.4	44.8	\$61,269,158	\$2,058.36	14.3
\$9,000-\$11,999	84,116	74,706	3,622,907	39.2	48.5	\$167,339,563	\$2,239.97	39.0
\$12,000-\$14,000	51,668	47,420	2,326,321	25.2	49.1	\$108,249,181	\$2,282.77	25.2
MORATORIUM	11,055	10,341	466,384	5.0	45.1	\$21,799,246	\$2,108.04	5.1
INCOME - MARRIED								
\$0-\$2,999	61	45	1,432	0.0	31.8	\$65,341	\$1,452.02	0.0
\$3,000-\$5,999	169	147	5,323	0.1	36.2	\$237,446	\$1,615.28	0.1
\$6,000-\$8,999	577	480	17,882	0.2	37.3	\$870,235	\$1,812.99	0.2
\$9,000-\$11,999	2,311	1,958	76,882	0.8	39.3	\$3,618,030	\$1,847.82	0.8
\$12,000-\$14,999	8,671	7,515	320,189	3.5	42.6	\$15,458,146	\$2,056.97	3.6
\$15,000-\$17,200	12,107	10,700	471,572	5.1	44.1	\$22,503,501	\$2,103.13	5.2
MORATORIUM	4,980	4,535	198,811	2.2	43.8	\$9,417,886	\$2,076.71	2.2

SOURCE: PDA/CLAIMS HX, CARDHOLDER FILE

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS

TABLE 4.2B
PACENET CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES
BY DEMOGRAPHIC CHARACTERISTICS
JANUARY - DECEMBER 2003

	TOTAL ENROLLED CARDHOLDERS	TOTAL PARTICIPATING CARDHOLDERS	TOTAL CLAIMS	% OF TOTAL CLAIMS	CLAIMS PER PARTI- CIPANT	TOTAL EXPENDITURES	TOTAL CARDHOLDER EXPENDITURES	CARDHOLDER SHARE (%) OF TOTAL EXPENDITURES	STATE SHARE EXPEN- TURES	STATE SHARE (%) OF TOTAL EXPEN- TURES	STATE SHARE PER PARTICIPATING CARDHOLDER	% OF STATE SHARE EXPEN- TURES
TOTAL	46,880	37,860	1,365,487	100.0	36.1	\$75,629,471	\$28,348,647	37.5	\$47,280,823	62.5	\$1,248.83	100.0
SEX												
FEMALE	34,971	29,207	1,088,277	79.7	37.3	\$60,356,355	\$22,540,914	37.3	\$37,815,441	62.7	\$1,294.74	80.0
MALE	11,909	8,653	277,210	20.3	32.0	\$15,273,116	\$5,807,734	38.0	\$9,465,382	62.0	\$1,093.88	20.0
AGE												
65-69 YEARS	6,926	5,046	156,191	11.4	31.0	\$8,997,289	\$3,404,561	37.8	\$5,592,728	62.2	\$1,108.35	11.8
70-74 YEARS	9,323	7,377	259,864	19.0	35.2	\$14,770,644	\$5,494,899	37.2	\$9,275,746	62.8	\$1,257.39	19.6
75-79 YEARS	11,387	9,182	334,070	24.5	36.4	\$18,656,243	\$7,001,276	37.5	\$11,654,967	62.5	\$1,269.33	24.7
80-84 YEARS	10,431	8,728	331,766	24.3	38.0	\$18,139,944	\$6,796,220	37.5	\$11,343,724	62.5	\$1,299.69	24.0
85 YEARS OR OVER	8,813	7,527	283,596	20.8	37.7	\$15,065,350	\$5,651,691	37.5	\$9,413,659	62.5	\$1,250.65	19.9
RESIDENCE TYPE												
OWN	27,763	22,015	748,682	54.8	34.0	\$40,840,187	\$15,779,851	38.6	\$25,060,336	61.4	\$1,138.33	53.0
RENT	10,742	8,787	322,202	23.6	36.7	\$17,671,310	\$6,609,714	37.4	\$11,061,596	62.6	\$1,258.86	23.4
NURSING HOME/ PERSONAL CARE HOME	2,772	2,362	113,037	8.3	47.9	\$6,769,209	\$2,197,726	32.5	\$4,571,482	67.5	\$1,935.43	9.7
LIVE WITH RELATIVE	3,303	2,819	116,005	8.5	41.2	\$6,728,743	\$2,383,948	35.4	\$4,344,794	64.6	\$1,541.25	9.2
OTHER	1,750	1,474	54,779	4.0	37.2	\$3,036,501	\$1,116,055	36.8	\$1,920,446	63.2	\$1,302.88	4.1
MISSING	550	403	10,782	0.8	26.8	\$583,523	\$261,353	44.8	\$322,169	55.2	\$799.43	0.7
MARITAL STATUS												
SINGLE OR WIDOWED	30,521	25,593	950,391	69.6	37.1	\$52,780,969	\$19,638,108	37.2	\$33,142,862	62.8	\$1,295.00	70.1
MARRIED	13,181	9,756	332,533	24.4	34.1	\$18,138,123	\$6,932,348	38.2	\$11,205,774	61.8	\$1,148.60	23.7
DIVORCED	2,542	2,043	68,763	5.0	33.7	\$3,917,163	\$1,479,741	37.8	\$2,437,422	62.2	\$1,193.06	5.2
MARRIED, LIVING SEPARATELY	636	468	13,800	1.0	29.5	\$793,215	\$298,450	37.6	\$494,765	62.4	\$1,057.19	1.0
ETHNIC ORIGIN												
WHITE	43,299	35,280	1,295,262	94.9	36.7	\$71,815,990	\$26,748,321	37.2	\$45,067,669	62.8	\$1,277.43	95.3
AFRICAN-AMERICAN	2,297	1,704	45,619	3.3	26.8	\$2,465,986	\$1,030,064	41.8	\$1,435,923	58.2	\$842.68	3.0
AMERICAN INDIAN	24	17	472	0.0	27.8	\$25,515	\$10,484	41.1	\$15,031	58.9	\$884.15	0.0
HISPANIC	243	170	4,307	0.3	25.3	\$238,931	\$100,167	41.9	\$138,764	58.1	\$816.26	0.3
ASIAN	76	50	1,534	0.1	30.7	\$83,951	\$33,001	39.3	\$50,950	60.7	\$1,019.00	0.1
OTHER	72	51	1,724	0.1	33.8	\$98,812	\$34,909	35.3	\$63,904	64.7	\$1,253.01	0.1
MISSING	869	588	16,569	1.2	28.2	\$900,286	\$391,701	43.5	\$508,585	56.5	\$864.94	1.1

TABLE 4.2B
PACENET CARDHOLDER ENROLLMENT, PARTICIPATION, UTILIZATION, AND EXPENDITURES
BY DEMOGRAPHIC CHARACTERISTICS
JANUARY - DECEMBER 2003


	<u>TOTAL</u> <u>ENROLLED</u> <u>CARDHOLDERS</u>	<u>TOTAL</u> <u>PARTICIPATING</u> <u>CARDHOLDERS</u>	<u>TOTAL</u> <u>CLAIMS</u>	<u>% OF</u> <u>TOTAL</u> <u>CLAIMS</u>	<u>CLAIMS</u> <u>PER</u> <u>PARTI-</u> <u>CIPANT</u>	<u>TOTAL</u> <u>EXPENDITURES</u>	<u>TOTAL</u> <u>CARDHOLDER</u> <u>EXPENDITURES</u>	<u>CARDHOLDER</u> <u>SHARE (%)</u> <u>OF TOTAL</u> <u>EXPENDITURES</u>	<u>STATE</u> <u>SHARE</u> <u>EXPENDI-</u> <u>TURES</u>	<u>STATE</u> <u>SHARE (%)</u> <u>OF TOTAL</u> <u>EXPENDI-</u> <u>TURES</u>	<u>STATE SHARE</u> <u>PER</u> <u>PARTICIPATING</u> <u>CARDHOLDER</u>	<u>% OF</u> <u>STATE</u> <u>SHARE</u> <u>EXPENDI-</u> <u>TURES</u>
INCOME - SINGLE												
\$14,001 - \$17,000	31,658	26,352	961,739	70.4	36.5	\$53,482,737	\$19,984,368	37.4	\$33,498,369	62.6	\$1,271.19	70.8
MORATORIUM	2,041	1,752	71,215	5.2	40.6	\$4,008,611	\$1,431,931	35.7	\$2,576,680	64.3	\$1,470.71	5.4
INCOME - MARRIED												
\$17,201 - \$20,200	12,174	8,976	303,298	22.2	33.8	\$16,491,110	\$6,342,665	38.5	\$10,148,445	61.5	\$1,130.62	21.5
MORATORIUM	1,007	780	29,235	2.1	37.5	\$1,647,012	\$589,683	35.8	\$1,057,329	64.2	\$1,355.55	2.2

SOURCE: PDA/CLAIMS HX, CARDHOLDER FILE


NOTE: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF SERVICE. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.

**FIGURE 4.1
 PERCENT OF ENROLLED PACE CARDHOLDERS
 BY INCOME AND MARITAL STATUS
 JANUARY - DECEMBER 2003
 (TOTAL N = 220,794)**

**SINGLE
 N=191,918**



**MARRIED
 N=28,876**



SOURCE: PDA/CLAIMS HX, CARDHOLDER FILE


TABLE 4.3
OTHER PRESCRIPTION INSURANCE COVERAGE OF PACE AND PACENET ENROLLED CARDHOLDERS
JANUARY - DECEMBER 2003

A. PACE	PACE ENROLLED CARDHOLDERS		PACE CLAIMS		STATE SHARE EXPENDITURES	
	<u>NUMBER</u>	<u>% OF TOTAL</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER ENROLLED CARDHOLDER</u>	<u>TOTAL STATE SHARE EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>
OTHER PRESCRIPTION COVERAGE IDENTIFIED	50,635	22.9%	2,169,504	42.8	\$99,092,115	\$1,956.99
BASED ON MATCH WITH CARRIER	24,223	11.0%	963,258	39.8	\$42,375,960	\$1,749.41
BASED ON CARDHOLDER SELF-REPORT	26,412	12.0%	1,206,246	45.7	\$56,716,154	\$2,147.36
NO OTHER KNOWN PRESCRIPTION COVERAGE	170,159	77.1%	7,066,331	41.5	\$330,524,393	\$1,942.44
TOTAL PACE ENROLLED	220,794	100.0%	9,235,835	41.8	\$429,616,507	\$1,945.78
B. PACENET	PACENET ENROLLED CARDHOLDERS		PACENET CLAIMS		STATE SHARE EXPENDITURES	
	<u>NUMBER</u>	<u>% OF TOTAL</u>	<u>TOTAL CLAIMS</u>	<u>CLAIMS PER ENROLLED CARDHOLDER</u>	<u>TOTAL STATE SHARE EXPENDITURES</u>	<u>EXPENDITURES PER ENROLLED CARDHOLDER</u>
OTHER PRESCRIPTION COVERAGE IDENTIFIED	11,253	24.0%	314,845	28.0	\$10,638,383	\$945.38
BASED ON MATCH WITH CARRIER	6,463	13.8%	158,217	24.5	\$4,975,502	\$769.84
BASED ON CARDHOLDER SELF-REPORT	4,790	10.2%	156,628	32.7	\$5,662,881	\$1,182.23
NO OTHER KNOWN PRESCRIPTION COVERAGE	35,627	76.0%	1,050,642	29.5	\$36,642,440	\$1,028.50
TOTAL PACENET ENROLLED	46,880	100.0%	1,365,487	29.1	\$47,280,823	\$1,008.55

SOURCE: PDA/CARDHOLDER FILE, CLAIMS HISTORY

NOTES: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE. SOME CARDHOLDERS WERE ENROLLED IN BOTH PROGRAMS FOR SOME PORTION OF THE YEAR. NOT ALL CARDHOLDERS WITH IDENTIFIED R_x INSURANCE HAD ACTIVE THIRD PARTY COVERAGE FOR DRUGS REIMBURSED BY PACE AT THE TIME OF DISPENSING.

**FIGURE 4.2
PACE GENERIC UTILIZATION RATES BY QUARTER
DECEMBER 1988 - DECEMBER 2003**



SOURCE: PDA/MONTHLY COST CONTAINMENT REPORT

SECTION 5

COUNTY DATA

TABLE 5.1
NUMBER AND PERCENT OF PACE AND PACENET CARDHOLDERS
AND NUMBER OF PROVIDERS BY COUNTY
JANUARY - DECEMBER 2003

<u>COUNTY</u>	<u>NUMBER OF PACE ENROLLED CARDHOLDERS</u>	<u>NUMBER OF PACENET ENROLLED CARDHOLDERS</u>	<u>TOTAL NUMBER ENROLLED*</u>	<u>% OF TOTAL</u>	<u>NUMBER OF PARTICIPATING CARDHOLDERS</u>	<u>NUMBER OF PROVIDERS</u>	<u>TYPE OF COUNTY</u>	<u>STATE SHARE</u>
ADAMS	1,368	359	1,620	0.6	1,444	17	RURAL	\$3,016,530
ALLEGHENY	21,907	3,907	24,982	9.7	21,572	301	ALLEGHENY	\$45,516,449
ARMSTRONG	1,368	241	1,556	0.6	1,324	18	RURAL	\$2,914,456
BEAVER	3,449	705	3,983	1.5	3,538	43	URBAN	\$7,855,165
BEDFORD	1,442	288	1,659	0.6	1,452	15	RURAL	\$3,424,433
BERKS	5,542	1,573	6,823	2.7	6,007	58	SUBURBAN	\$12,028,434
BLAIR	3,273	745	3,833	1.5	3,376	40	SUBURBAN	\$7,638,155
BRADFORD	1,494	359	1,786	0.7	1,556	18	RURAL	\$3,360,636
BUCKS	5,298	1,298	6,322	2.5	5,580	115	URBAN	\$12,952,988
BUTLER	2,505	479	2,868	1.1	2,500	30	SEMIRURAL	\$5,679,286
CAMBRIA	3,906	692	4,430	1.7	3,888	42	SUBURBAN	\$8,022,680
CAMERON	131	27	154	0.1	136	2	SEMIRURAL	\$274,647
CARBON	1,818	473	2,187	0.8	1,925	16	SUBURBAN	\$4,088,041
CENTRE	1,431	339	1,703	0.7	1,491	32	SUBURBAN	\$3,017,983
CHESTER	3,081	724	3,656	1.4	3,202	84	SUBURBAN	\$6,645,508
CLARION	962	245	1,150	0.4	996	14	RURAL	\$2,320,949
CLEARFIELD	2,212	528	2,637	1.0	2,343	19	RURAL	\$5,222,770
CLINTON	1,060	267	1,274	0.5	1,133	8	SEMIRURAL	\$2,263,463
COLUMBIA	2,017	491	2,418	0.9	2,162	16	SEMIRURAL	\$4,337,019
CRAWFORD	1,936	468	2,294	0.9	2,020	17	RURAL	\$4,241,035
CUMBERLAND	2,541	678	3,068	1.2	2,753	50	SUBURBAN	\$6,227,755
DAUPHIN	2,882	733	3,473	1.3	3,034	55	URBAN	\$6,201,159
DELAWARE	6,383	1,322	7,440	2.9	6,473	130	URBAN	\$12,891,426
ELK	760	249	948	0.4	839	9	SEMIRURAL	\$1,831,599
ERIE	4,836	1,132	5,724	2.2	5,012	64	URBAN	\$10,601,900

TABLE 5.1
NUMBER AND PERCENT OF PACE AND PACENET CARDHOLDERS
AND NUMBER OF PROVIDERS BY COUNTY
JANUARY - DECEMBER 2003

<u>COUNTY</u>	<u>NUMBER OF PACE ENROLLED CARDHOLDERS</u>	<u>NUMBER OF PACENET ENROLLED CARDHOLDERS</u>	<u>TOTAL NUMBER ENROLLED*</u>	<u>% OF TOTAL</u>	<u>NUMBER OF PARTICIPATING CARDHOLDERS</u>	<u>NUMBER OF PROVIDERS</u>	<u>TYPE OF COUNTY</u>	<u>STATE SHARE</u>
FAYETTE	3,867	626	4,356	1.7	3,822	42	SEMIRURAL	\$8,151,960
FOREST	169	36	193	0.1	168	2	RURAL	\$401,040
FRANKLIN	1,925	497	2,311	0.9	2,028	20	SEMIRURAL	\$4,537,503
FULTON	314	70	361	0.1	312	3	RURAL	\$693,516
GREENE	752	115	847	0.3	745	8	RURAL	\$1,583,887
HUNTINGDON	1,058	215	1,217	0.5	1,069	8	RURAL	\$2,355,630
INDIANA	1,547	293	1,765	0.7	1,545	21	RURAL	\$3,663,648
JEFFERSON	1,356	342	1,608	0.6	1,440	11	SEMIRURAL	\$3,138,889
JUNIATA	503	135	603	0.2	542	5	RURAL	\$1,299,549
LACKAWANNA	7,808	1,527	9,028	3.5	8,052	74	URBAN	\$17,644,785
LANCASTER	5,320	1,547	6,542	2.5	5,842	89	SUBURBAN	\$12,420,447
LAWRENCE	2,656	552	3,083	1.2	2,717	24	SEMIRURAL	\$5,420,659
LEBANON	1,908	578	2,356	0.9	2,086	22	SEMIRURAL	\$4,619,527
LEHIGH	4,537	1,257	5,533	2.1	4,898	62	URBAN	\$10,026,553
LUZERNE	13,372	2,389	15,201	5.9	13,439	96	SUBURBAN	\$29,724,938
LYCOMING	2,678	615	3,154	1.2	2,844	27	SUBURBAN	\$6,080,546
MCKEAN	1,017	264	1,207	0.5	1,073	17	SEMIRURAL	\$2,359,829
MERCER	2,465	590	2,925	1.1	2,567	32	SUBURBAN	\$5,329,300
MIFFLIN	1,340	338	1,620	0.6	1,471	11	RURAL	\$3,453,568
MONROE	1,844	493	2,248	0.9	1,936	32	RURAL	\$4,159,934
MONTGOMERY	6,916	1,715	8,255	3.2	7,239	165	URBAN	\$15,191,812
MONTOUR	334	78	397	0.2	355	7	SEMIRURAL	\$662,905
NORTHAMPTON	5,071	1,530	6,319	2.5	5,631	68	SUBURBAN	\$11,465,069
NORTHUMBERLAND	3,995	815	4,637	1.8	4,191	26	SEMIRURAL	\$9,675,534
PERRY	741	173	875	0.3	771	9	RURAL	\$1,868,432

**TABLE 5.1
NUMBER AND PERCENT OF PACE AND PACENET CARDHOLDERS
AND NUMBER OF PROVIDERS BY COUNTY
JANUARY - DECEMBER 2003**

<u>COUNTY</u>	<u>NUMBER OF PACE ENROLLED CARDHOLDERS</u>	<u>NUMBER OF PACENET ENROLLED CARDHOLDERS</u>	<u>TOTAL NUMBER ENROLLED*</u>	<u>% OF TOTAL</u>	<u>NUMBER OF PARTICIPATING CARDHOLDERS</u>	<u>NUMBER OF PROVIDERS</u>	<u>TYPE OF COUNTY</u>	<u>STATE SHARE</u>
PHILADELPHIA	29,018	4,240	32,357	12.6	27,704	354	PHILADELPHIA	\$52,799,139
PIKE	659	194	819	0.3	720	8	RURAL	\$1,636,967
POTTER	478	97	552	0.2	470	4	RURAL	\$923,798
SCHUYLKILL	6,735	1,313	7,712	3.0	6,773	39	SEMIRURAL	\$14,268,250
SNYDER	799	225	963	0.4	870	8	RURAL	\$2,184,907
SOMERSET	2,211	423	2,542	1.0	2,258	17	RURAL	\$5,036,566
SULLIVAN	218	45	252	0.1	211	2	RURAL	\$391,256
SUSQUEHANNA	1,050	216	1,219	0.5	1,064	8	RURAL	\$2,055,260
TIOGA	1,000	219	1,183	0.5	1,027	9	RURAL	\$2,310,406
UNION	639	192	787	0.3	701	7	SEMIRURAL	\$1,419,495
VENANGO	1,061	256	1,256	0.5	1,116	15	SEMIRURAL	\$2,412,437
WARREN	678	199	837	0.3	748	9	SEMIRURAL	\$1,506,597
WASHINGTON	3,812	705	4,345	1.7	3,819	47	SUBURBAN	\$8,176,808
WAYNE	1,143	253	1,343	0.5	1,133	13	RURAL	\$2,411,546
WESTMORELAND	7,865	1,434	8,962	3.5	7,773	84	SUBURBAN	\$16,472,969
WYOMING	726	141	826	0.3	734	10	RURAL	\$1,636,939
YORK	5,607	1,616	6,843	2.7	6,072	80	SUBURBAN	\$12,750,066
TOTAL	220,794	46,880	257,427	100.0	225,732	2,808		\$476,897,332


* TOTAL NUMBER ENROLLED IS AN UNDUPLICATED COUNT OF CARDHOLDERS, SOME OF WHOM MAY HAVE BEEN ENROLLED IN BOTH PROGRAMS DURING THE YEAR.

SOURCE: PDA/CARDHOLDER FILE; CLAIMS HX


NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE

**FIGURE 5.1
PACE AND PACENET CARDHOLDER, CLAIM, AND PROVIDER INFORMATION
BY COUNTY TYPE
JANUARY - DECEMBER 2003**


**PENNSYLVANIA SENIOR
CITIZEN POPULATION
N = 1,919,165**




**PARTICIPATING
CARDHOLDERS
N = 225,732**




**ENROLLED
CARDHOLDERS
N = 257,427**




**TOTAL CLAIMS
N = 10,601,322**



**PENNSYLVANIA COUNTIES
N = 67**



**PACE PROVIDERS
N = 2,808**



SOURCE: PDA/CARDHOLDER FILE, CLAIMS HX, AND 2000 CENSUS COUNTS
NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE

SECTION 6

PROVIDER DATA

**TABLE 6.1
PACE CLAIMS AND EXPENDITURES BY PROVIDER TYPE
JANUARY - DECEMBER 2003**

PROVIDER TYPE	PROVIDERS				CLAIMS				EXPENDITURES				PERCENT OF CLAIMS REDUCED TO AWP-10%+\$3.50	
	JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC		JAN- JUNE	JULY - DEC
	NO.	%	NO.	%	NO.	%	NO.	%	AMOUNT	%	AMOUNT	%		
INDEPENDENT PHARMACIES	1,017	36.8	1,009	36.2	1,892,329	41.5	1,920,812	41.4	\$89,238,441	43.0	\$93,870,237	42.9	85.3	86.0
DISPENSING PHYSICIANS	5	0.2	6	0.2	65	< 0.1	34	< 0.1	\$11,374	< 0.1	\$6,411	< 0.1	98.5	61.8
INSTITUTIONAL PHARMACIES	31	1.1	33	1.2	19,927	0.4	23,813	0.5	\$1,037,420	0.5	\$1,193,143	0.5	81.0	76.1
CHAIN PHARMACIES	1,651	59.8	1,681	60.4	2,528,941	55.5	2,576,647	55.5	\$111,557,621	53.7	\$117,841,096	53.8	66.2	66.4
NURSING HOME PHARMACIES	48	1.7	46	1.7	105,912	2.3	104,522	2.3	\$4,995,663	2.4	\$5,136,176	2.3	89.4	91.0
MAIL ORDER PHARMACIES	8	0.3	9	0.3	13,345	0.3	14,649	0.3	\$786,724	0.4	\$929,996	0.4	78.5	79.7
TOTAL	2,760	100.0	2,784	100.0	4,560,519	100.0	4,640,477	100.0	\$207,627,243	100.0	\$218,977,059	100.0	74.7	75.2

SOURCE: PDA/PS-0-100, CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS

**TABLE 6.2
PACE CLAIMS VOLUME BY PRODUCT AND PROVIDER TYPE
JANUARY - DECEMBER 2003**

PROVIDER TYPE	BRAND SINGLE-SOURCE				BRAND MULTI-SOURCE				GENERIC				TOTAL			
	JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC	
	NO.	%	NO.	%	NO.	%	NO.	%	NO.	%	NO.	%	NO.	%	NO.	%
INDEPENDENT PHARMACIES	825,906	43.6	870,249	45.3	188,769	10.0	163,733	8.5	877,654	46.4	886,830	46.2	1,892,329	100.0	1,920,812	100.0
DISPENSING PHYSICIANS	48	73.9	24	70.6	15	23.1	8	23.5	2	3.1	2	5.9	65	100.0	34	100.0
INSTITUTIONAL PHARMACIES	10,391	52.2	12,800	53.8	1,621	8.1	1,600	6.7	7,915	39.7	9,413	39.5	19,927	100.0	23,813	100.0
CHAIN PHARMACIES	1,106,311	43.8	1,169,193	45.4	210,941	8.3	182,849	7.1	1,211,689	47.9	1,224,605	47.5	2,528,941	100.0	2,576,647	100.0
NURSING HOME PHARMACIES	45,945	43.4	47,437	45.4	10,423	9.8	8,077	7.7	49,544	46.8	49,008	46.9	105,912	100.0	104,522	100.0
MAIL ORDER PHARMACIES	5,774	43.3	6,706	45.8	1,387	10.4	1,126	7.7	6,184	46.3	6,817	46.5	13,345	100.0	14,649	100.0
TOTAL	1,994,375	43.7	2,106,409	45.4	413,156	9.1	357,393	7.7	2,152,988	47.2	2,176,675	46.9	4,560,519	100.0	4,640,477	100.0

SOURCE: PDA/PS-0-100, CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS

**TABLE 6.3
PACE EXPENDITURES BY PRODUCT AND PROVIDER TYPE
JANUARY - DECEMBER 2003**

PROVIDER TYPE	BRAND SINGLE-SOURCE				BRAND MULTI-SOURCE				GENERIC				TOTAL			
	JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC		JAN - JUNE		JULY - DEC	
<u>TYPE</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>	<u>AMOUNT</u>	<u>%</u>
INDEPENDENT PHARMACIES	\$59,097,759	66.2	\$64,881,793	69.1	\$6,738,892	7.6	\$5,050,710	5.4	\$23,401,790	26.2	\$23,937,734	25.5	\$89,238,441	100.0	\$93,870,237	100.0
DISPENSING PHYSICIANS	\$8,794	77.3	\$3,996	62.3	\$2,491	21.9	\$2,331	36.4	\$89	0.8	\$83	1.3	\$11,374	100.0	\$6,411	100.0
INSTITUTIONAL PHARMACIES	\$713,315	68.8	\$856,578	71.8	\$92,246	8.9	\$51,420	4.3	\$231,859	22.3	\$285,145	23.9	\$1,037,420	100.0	\$1,193,143	100.0
CHAIN PHARMACIES	\$77,540,257	69.5	\$85,611,559	72.7	\$8,055,708	7.2	\$6,072,031	5.2	\$25,961,656	23.3	\$26,157,506	22.2	\$111,557,621	100.0	\$117,841,096	100.0
NURSING HOME PHARMACIES	\$3,394,924	68.0	\$3,639,229	70.9	\$491,262	9.8	\$355,991	6.9	\$1,109,476	22.2	\$1,140,957	22.2	\$4,995,663	100.0	\$5,136,177	100.0
MAIL ORDER PHARMACIES	\$423,006	53.8	\$688,920	74.1	\$202,861	25.8	\$58,807	6.3	\$160,857	20.4	\$182,268	19.6	\$786,724	100.0	\$929,995	100.0
TOTAL	\$141,178,056	68.0	\$155,682,075	71.1	\$15,583,460	7.5	\$11,591,290	5.3	\$50,865,727	24.5	\$51,703,693	23.6	\$207,627,243	100.0	\$218,977,059	100.0

SOURCE: PDA/PS-0-100, CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS

TABLE 6.4
AVERAGE STATE SHARE PER PACE CLAIM BY PRODUCT AND PROVIDER TYPE
JANUARY - DECEMBER 2003

<u>PROVIDER TYPE</u>	<u>BRAND SINGLE-SOURCE</u>		<u>BRAND MULTI-SOURCE</u>		<u>GENERIC</u>		<u>AVERAGE FOR ALL TYPES</u>	
	<u>JAN - JUNE</u>	<u>JULY - DEC</u>	<u>JAN - JUNE</u>	<u>JULY - DEC</u>	<u>JAN - JUNE</u>	<u>JULY - DEC</u>	<u>JAN - JUNE</u>	<u>JULY - DEC</u>
INDEPENDENT PHARMACIES	\$71.56	\$74.56	\$35.70	\$30.85	\$26.66	\$26.99	\$47.16	\$48.87
DISPENSING PHYSICIANS	\$183.21	\$166.51	\$166.06	\$291.43	\$44.46	\$41.46	\$174.99	\$188.55
INSTITUTIONAL PHARMACIES	\$68.65	\$66.92	\$56.91	\$32.14	\$29.29	\$30.29	\$52.06	\$50.10
CHAIN PHARMACIES	\$70.09	\$73.22	\$38.19	\$33.21	\$21.43	\$21.36	\$44.11	\$45.73
NURSING HOME PHARMACIES	\$73.89	\$76.72	\$47.13	\$44.07	\$22.39	\$23.28	\$47.17	\$49.14
MAIL ORDER PHARMACIES	\$73.26	\$102.73	\$146.26	\$52.23	\$26.01	\$26.74	\$58.95	\$63.49
ALL PROVIDER TYPES	\$70.79	\$73.91	\$37.72	\$32.43	\$23.63	\$23.75	\$45.53	\$47.19

SOURCE: PDA/PS-0-100, CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT, EXCLUDE PACENET CLAIMS

**TABLE 6.5
PACENET CLAIMS AND EXPENDITURES BY PROVIDER TYPE
JANUARY - DECEMBER 2003**

PROVIDER TYPE	PROVIDERS		CLAIMS				EXPENDITURES			
	ENROLLED	PARTICIPATING	DEDUCTIBLE CLAIMS	COPAID CLAIMS	TOTAL CLAIMS	% OF CLAIMS	CARDHOLDER EXPENDITURES	STATE SHARE EXPENDITURES	TOTAL EXPENDITURES	% OF TOTAL EXPENDITURES
INDEPENDENT PHARMACIES	1,081	976	115,596	429,208	544,804	40.4	\$11,379,258	\$20,109,190	\$31,488,447	42.2
DISPENSING PHYSICIANS	86	1	8	1	9	0.0	\$421	\$136	\$557	0.0
INSTITUTIONAL PHARMACIES	40	29	1,411	2,237	3,648	0.3	\$84,348	\$111,631	\$195,979	0.3
CHAIN PHARMACIES	1,697	1,661	188,509	570,239	758,748	56.2	\$15,828,014	\$24,441,018	\$40,269,032	54.0
NURSING HOME PHARMACIES	53	47	5,302	31,890	37,192	2.8	\$695,578	\$1,562,634	\$2,258,212	3.0
MAIL ORDER PHARMACIES	10	7	1,284	3,849	5,133	0.4	\$106,897	\$249,010	\$355,907	0.5
TOTAL (ALL PROVIDERS)	2,967	2,721	312,110	1,037,424	1,349,534	100.0	\$28,094,516	\$46,473,619	\$74,568,134	100.0

SOURCE: PDA/CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT

TABLE 6.6
PACENET CLAIMS VOLUME BY PHASE OF COVERAGE¹, PRODUCT TYPE, AND PROVIDER TYPE
JANUARY-DECEMBER 2003

DEDUCTIBLE PHASE CLAIMS

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		TOTAL (ALL PRODUCTS)	
	NO.	%	NO.	%	NO.	%	NO.	%
INDEPENDENT PHARMACIES	45,030	39.0	11,121	9.6	59,445	51.4	115,596	100.0
DISPENSING PHYSICIANS	0	0.0	8	100.0	0	0.0	8	100
INSTITUTIONAL PHARMACIES	671	47.6	98	7.0	642	45.5	1,411	100.0
CHAIN PHARMACIES	70,398	37.3	15,468	8.2	102,643	54.5	188,509	100.0
NURSING HOME PHARMACIES	2,179	41.1	452	8.5	2,671	50.4	5,302	100.0
MAIL ORDER PHARMACIES	448	34.9	118	9.2	718	55.9	1,284	100.0
TOTAL (ALL PROVIDERS)	118,726	38.0	27,265	8.7	166,119	53.2	312,110	100.0

COPAYMENT PHASE CLAIMS

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		TOTAL (ALL PRODUCTS)	
	NO.	%	NO.	%	NO.	%	NO.	%
INDEPENDENT PHARMACIES	200,818	46.8	30,225	7.0	198,165	46.2	429,208	100.0
DISPENSING PHYSICIANS	0	0.0	1	100.0	0	0.0	1	100.0
INSTITUTIONAL PHARMACIES	1,049	46.9	145	6.5	1,043	46.6	2,237	100.0
CHAIN PHARMACIES	264,977	46.5	37,383	6.6	267,879	47.0	570,239	100.0
NURSING HOME PHARMACIES	15,053	47.2	2,209	6.9	14,628	45.9	31,890	100.0
MAIL ORDER PHARMACIES	1,708	44.4	275	7.1	1,866	48.5	3,849	100.0
TOTAL (ALL PROVIDERS)	483,605	46.6	70,238	6.8	483,581	46.6	1,037,424	100.0

¹THE DEDUCTIBLE AND COPAYMENT PHASES DIFFER IN THE TYPES OF CLAIMS SUBMITTED. LOW-PRICED PRESCRIPTIONS FOR WHICH THE TOTAL PRICE IS LESS THAN THE \$8 OR \$15 COPAY ARE NOT NECESSARILY SUBMITTED DURING THE COPAYMENT PHASE, BUT MAY BE SUBMITTED DURING THE DEDUCTIBLE PHASE TO SATISFY THE DEDUCTIBLE. GENERIC UTILIZATION RATES MAY THEREFORE BE HIGHER DURING THE DEDUCTIBLE PHASE THAN IN THE COPAYMENT PHASE, DUE TO THE OVER-REPRESENTATION OF LOW-PRICED GENERIC CLAIMS DURING THE DEDUCTIBLE PHASE.

SOURCE: PDA/CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT

TABLE 6.7
PACENET EXPENDITURES BY PHASE OF COVERAGE, PRODUCT TYPE, AND PROVIDER TYPE
JANUARY - DECEMBER 2003

A. DEDUCTIBLE PHASE CLAIMS

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		ALL PRODUCTS	
	AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
INDEPENDENT PHARMACIES								
CARDHOLDER EXPENDITURES	\$3,480,903	60.6	\$397,235	6.9	\$1,867,944	32.5	\$5,746,133	100.0
STATE SHARE EXPENDITURES ¹	\$292,838	71.0	\$42,632	10.3	\$76,798	18.6	\$412,267	100.0
TOTAL EXPENDITURES	\$3,773,741	61.3	\$439,867	7.1	\$1,944,792	31.6	\$6,158,400	100.0
DISPENSING PHYSICIANS								
CARDHOLDER EXPENDITURES	\$0	0.0	\$406	100.0	\$0	0.0	\$406	100
STATE SHARE EXPENDITURES ¹	\$0	0.0	\$0	0.0	\$0	0.0	\$0	0.0
TOTAL EXPENDITURES	\$0	0.0	\$406	100.0	\$0	0.0	\$406	100
INSTITUTIONAL PHARMACIES								
CARDHOLDER EXPENDITURES	\$33,663	58.2	\$2,709	4.7	\$21,432	37.1	\$57,804	100.0
STATE SHARE EXPENDITURES ¹	\$5,127	84.2	\$0	0.0	\$964	15.8	\$6,090	100.0
TOTAL EXPENDITURES	\$38,789	60.7	\$2,709	4.2	\$22,396	35.1	\$63,894	100.0
CHAIN PHARMACIES								
CARDHOLDER EXPENDITURES	\$5,258,098	63.3	\$537,201	6.5	\$2,516,734	30.3	\$8,312,033	100.0
STATE SHARE EXPENDITURES ¹	\$375,143	78.5	\$39,839	8.3	\$63,119	13.2	\$478,101	100.0
TOTAL EXPENDITURES	\$5,633,242	64.1	\$577,040	6.6	\$2,579,853	29.4	\$8,790,135	100.0
NURSING HOME PHARMACIES								
CARDHOLDER EXPENDITURES	\$178,934	64.9	\$19,069	6.9	\$77,540	28.1	\$275,542	100.0
STATE SHARE EXPENDITURES ¹	\$17,718	74.9	\$2,809	11.9	\$3,133	13.2	\$23,660	100.0
TOTAL EXPENDITURES	\$196,651	65.7	\$21,878	7.3	\$80,673	27.0	\$299,202	100.0
MAIL ORDER PHARMACIES								
CARDHOLDER EXPENDITURES	\$36,119	62.1	\$2,844	4.9	\$19,228	33.0	\$58,192	100.0
STATE SHARE EXPENDITURES ¹	\$9,407	93.3	\$9	0.1	\$668	6.6	\$10,084	100.0
TOTAL EXPENDITURES	\$45,527	66.7	\$2,853	4.2	\$19,896	29.1	\$68,276	100.0
TOTAL (ALL PROVIDERS)								
CARDHOLDER EXPENDITURES	\$8,987,717	62.2	\$959,464	6.6	\$4,502,929	31.2	\$14,450,109	100.0
STATE SHARE EXPENDITURES ¹	\$700,233	75.3	\$85,289	9.2	\$144,681	15.6	\$930,203	100.0
TOTAL EXPENDITURES	\$9,687,950	63.0	\$1,044,753	6.8	\$4,647,610	30.2	\$15,380,312	100.0

¹ STATE SHARE EXPENDITURES ARE ONLY INCURRED FOR TRANSITION CLAIMS WHICH COMPLETE THE \$500 DEDUCTIBLE ACCUMULATION. FOR THESE CLAIMS, THE CARDHOLDER PAYS THE OUTSTANDING DEDUCTIBLE AMOUNT AND A COPAYMENT, WHILE PACENET COVERS THE REMAINING COST, IF ANY, OF THE PRESCRIPTION.

SOURCE: PDA/CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

TABLE 6.7
PACENET EXPENDITURES BY PHASE OF COVERAGE, PRODUCT TYPE, AND PROVIDER TYPE
JANUARY - DECEMBER 2003

B. COPAYMENT PHASE CLAIMS

PROVIDER TYPE	BRAND SINGLE-SOURCE		BRAND MULTI-SOURCE		GENERIC		ALL PRODUCTS	
	AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
INDEPENDENT PHARMACIES								
CARDHOLDER EXPENDITURES	\$3,376,812	60.0	\$542,807	9.6	\$1,713,506	30.4	\$5,633,125	100.0
STATE SHARE EXPENDITURES ¹	\$13,205,889	67.1	\$1,162,912	5.9	\$5,328,122	27.1	\$19,696,923	100.0
TOTAL EXPENDITURES	\$16,582,700	65.5	\$1,705,719	6.7	\$7,041,629	27.8	\$25,330,047	100.0
DISPENSING PHYSICIANS								
CARDHOLDER EXPENDITURES	\$0	0.0	\$15	100.0	\$0	0.0	\$15	100
STATE SHARE EXPENDITURES ¹	\$0	0.0	\$136	100.0	\$0	0.0	\$136	100
TOTAL EXPENDITURES	\$0	0.0	\$151	100.0	\$0	0.0	\$151	100
INSTITUTIONAL PHARMACIES								
CARDHOLDER EXPENDITURES	\$15,991	60.2	\$2,151	8.1	\$8,402	31.7	\$26,544	100.0
STATE SHARE EXPENDITURES ¹	\$63,257	59.9	\$12,431	11.8	\$29,853	28.3	\$105,541	100.0
TOTAL EXPENDITURES	\$79,248	60.0	\$14,581	11.0	\$38,255	29.0	\$132,085	100.0
CHAIN PHARMACIES								
CARDHOLDER EXPENDITURES	\$4,544,479	60.5	\$666,753	8.9	\$2,304,749	30.7	\$7,515,981	100.0
STATE SHARE EXPENDITURES ¹	\$17,066,590	71.2	\$1,307,907	5.5	\$5,588,419	23.3	\$23,962,916	100.0
TOTAL EXPENDITURES	\$21,611,069	68.7	\$1,974,660	6.3	\$7,893,168	25.1	\$31,478,897	100.0
NURSING HOME PHARMACIES								
CARDHOLDER EXPENDITURES	\$256,152	61.0	\$41,709	9.9	\$122,175	29.1	\$420,036	100.0
STATE SHARE EXPENDITURES ¹	\$1,050,244	68.2	\$147,716	9.6	\$341,014	22.2	\$1,538,974	100.0
TOTAL EXPENDITURES	\$1,306,396	66.7	\$189,425	9.7	\$463,189	23.6	\$1,959,010	100.0
MAIL ORDER PHARMACIES								
CARDHOLDER EXPENDITURES	\$27,306	56.1	\$5,848	12.0	\$15,552	31.9	\$48,706	100.0
STATE SHARE EXPENDITURES ¹	\$153,187	64.1	\$36,002	15.1	\$49,737	20.8	\$238,925	100.0
TOTAL EXPENDITURES	\$180,492	62.8	\$41,850	14.6	\$65,289	22.7	\$287,631	100.0
TOTAL (ALL PROVIDERS)								
CARDHOLDER EXPENDITURES	\$8,220,739	60.3	\$1,259,282	9.2	\$4,164,385	30.5	\$13,644,406	100.0
STATE SHARE EXPENDITURES ¹	\$31,539,167	69.3	\$2,667,104	5.9	\$11,337,145	24.9	\$45,543,415	100.0
TOTAL EXPENDITURES	\$39,759,906	67.2	\$3,926,386	6.6	\$15,501,530	26.2	\$59,187,822	100.0

¹ STATE SHARE EXPENDITURES ARE ONLY INCURRED FOR TRANSITION CLAIMS WHICH COMPLETE THE \$500 DEDUCTIBLE ACCUMULATION. FOR THESE CLAIMS, THE CARDHOLDER PAYS THE OUTSTANDING DEDUCTIBLE AMOUNT AND A COPAYMENT, WHILE PACENET COVERS THE REMAINING COST, IF ANY, OF THE PRESCRIPTION.

SOURCE: PDA/CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

TABLE 6.8
AVERAGE CARDHOLDER AND STATE SHARE COST PER PACENET CLAIM
BY PHASE OF COVERAGE, PRODUCT TYPE, AND PROVIDER TYPE
JANUARY - DECEMBER 2003

PROVIDER TYPE	<u>DEDUCTIBLE PHASE</u>				<u>COPAYMENT PHASE</u>			
	BRAND SINGLE- SOURCE	BRAND MULTI- SOURCE	GENERIC	TOTAL	BRAND SINGLE- SOURCE	BRAND MULTI- SOURCE	GENERIC	TOTAL
INDEPENDENT PHARMACIES								
AVERAGE CARDHOLDER SHARE ¹	\$77.30	\$35.72	\$31.42	\$49.71	\$16.82	\$17.96	\$8.65	\$13.12
AVERAGE STATE SHARE ²	\$6.50	\$3.83	\$1.29	\$3.57	\$65.76	\$38.48	\$26.89	\$45.89
AVERAGE TOTAL RX COST	\$83.81	\$39.55	\$32.72	\$53.28	\$82.58	\$56.43	\$35.53	\$59.02
DISPENSING PHYSICIANS								
AVERAGE CARDHOLDER SHARE ¹	-	\$50.72	-	\$50.72	-	\$15.00	-	\$15.00
AVERAGE STATE SHARE ²	-	\$0.00	-	\$0.00	-	\$136.12	-	\$136.12
AVERAGE TOTAL RX COST	-	\$50.72	-	\$50.72	-	\$151.12	-	\$151.12
INSTITUTIONAL PHARMACIES								
AVERAGE CARDHOLDER SHARE ¹	\$50.17	\$27.64	\$33.38	\$40.97	\$15.24	\$14.83	\$8.06	\$11.87
AVERAGE STATE SHARE ²	\$7.64	\$0.00	\$1.50	\$4.32	\$60.30	\$85.73	\$28.62	\$47.18
AVERAGE TOTAL RX COST	\$57.81	\$27.64	\$34.88	\$45.28	\$75.55	\$100.56	\$36.68	\$59.05
CHAIN PHARMACIES								
AVERAGE CARDHOLDER SHARE ¹	\$74.69	\$34.73	\$24.52	\$44.09	\$17.15	\$17.84	\$8.60	\$13.18
AVERAGE STATE SHARE ²	\$5.33	\$2.58	\$0.61	\$2.54	\$64.41	\$34.99	\$20.86	\$42.02
AVERAGE TOTAL RX COST	\$80.02	\$37.31	\$25.13	\$46.63	\$81.56	\$52.82	\$29.47	\$55.20
NURSING HOME PHARMACIES								
AVERAGE CARDHOLDER SHARE ¹	\$82.12	\$42.19	\$29.03	\$51.97	\$17.02	\$18.88	\$8.35	\$13.17
AVERAGE STATE SHARE ²	\$8.13	\$6.21	\$1.17	\$4.46	\$69.77	\$66.87	\$23.31	\$48.26
AVERAGE TOTAL RX COST	\$90.25	\$48.40	\$30.20	\$56.43	\$86.79	\$85.75	\$31.66	\$61.43
MAIL ORDER PHARMACIES								
AVERAGE CARDHOLDER SHARE ¹	\$80.62	\$24.10	\$26.78	\$45.32	\$15.99	\$21.27	\$8.33	\$12.65
AVERAGE STATE SHARE ²	\$21.00	\$0.08	\$0.93	\$7.85	\$89.69	\$130.92	\$26.65	\$62.07
AVERAGE TOTAL RX COST	\$101.62	\$24.18	\$27.71	\$53.17	\$105.67	\$152.18	\$34.99	\$74.73
TOTAL (ALL PROVIDERS)								
AVERAGE CARDHOLDER SHARE ¹	\$75.70	\$35.19	\$27.11	\$46.30	\$17.00	\$17.93	\$8.61	\$13.15
AVERAGE STATE SHARE ²	\$5.90	\$3.13	\$0.87	\$2.98	\$65.22	\$37.97	\$23.44	\$43.90
AVERAGE TOTAL RX COST	\$81.60	\$38.32	\$27.98	\$49.28	\$82.22	\$55.90	\$32.06	\$57.05

¹ THE CARDHOLDER SHARE INCLUDES THE DEDUCTIBLE PAYMENTS, COPAYMENTS, GENERIC DIFFERENTIAL PAYMENTS IF BRAND IS CHOSEN OVER GENERIC, AND THIRD PARTY PAYMENTS. THE CARDHOLDER SHARE DURING THE COPAYMENT PHASE MAY THEREFORE EXCEED THE \$8 OR \$15 COPAYMENT.

² STATE SHARE EXPENDITURES ARE ONLY INCURRED FOR COPAID CLAIMS AND FOR DEDUCTIBLE TRANSITION CLAIMS WHICH COMPLETE THE \$500 DEDUCTIBLE ACCUMULATION. FOR THESE CLAIMS, THE CARDHOLDER PAYS THE OUTSTANDING DEDUCTIBLE AMOUNT AND A COPAYMENT, WHILE PACENET COVERS THE REMAINING COST, IF ANY, OF THE PRESCRIPTION.

SOURCE: PDA/CLAIMS HX

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF PAYMENT.

SECTION 7

**THERAPEUTIC
CLASS DATA
AND
DRUG UTILIZATION
REVIEW DATA**

**TABLE 7.1A
NUMBER AND PERCENT OF PACE CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS
BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003**

<u>THERAPEUTIC CLASS</u>	<u>TOTAL CLAIMS</u>	<u>% OF TOTAL</u>	<u>TOTAL EXPENDITURE</u>	<u>% OF TOTAL</u>	<u>CARD-HOLDERS WITH ANY CLAIMS</u>	<u>% OF PARTICIPATING CARDHOLDERS</u>	<u>ANNUAL COST (PERSONS WITH CLAIMS IN CLASS)</u>	<u>ANNUAL COST (ALL ENROLLED)¹</u>
ANTI-INFECTIVE AGENTS	251,926	2.7%	\$10,966,381.14	2.6%	93,999	47.9%	\$116.66	\$49.67
QUINOLONES	57,773	0.6%	\$4,032,543.33	0.9%	36,130	18.4%	\$111.61	\$18.26
CEPHALOSPORINS	31,376	0.3%	\$1,106,946.80	0.3%	21,298	10.9%	\$51.97	\$5.01
ANTINEOPLASTIC AGENTS	52,121	0.6%	\$6,813,383.63	1.6%	7,930	4.0%	\$859.19	\$30.86
AUTONOMIC DRUGS	263,704	2.9%	\$16,492,208.74	3.8%	47,591	24.3%	\$346.54	\$74.70
ANTICHOLINERGICS	45,075	0.5%	\$1,152,027.49	0.3%	11,058	5.6%	\$104.18	\$5.22
ADRENERGIC AGENTS	123,449	1.3%	\$4,776,825.67	1.1%	26,357	13.4%	\$181.24	\$21.63
BLOOD FORMATION & COAGULATION AGENTS	375,908	4.1%	\$26,770,806.09	6.2%	47,447	24.2%	\$564.23	\$121.25
CARDIOVASCULAR DRUGS	3,161,637	34.2%	\$134,441,216.44	31.3%	161,687	82.4%	\$831.49	\$608.90
CARDIAC DRUGS	2,175,204	23.6%	\$71,226,132.21	16.6%	147,853	75.3%	\$481.74	\$322.59
ACE INHIBITORS	501,719	5.4%	\$15,778,968.39	3.7%	60,008	30.6%	\$262.95	\$71.46
CARDIAC GLYCOSIDES	175,646	1.9%	\$406,900.68	0.1%	21,794	11.1%	\$18.67	\$1.84
ANTIARRHYTHMIC AGENTS	36,130	0.4%	\$2,456,291.21	0.6%	5,111	2.6%	\$480.59	\$11.12
BETA BLOCKERS	615,615	6.7%	\$14,008,482.37	3.3%	73,186	37.3%	\$191.41	\$63.45
CALCIUM CHANNEL BLOCKERS	563,905	6.1%	\$25,380,917.08	5.9%	64,830	33.0%	\$391.50	\$114.95
LIPID-LOWERING AGENTS	621,504	6.7%	\$52,177,636.72	12.1%	72,909	37.2%	\$715.65	\$236.32
HYPOTENSIVE AGENTS	104,358	1.1%	\$2,847,913.20	0.7%	12,887	6.6%	\$220.99	\$12.90
VASODILATING AGENTS	260,571	2.8%	\$8,189,534.31	1.9%	34,264	17.5%	\$239.01	\$37.09
ANALGESICS/ANTIPYRETICS	567,319	6.1%	\$32,994,183.80	7.7%	88,565	45.1%	\$372.54	\$149.43
NSAIDS	282,727	3.1%	\$21,084,919.69	4.9%	52,730	26.9%	\$399.87	\$95.50
COX-2 INHIBITORS	210,374	2.3%	\$17,709,873.58	4.1%	37,399	19.1%	\$473.54	\$80.21
OPIATE AGONISTS	244,917	2.7%	\$10,165,786.95	2.4%	54,556	27.8%	\$186.34	\$46.04
PSYCHOTHERAPEUTIC AGENTS	417,707	4.5%	\$28,903,710.04	6.7%	49,554	25.3%	\$583.28	\$130.91
ANTIDEPRESSANTS	351,463	3.8%	\$20,333,491.92	4.7%	45,671	23.3%	\$445.22	\$92.09
SSRI ANTIDEPRESSANTS	197,593	2.1%	\$13,650,526.96	3.2%	28,005	14.3%	\$487.43	\$61.82
ANTIPSYCHOTICS	66,244	0.7%	\$8,570,218.12	2.0%	9,576	4.9%	\$894.97	\$38.82
ANXIOLYTICS/SEDATIVES/HYPNOTICS	292,752	3.2%	\$9,539,426.55	2.2%	47,566	24.2%	\$200.55	\$43.21
BENZODIAZEPINES	212,941	2.3%	\$5,363,991.83	1.2%	36,893	18.8%	\$145.39	\$24.29
MISCELLANEOUS ANX/SED/HYPNOTICS	74,923	0.8%	\$4,158,090.54	1.0%	15,062	7.7%	\$276.06	\$18.83

**TABLE 7.1A
NUMBER AND PERCENT OF PACE CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS
BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003**

<u>THERAPEUTIC CLASS</u>	<u>TOTAL CLAIMS</u>	<u>% OF TOTAL</u>	<u>TOTAL EXPENDITURE</u>	<u>% OF TOTAL</u>	<u>CARD-HOLDERS WITH ANY CLAIMS</u>	<u>% OF PARTICIPATING CARDHOLDERS</u>	<u>ANNUAL COST (PERSONS WITH CLAIMS IN CLASS)</u>	<u>ANNUAL COST (ALL ENROLLED)¹</u>
REPLACEMENT PREPARATIONS	238,749	2.6%	\$2,931,109.39	0.7%	35,190	17.9%	\$83.29	\$13.28
DIURETICS	585,163	6.3%	\$4,200,962.44	1.0%	78,575	40.0%	\$53.46	\$19.03
LOOP DIURETICS	334,596	3.6%	\$2,218,208.42	0.5%	50,708	25.8%	\$43.74	\$10.05
POTASSIUM-SPARING DIURETICS	124,956	1.4%	\$1,111,242.53	0.3%	17,591	9.0%	\$63.17	\$5.03
THIAZIDE DIURETICS	121,590	1.3%	\$774,144.18	0.2%	20,863	10.6%	\$37.11	\$3.51
ANTITUSSIVES, EXPECTORANTS AND MUCOLYTICS	55,055	0.6%	\$887,433.15	0.2%	25,601	13.0%	\$34.66	\$4.02
EYE, EAR, NOSE AND THROAT PREPARATIONS	295,018	3.2%	\$10,979,083.11	2.6%	49,492	25.2%	\$221.84	\$49.73
GASTROINTESTINAL AGENTS	571,713	6.2%	\$49,638,996.74	11.6%	79,111	40.3%	\$627.46	\$224.82
H2-RECEPTOR ANTAGONISTS	95,248	1.0%	\$4,285,115.33	1.0%	16,737	8.5%	\$256.03	\$19.41
PROTON PUMP INHIBITORS	373,259	4.0%	\$42,215,778.78	9.8%	52,897	27.0%	\$798.08	\$191.20
OTHER MISCELL. ANTI-ULCER AGENTS	20,950	0.2%	\$1,531,876.06	0.4%	3,696	1.9%	\$414.47	\$6.94
HORMONES AND SYNTHETIC SUBSTANCES	1,072,972	11.6%	\$39,351,153.59	9.2%	95,612	48.7%	\$411.57	\$178.23
ADRENALS AND COMB.	129,291	1.4%	\$8,141,069.48	1.9%	30,567	15.6%	\$266.34	\$36.87
ESTROGENS AND COMB.	49,345	0.5%	\$1,228,427.27	0.3%	8,270	4.2%	\$148.54	\$5.56
ANTIDIABETIC AGENTS	532,412	5.8%	\$26,577,788.99	6.2%	42,260	21.5%	\$628.91	\$120.37
THYROID AND ANTITHYROID AGENTS	358,187	3.9%	\$3,017,126.69	0.7%	38,030	19.4%	\$79.34	\$13.66
SMOOTH MUSCLE RELAXANTS	117,278	1.3%	\$7,290,528.76	1.7%	17,717	9.0%	\$411.50	\$33.02
THEOPHYLLINE AND RELATED DRUGS	26,269	0.3%	\$477,745.44	0.1%	3,574	1.8%	\$133.67	\$2.16
DRUGS FOR OSTEOPOROSIS	267,642	2.9%	\$16,024,471.48	3.7%	34,759	17.7%	\$461.02	\$72.58
ALL OTHER DRUGS	649,171	7.0%	\$31,391,452.04	7.3%	97,035	49.4%	\$323.51	\$142.18
ALL CLASSES COMBINED	9,235,835	100.0%	\$429,616,507.13	100.0%	196,243	100.0%	\$2,189.21	\$1,945.78

¹ The annual cost per enrollee is based on total cardholders enrolled in PACE for any portion of calendar year 2003 (N=220,794).

SOURCE: PDA/CLAIMS HISTORY AND DRUG FILES

NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS.

**TABLE 7.1B
NUMBER AND PERCENT OF PACENET CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS
BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003**

<u>THERAPEUTIC CLASS</u>	<u>TOTAL CLAIMS</u>	<u>% OF TOTAL</u>	<u>STATE SHARE EXPENDITURE</u>	<u>% OF TOTAL</u>	<u>CARD-HOLDERS WITH ANY CLAIMS</u>	<u>% OF PARTICIPATING CARDHOLDERS</u>	<u>ANNUAL COST (PERSONS WITH CLAIMS IN CLASS)</u>	<u>ANNUAL COST (ALL ENROLLED)¹</u>
ANTI-INFECTIVE AGENTS	39,855	2.9%	\$1,200,804.67	2.5%	15,726	41.5%	\$76.36	\$25.61
QUINOLONES	8,952	0.7%	\$430,167.29	0.9%	5,756	15.2%	\$74.73	\$9.18
CEPHALOSPORINS	5,048	0.4%	\$116,895.65	0.2%	3,485	9.2%	\$33.54	\$2.49
ANTINEOPLASTIC AGENTS	8,395	0.6%	\$1,037,577.29	2.2%	1,429	3.8%	\$726.09	\$22.13
AUTONOMIC DRUGS	40,387	3.0%	\$2,009,030.78	4.2%	8,113	21.4%	\$247.63	\$42.85
ANTICHOLINERGICS	6,643	0.5%	\$121,228.00	0.3%	1,782	4.7%	\$68.03	\$2.59
ADRENERGIC AGENTS	17,875	1.3%	\$497,636.51	1.1%	4,304	11.4%	\$115.62	\$10.62
BLOOD FORMATION & COAGULATION AGENTS	61,186	4.5%	\$3,440,670.94	7.3%	9,283	24.5%	\$370.64	\$73.39
CARDIOVASCULAR DRUGS	467,489	34.2%	\$14,003,188.39	29.6%	30,309	80.1%	\$462.01	\$298.70
CARDIAC DRUGS	317,060	23.2%	\$7,024,126.14	14.9%	27,505	72.6%	\$255.38	\$149.83
ACE INHIBITORS	77,028	5.6%	\$1,555,374.22	3.3%	11,121	29.4%	\$139.86	\$33.18
CARDIAC GLYCOSIDES	16,631	1.2%	\$6,269.96	0.0%	3,289	8.7%	\$1.91	\$0.13
ANTIARRHYTHMIC AGENTS	6,899	0.5%	\$365,195.23	0.8%	1,145	3.0%	\$318.95	\$7.79
BETA BLOCKERS	94,480	6.9%	\$1,466,878.80	3.1%	13,970	36.9%	\$105.00	\$31.29
CALCIUM CHANNEL BLOCKERS	82,050	6.0%	\$2,428,757.95	5.1%	11,640	30.7%	\$208.66	\$51.81
LIPID-LOWERING AGENTS	92,863	6.8%	\$5,657,284.28	12.0%	13,395	35.4%	\$422.34	\$120.68
HYPOTENSIVE AGENTS	16,701	1.2%	\$321,790.03	0.7%	2,425	6.4%	\$132.70	\$6.86
VASODILATING AGENTS	40,865	3.0%	\$999,987.94	2.1%	6,225	16.4%	\$160.64	\$21.33
ANALGESICS/ANTIPYRETICS	78,553	5.8%	\$3,520,201.52	7.4%	14,377	38.0%	\$244.85	\$75.09
NSAIDS	36,211	2.7%	\$1,998,934.88	4.2%	7,865	20.8%	\$254.16	\$42.64
COX-2 INHIBITORS	26,740	2.0%	\$1,679,664.83	3.6%	5,493	14.5%	\$305.78	\$35.83
OPIATE AGONISTS	36,375	2.7%	\$1,329,257.98	2.8%	8,975	23.7%	\$148.11	\$28.35
PSYCHOTHERAPEUTIC AGENTS	67,716	5.0%	\$3,620,057.29	7.7%	9,178	24.2%	\$394.43	\$77.22
ANTIDEPRESSANTS	57,097	4.2%	\$2,435,668.95	5.2%	8,515	22.5%	\$286.04	\$51.96
SSRI ANTIDEPRESSANTS	31,118	2.3%	\$1,570,309.67	3.3%	5,156	13.6%	\$304.56	\$33.50
ANTIPSYCHOTICS	10,619	0.8%	\$1,184,388.34	2.5%	1,748	4.6%	\$677.57	\$25.26
ANXIOLYTICS/SEDATIVES/HYPNOTICS	45,043	3.3%	\$1,045,804.50	2.2%	8,482	22.4%	\$123.30	\$22.31
BENZODIAZEPINES	33,488	2.5%	\$580,803.73	1.2%	6,755	17.8%	\$85.98	\$12.39
MISCELLANEOUS ANX/SED/HYPNOTICS	11,016	0.8%	\$463,626.21	1.0%	2,468	6.5%	\$187.86	\$9.89

TABLE 7.1B
NUMBER AND PERCENT OF PACENET CLAIMS, STATE SHARE EXPENDITURES, AND CARDHOLDERS WITH CLAIMS
BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003


<u>THERAPEUTIC CLASS</u>	<u>TOTAL CLAIMS</u>	<u>% OF TOTAL</u>	<u>STATE SHARE EXPENDITURE</u>	<u>% OF TOTAL</u>	<u>CARD-HOLDERS WITH ANY CLAIMS</u>	<u>% OF PARTICIPATING CARDHOLDERS</u>	<u>ANNUAL COST (PERSONS WITH CLAIMS IN CLASS)</u>	<u>ANNUAL COST (ALL ENROLLED)¹</u>
REPLACEMENT PREPARATIONS	35,690	2.6%	\$304,311.60	0.6%	6,254	16.5%	\$48.66	\$6.49
DIURETICS	78,975	5.8%	\$383,398.51	0.8%	13,465	35.6%	\$28.47	\$8.18
LOOP DIURETICS	44,330	3.2%	\$218,911.23	0.5%	8,503	22.5%	\$25.75	\$4.67
POTASSIUM-SPARING DIURETICS	18,467	1.4%	\$92,472.80	0.2%	3,150	8.3%	\$29.36	\$1.97
THIAZIDE DIURETICS	15,611	1.1%	\$64,045.05	0.1%	3,487	9.2%	\$18.37	\$1.37
ANTITUSSIVES, EXPECTORANTS AND MUCOLYTICS	7,864	0.6%	\$88,625.58	0.2%	3,849	10.2%	\$23.03	\$1.89
EYE, EAR, NOSE AND THROAT PREPARATIONS	42,935	3.1%	\$994,784.43	2.1%	8,292	21.9%	\$119.97	\$21.22
GASTROINTESTINAL AGENTS	77,832	5.7%	\$5,244,373.97	11.1%	12,948	34.2%	\$405.03	\$111.87
H2-RECEPTOR ANTAGONISTS	13,185	1.0%	\$452,742.12	1.0%	2,687	7.1%	\$168.49	\$9.66
PROTON PUMP INHIBITORS	48,661	3.6%	\$4,364,963.95	9.2%	8,375	22.1%	\$521.19	\$93.11
OTHER MISCELL. ANTI-ULCER AGENTS	3,759	0.3%	\$212,724.46	0.4%	671	1.8%	\$317.03	\$4.54
HORMONES AND SYNTHETIC SUBSTANCES	159,270	11.7%	\$4,335,485.63	9.2%	17,971	47.5%	\$241.25	\$92.48
ADRENALS AND COMB.	19,421	1.4%	\$969,914.09	2.1%	5,200	13.7%	\$186.52	\$20.69
ESTROGENS AND COMB.	8,303	0.6%	\$103,099.62	0.2%	1,628	4.3%	\$63.33	\$2.20
ANTIDIABETIC AGENTS	86,857	6.4%	\$3,130,898.30	6.6%	8,425	22.3%	\$371.62	\$66.79
THYROID AND ANTITHYROID AGENTS	44,034	3.2%	\$43,688.30	0.1%	6,910	18.3%	\$6.32	\$0.93
SMOOTH MUSCLE RELAXANTS	17,271	1.3%	\$767,277.12	1.6%	3,058	8.1%	\$250.91	\$16.37
THEOPHYLLINE AND RELATED DRUGS	3,884	0.3%	\$41,797.52	0.1%	605	1.6%	\$69.09	\$0.89
DRUGS FOR OSTEOPOROSIS	39,773	2.9%	\$1,604,844.13	3.4%	6,196	16.4%	\$259.01	\$34.23
ALL OTHER DRUGS	97,253	7.1%	\$3,680,387.14	7.8%	16,273	43.0%	\$226.17	\$78.51
ALL CLASSES COMBINED	1,365,487	100.0%	\$47,280,823.49	100.0%	37,860	100.0%	\$1,248.83	\$1,008.55

¹ The annual cost per enrollee is based on total cardholders enrolled in PACENET for any portion of calendar year 2003 (N=46,880).

SOURCE: PDA/CLAIMS HISTORY AND DRUG FILES

NOTE: DATA INCLUDE ORIGINAL, PAID PACENET CLAIMS BY DATE OF SERVICE. TOTAL CLAIMS INCLUDE DEDUCTIBLE CLAIMS AND COPAID CLAIMS.

FIGURE 7.1
PERCENT OF PACE STATE SHARE EXPENDITURES BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003
(TOTAL EXPENDITURES = \$429,616,507)



SOURCE: PDA/CLAIMS HISTORY AND DRUG FILES
 NOTE: DATA INCLUDE ORIGINAL, PAID CLAIMS BY DATE OF SERVICE, EXCLUDE PACENET CLAIMS

**FIGURE 7.2
TIMELINE OF PRODUR IMPLEMENTATION**






FIGURE 7.3
NUMBER AND PERCENT OF PACE AND PACENET CLAIMS WITH A
PROSPECTIVE REVIEW MESSAGE BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003
N=124,673



SOURCE: PDA/CLAIMS HISTORY

NOTE: DATA INCLUDE CLAIMS BY DATE OF SERVICE WITH MULTIPLE SUBMISSIONS OF SAME CLAIM ON SAME DAY DELETED.

FIGURE 7.3 (CONTINUED)
NUMBER AND PERCENT OF PACE AND PACENET CLAIMS WITH A
PROSPECTIVE REVIEW MESSAGE BY THERAPEUTIC CLASS
JANUARY - DECEMBER 2003
N=124,673



SOURCE: PDA/CLAIMS HISTORY
 NOTE: DATA INCLUDE CLAIMS BY DATE OF SERVICE WITH MULTIPLE SUBMISSIONS OF SAME CLAIM ON SAME DAY DELETED.

TABLE 7.2
NUMBER OF CASES IN THE
SURVEILLANCE UTILIZATION REVIEW SYSTEM
JANUARY - DECEMBER 2003

<u>MONTH OF REVIEW</u>	<u>NUMBER OF CASES REQUIRING INVESTIGATION OR RESTRICTION</u>	<u>NUMBER OF CARDHOLDERS RESTRICTED TO ONE PHARMACY*</u>	<u>NUMBER OF CARDHOLDERS RECEIVING THERAPEUTIC CLASS RESTRICTIONS *</u>	<u>NUMBER OF CARDHOLDERS WITH THERAPEUTIC CLASS RESTRICTIONS LIFTED *</u>
JANUARY	1	5	3	0
FEBRUARY	1	10	10	0
MARCH	9	5	5	0
APRIL	15	11	11	0
MAY	4	10	2	0
JUNE	2	17	16	1
JULY	0	9	10	1
AUGUST	1	10	10	2
SEPTEMBER	13	4	4	1
OCTOBER	20	10	7	0
NOVEMBER	0	7	5	1
DECEMBER	3	5	5	0
TOTAL	69	103	88	6

* The number of cardholders may represent cases reviewed during previous periods.

SOURCE: PDA/SUR REPORTS



SECTION 8

PACE PhRMA REFERRAL PROGRAM DATA



PACE PhRMA Referral Program


In January 2001, The PACE Program began a referral program that facilitates contact between the Area Agency on Aging offices throughout Pennsylvania and the patient assistance programs offered by pharmaceutical manufacturers. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading research-based pharmaceutical and biotechnology companies. Some of these manufacturers offer limited prescription drug assistance to persons who are not eligible for other forms of pharmaceutical coverage and who cannot afford the cost of one or more of their medications. The PACE Program coordinator provides the expertise needed to determine the likelihood of eligibility for persons seeking assistance from manufactures. The Pennsylvania Department of Aging supports and trains the APPRISE coordinators in the Area Agencies on Aging to handle the insurance coverage inquiries of Medicare beneficiaries in Pennsylvania. The APPRISE coordinator or an APPRISE volunteer at the local aging office gathers patient information in order to complete the manufacturers pharmacy assistance application.

The PACE PhRMA Referral Program recently changed its age requirements to persons who are 55 years of age and older or individuals who are disabled without regard to age. Pharmaceutical manufactures set the income and eligibility guidelines as individual companies. As individual entities, manufacturers limit the products and the length of time given as assistance to persons seeking help. Typically, the income must be below \$20,000 for a single person, \$25,000 for married couples and less than \$30,000 for persons with more than two dependants. These income levels are a compilation of many levels used by the manufacturers and only serve as guideposts. Manufacturers require a wide range of information on company specific forms that further complicates the application and review process. A substantial amount of coordination needs to occur between the area agency on aging office, the PACE Program coordinator, the patient and the patient's physician.

Despite the inherent difficulties of application, the lengthy wait for approval from the manufacturer, and the strictly limited amount of medication granted with each approval, the collaborative efforts of the local and central coordinators responded to inquires from 3,444 patients after three years of operation. At the beginning of 2004, 14% (482 persons) were receiving medication assistance through the PhRMA Program. This decline is attributed to the fact that PACE and PACENET increased their income guidelines. The Program successfully referred persons to the PACE Program (295), PACENET Program (1,446), VA benefits (52), or other insurance (173). Among the remaining inactive patients, 279 were over the income limits set by the manufacturer and were not eligible for PACE or PACENET benefits. Of the 482 persons receiving assistance through the PhRMA Program, a total of 2,071 medications were obtained. Prior to being determined inactive, 1,565 patients received medication assistance through this Program.

The Program currently has all 67 counties participating and is in the process of training other organizations to process applications.

**FIGURE 8.1
PACE PhRMA REFERRAL PROGRAM FLOWCHART**



APPENDIX A

THE PACE/PACENET MEDICAL EXCEPTION PROCESS

BACKGROUND:

Act 134-96, the State Lottery Law, requires publication and dissemination of the medical exception process used by the Department of Aging for the Pharmaceutical Assistance Contract for the Elderly (PACE) and for the Pharmaceutical Assistance Contract for the Elderly Needs Enhancement Tier (PACENET). Specifically, the legislation addresses the medical exception process with regard to generic substitution when an A-rated therapeutically equivalent medication is available. The law further requires that the Department of Aging distribute the medical exception process to providers and recipients in the Program.

THE MEDICAL EXCEPTION PROCESS:

Through the online claims processing system, the PACE/PACENET Program provides prospective therapeutic review of prescriptions before the pharmacist dispenses the medication to the cardholder. The review checks for potential drug interactions, duplicative therapies, over-utilization, under-utilization and other misutilization. The Department of Aging, of course, recognizes the possibility of exceptional circumstances in connection with the application of therapeutic criteria and reimbursement edits. A medical exception will be considered by the Program when the cardholder's physician indicates the diagnosis, medical rationale, anticipated therapeutic outcomes, the expected length of exception therapy, and the last trial at alternative therapy.

Act 134-96 requires a pharmacist to dispense the A-rated, therapeutically equivalent, generic drug to the cardholder if they have a prescription for a multi-source brand product. If a cardholder seeks an exception to this mandate, a pharmacist may request a short term medical exception at the time of dispensing by calling 1-800-835-4080. The PACE Program may grant a 30-day medical exception if requested. Immediately following approval of the exception, the Program sends a follow-up letter to the cardholder's prescribing physician. This letter serves as notice that the Program granted a temporary medical exception to the mandatory substitution requirement. The letter seeks the therapeutic rationale for continuing the medical exception. The Program allows 30 days for the return of the written medical exception request from the prescriber. If the Program does not receive written documentation, the short term medical exception will expire. If the prescriber does respond to the letter and provides appropriate information, the Program may grant a longer medical exception period. The cardholder may continue to obtain the brand medication without paying the extra cost of a generic differential.

The Program may refer a request to a physician consultant or to a therapeutics committee for special review and consideration. The cardholder will receive a short term medical exception until completion of the review process.

If the Program denies a request for a medical exception to the mandatory generic requirement, the cardholder may opt to continue using the brand multi-source product and, then, pay the generic differential. If this occurs, the pharmacist must collect the copay for the brand name product plus 70 percent of the average wholesale price of the brand name product from the cardholder.

Please direct questions regarding the implementation of the medical exception process to 1-800-835-4080 or in writing to:

Mr. Thomas M. Snedden
Director, Bureau of Pharmaceutical Assistance
Pennsylvania Department of Aging
555 Walnut Street, 5th Floor
Harrisburg, PA 17101-1919

Source: Pennsylvania Bulletin, Vol. 26, No. 52, December 28, 1996; address change December 8, 1997.

APPENDIX B
AMERICAN HOSPITAL FORMULARY SERVICE (AHFS) CLASSIFICATIONS
FOR THERAPEUTIC CLASSES USED IN REPORT

The American Hospital Formulary Service (AHFS) provides a universal standard of drug classification. Listed below are the AHFS classifications corresponding to the drug classes reported in the tables and figures of this report.

<u>Name of Therapeutic Class</u>	<u>AHFS Classification</u>
Anti-infective agents	08
Quinolones	08:22
Cephalosporins	08:12.06
Antineoplastic agents	10
Autonomic drugs	12
Anticholinergics	12:08
Adrenergic agents	12:12
Blood formation and coagulation agents	20
Cardiovascular drugs	24
Cardiac drugs	24:04
ACE inhibitors	24:04.04 (Red Book)*
Cardiac glycosides	24:04.08 (Red Book)*
Antiarrhythmic agents	24:04.10 (Red Book)*
Beta blockers	24:04.16 (Red Book)*
Calcium channel blockers	24:04.20 (Red Book)*
Lipid-lowering agents	24:06
Antihypertensive agents	24:08
Vasodilating agents	24:12
Analgesics/antipyretics	28:08
NSAID's/Cox II's	28:08.04
Opiate agonists	28:08.08
Psychotropic drugs	28:12,16,20,24,28
Anxiolytics, sedatives, hypnotics	28:24
Antidepressants	28:16.04
Antipsychotic agents	28:16.08
Replacement solutions	40:12
Diuretics	40:28
Loop diuretics	40:28.02 (Red Book)*
Thiazide diuretics	40:28.12 (Red Book)*
Potassium-sparing diuretics	40:28.10 (Red Book)*
Antitussive, expectorant and mucolytic agents	48
Eye, ear, nose and throat preparations	52
Gastrointestinal agents	56
Miscellaneous gastrointestinal drugs	56:40
H ₂ -receptor antagonists (H ₂ RA's)	56:24 (Red Book)*
Hormones and synthetic substances	68
Adrenals and comb.	68:04
Estrogens	68:16
Antidiabetic agents (including insulin)	68:20
Thyroid and antithyroid agents	68:36
Drugs for Osteoporosis	multiple classes (68:16.12, 68:24, 92:01)
Theophylline and related smooth muscle relaxants	86:16

*The Red Book therapeutic classification system expands upon AHFS for these categories.

SOURCE: AHFS Drug Information 2003 and Red Book Database Services.

APPENDIX C

PACE

PROSPECTIVE DRUG UTILIZATION REVIEW CRITERIA

Updated 3/26/04

Angiotensin Converting Enzyme Inhibitors - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Benazepril (Lotensin)	No Criteria	---	Less than or equal to 80 mg/day	05/15/99	No Criteria	---
Captopril (Capoten)	No Criteria	---	Less than or equal to 450 mg/day	05/15/99	No Criteria	---
Enalapril (Vasotec)	No Criteria	---	Less than or equal to 40 mg/day	10/15/95	No Criteria	---
Fosinopril (Monopril)	No Criteria	---	Less than or equal to 80 mg/day	10/15/95	No Criteria	---
Lisinopril (Prinivil)	No Criteria	---	Less than or equal to 40 mg/day	10/15/95	No Criteria	---
Quinapril (Accupril)	No Criteria	---	Less than or equal to 80 mg/day	10/15/95	No Criteria	---
Ramipril (Altace)	No Criteria	---	Less than or equal to 20 mg/day	10/15/95	No Criteria	---
Moexipril (Univas)	No Criteria	---	Less than or equal to 30 mg/day	01/12/98	No Criteria	---
Perindopril (Aceon)	No Criteria	---	Less than or equal to 16 mg/day	03/04/02	No Criteria	---
Olmesartan (benicar)	No Criteria	---	Less than or equal to 40 mg/day	08/16/03	No Criteria	---

Angiotensin II Receptor Antagonists - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Valsartan (Diovan)	No Criteria	---	Less than or equal to 320 mg/day	08/18/97	No Criteria	---
Losartan (Cozaar)	No Criteria	---	Less than or equal to 100 mg/day	04/22/98	No Criteria	---
Candesartan (Atacand)	No Criteria	---	Less than or equal to 32 mg/day	05/19/99	No Criteria	---
Irbesartan (Avapro)	No Criteria	---	Less than or equal to 300 mg/day	05/19/99	No Criteria	---
Eprosartan (Teveten)	No Criteria	---	Less than or equal to 800 mg/day	09/28/01	No Criteria	---
Telmisartan (Micardis)	No Criteria	---	Less than or equal to 80 mg/day	09/28/01	No Criteria	---

Beta Blockers - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Acebutolol (Sectral)	No Criteria	---	Less than or equal to 1200 mg/day	05/15/99	Concurrent with Beta Blockers.	10/15/95
Atenolol (Tenormin)	No Criteria	---	Less than or equal to 200 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Betaxolol (Kerlone)	No Criteria	---	Less than or equal to 20 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Carteolol (Cartrol)	No Criteria	---	Less than or equal to 10 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Labetalol (Normodyne)	No Criteria	---	Less than or equal to 2400 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Metoprolol (Lopressor)	No Criteria	---	Less than or equal to 450 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Metoprolol (Toprol XL)	No Criteria	---	Less than or equal to 400 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Nadolol (Corgard)	No Criteria	---	Less than or equal to 320 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Penbutolol (Levitol)	No Criteria	---	Less than or equal to 80 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Pindolol (Visken)	No Criteria	---	Less than or equal to 60 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Propranolol (Inderal)	No Criteria	---	Less than or equal to 640 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Propranolol LA (Inderal LA)	No Criteria	---	Less than or equal to 640 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Sotalol (Betapace)	No Criteria	---	Less than or equal to 320 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Timolol Blocadren)	No Criteria	---	Less than or equal to 60 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Bisoprolol (Zebeta)	No Criteria	---	Less than or equal to 20 mg/day	10/15/95	Concurrent with Beta Blockers.	10/15/95
Carvedilol (Coreg)	No Criteria	---	Less than or equal to 100 mg/day	08/18/97	Concurrent with Beta Blockers.	08/18/97
Propranolol (Innopran XL)	No Criteria	---	Less than or equal to 120 mg/day	03/29/04	Concurrent with Beta Blockers.	03/29/04

Cardiac Glycosides - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Digoxin (Lanoxin)	No Criteria	---	Less than or equal to .375 mg/day	10/15/95	No Criteria	---

Calcium Channel Blockers - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Amlodipine (Norvasc)	No Criteria	---	Less than or equal to 10 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Bepridil (Vascor)	No Criteria	---	Less than or equal to 400 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Diltiazem (Cardizem)	No Criteria	---	Less than or equal to 360 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Diltiazem SR (Cardizem SR)	No Criteria	---	Less than or equal to 360 mg/day	01/29/98	Concurrent with Calcium Channel Blockers.	10/15/95
Diltiazem CD (Cardizem CD)	No Criteria	---	Less than or equal to 540 mg/day	05/15/99	Concurrent with Calcium Channel Blockers.	10/15/95
Diltiazem (Dilacor XR)	No Criteria	---	Less than or equal to 540 mg/day	01/29/98	Concurrent with Calcium Channel Blockers.	10/15/95
Felodipine (Plendil)	No Criteria	---	Less than or equal to 20 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Isradipine (DynaCirc)	No Criteria	---	Less than or equal to 20 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Nicardipine (Cardene)	No Criteria	---	Less than or equal to 120 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Nicardipine SR (Cardene SR)	No Criteria	---	Less than or equal to 120 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Nifedipine (Procardia)	No Criteria	---	Less than or equal to 120 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Nifedipine XL (Procardia XL)	No Criteria	---	Less than or equal to 120 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Verapamil (Calan, Isoptin)	No Criteria	---	Less than or equal to 480 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Verapamil SR (Calan SR, Isoptin)	No Criteria	---	Less than or equal to 480 mg/day	10/15/95	Concurrent with Calcium Channel Blockers.	10/15/95
Nisoldipine (Sular)	No Criteria	---	Less than or equal to 60 mg/day	08/18/97	Concurrent with Calcium Channel Blockers.	08/18/97

Lipid Lowering Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Fluvastatin (Lescol)	No criteria	---	Less than or equal to 80 mg/day	04/15/97	Concurrent HMG- Co A Reductase Inhibitors.	04/15/97	No criteria	---
Simvastatin (Zocor)	No criteria	---	Less than or equal to 80 mg/day	05/15/99	Concurrent HMG- Co A Reductase Inhibitors.	04/15/97	No criteria	---
Lovastatin (Mevacor)	No criteria	---	Less than or equal to 80 mg/day	04/15/97	Concurrent HMG- Co A Reductase Inhibitors.	04/15/97	No criteria	---
Pravastatin (Pravachol)	No criteria	---	Less than or equal to 40 mg/day	04/15/97	Concurrent HMG- Co A Reductase Inhibitors.	04/15/97	No criteria	---
Atorvastatin (Lipitor)	No criteria	---	Less than or equal to 80 mg/day	12/04/97	Concurrent HMG- Co A Reductase Inhibitors.	12/03/97	No criteria	---
Ezetimibe (Zetia)	No criteria	---	Less than or equal to 200 mg/day	03/29/04	No criteria	---	No criteria	---

Antiplatelet Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Cilostazol (Pletal)	No criteria	---	Less than or equal to 200 mg/day	06/05/00	No criteria	---	No criteria	---
Ticlopidine (Ticlid)	No criteria	---	Less than or equal to 500 mg/day	05/15/99	No criteria	---	No criteria	---
Clopidrogel bisulfate (Plavix)	No criteria	---	Less than or equal to 75 mg/day	09/28/01	No criteria	---	No criteria	---
Aspirin/ dipyridamole (Aggrenox)	No criteria	---	Less than or equal to 50 mg/400 mg/day	09/28/01	No criteria	---	No criteria	---

Oral Antihyperglycemic Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Rosiglitazone (Avandia)	No criteria	---	Less than or equal to 8 mg/day	06/05/00	No criteria	---	No criteria	---
Metformin (Glucophage)	No criteria	---	Less than or equal to 2550 mg/day	06/05/00	No criteria	---	No criteria	---
Acarbose (Precose)	No criteria	---	Less than or equal to 300 mg/day	06/05/00	No criteria	---	No criteria	---
Repaglinide (Prandin)	No criteria	---	Less than or equal to 16 mg/day	06/05/00	No criteria	---	No criteria	---
Miglitol (Glyset)	No criteria	---	Less than or equal to 300 mg/day	06/05/00	No criteria	---	No criteria	---
Pioglitazone (Actos)	No criteria	---	Less than or equal to 45 mg/day	09/28/01	No criteria	---	No criteria	---
Nateglinide (Starlix)	No criteria	---	Less than or equal to 360 mg/day	09/28/01	No criteria	---	No criteria	---
Glyburide/ metformin (Glucovance)	No criteria	---	Less than or equal to 20 mg/2000 mg/day	09/28/01	No criteria	---	No criteria	---

Non-Steroidal Anti-Inflammatory Agents (NSAIDs) - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Aspirin (Legend) (Easprin, Zorprin)		Less than or equal to 6000 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Choline Magnesium Sulfate (Trilisate)		Less than or equal to 3000 mg/day	10/28/94	No Criteria	---	Concurrent NSAIDS.	10/28/94
Diclofenac (Voltaren) (Normal Release)		Less than or equal to 225 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Diclofenac (Cataflam) (Quick Release)		Less than or equal to 200 mg/day	10/28/94	No Criteria	---	Concurrent NSAIDS.	10/28/94
Diflunisal (Dolobid)		Less than or equal to 1500 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Etodolac (Lodine)		Less than or equal to 1200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Fenoprofen (Nalfon)		Less than or equal to 3200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Flurbiprofen (Ansaid)		Less than or equal to 300 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Ibuprofen (Motrin)		Less than or equal to 3200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Indomethacin (Indocin)		Less than or equal to 200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Indomethacin SR (Indocin SR)		Less than or equal to 200 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Ketoprofen (Orudis, Oruvail)		Less than or equal to 300 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Ketorolac (Toradol) I.M. Therapy		Less than or equal to 60 mg/day	07/05/93	5 days/ 30 days	05/15/95	Concurrent NSAIDS.	08/16/92
Oral Therapy		Less than or equal to 40 mg/day	07/05/93	5 days/ 30 days	05/15/95	Concurrent NSAIDS.	08/16/92
Meclofenamate (Meclomen)		Less than or equal to 400 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Mefenamic Acid (Ponstel)		Less than or equal to 1250 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Nabumetone (Relafen)		Less than or equal to 2000 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Naproxen (Naprosyn)		Less than or equal to 1500 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Naproxen Sodium (Anaprox)		Less than or equal to 1650 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Oxaprozin (Daypro)		Less than or equal to 1800 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Phenylbutazone (Butazolidin)		Less than or equal to 600 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Piroxicam (Feldene)		Less than or equal to 40 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Salsalate (Disalcid)		Less than or equal to 3000 mg/day	10/28/94	No Criteria	---	Concurrent NSAIDS.	10/28/94
Sulindac (Clinoril)		Less than or equal to 400 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Tolmetin (Tolectin)		Less than or equal to 2000 mg/day	07/05/93	No Criteria	---	Concurrent NSAIDS.	08/16/92
Meloxicam (Mobic)		Less than or equal to 15 mg/day	05/15/02	No Criteria	---	Concurrent NSAIDS.	05/13/02

COX-2 Inhibitors - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Celecoxib (Celebrex)		Less than or equal to 400 mg/day	06/05/00	No Criteria	---	Concurrent NSAIDS.	06/05/00
Rofecoxib (Vioxx)		Less than or equal to 25 mg/day	03/29/04	12.5 mg	3/29/2004	Concurrent NSAIDS.	06/05/00
Valdecoxib (Bextra)		Less than or equal to 10mg/day	08/19/03	No Criteria	---	Concurrent NSAIDS.	08/19/03

Centrally Acting Analgesics - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Tramadol (Ultram)		300 mg daily if over 75 years of age 400 mg daily if under 75 years of age	01/19/98	No Criteria	---	No Criteria	---

Combination Analgesics - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Hydrocodone and Ibuprofen (Vicoprofen)		Less than or equal to 37.5 mg/day	04/22/98	10 days/ 30 days	04/22/98	No Criteria	---

Opiate Agonists - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Tramadol/acetaminophen (Ultracet)		Less than or equal to 300 mg/day	08/23/03	5 days out of every 30	08/20/03	No Criteria	---

Other Analgesics - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Duration		Duplicate Therapy	
		MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Propoxyphene HCl (Darvon)		Less than or equal to 390 mg/day	05/13/02	No Criteria	---	No Criteria	---
Propoxyphene napsylate (Darvocet)		Less than or equal to 600 mg/day	05/13/02	No Criteria	---	No Criteria	---
Acetaminophen		Less than or equal to 4000 mg/day	05/13/02	No Criteria	---	No Criteria	---
Fentanyl citrate (Actiq)		Actiq only approved for a diagnosis of cancer					
Oxycodone (Oxycontin)		Less than or equal to 320 mg/day	03/29/04	No Criteria	---	No Criteria	---
Aspirin Combinations		Less than or equal to 4000 mg/day	03/29/04	No Criteria	---	No Criteria	---

Wakefulness Promoting Agent - Criteria Elements and Implementation Dates

Drug Name (Brand)	Generic	Maximum Daily Dose		Maximum Initial Dose		Duplicate Therapy	
		MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Modafinil (Provigil)		200 mg	03/29/04	No Criteria	03/29/04	No Criteria	---

Histamine H₂ Receptor Antagonists - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Cimetidine (Tagamet) Maintenance Therapy	Less than or equal to 400 mg/day	08/16/92	Unlimited	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Acute Therapy	401 mg to 1600 mg/day	08/16/92	90 Days	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Famotidine (Pepcid) Maintenance Therapy	Less than or equal to 20 mg/day	08/16/92	Unlimited	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Acute Therapy	21 mg to 40 mg/day	07/05/93	90 Days	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Nizatidine (Axid) Maintenance Therapy	Less than or equal to 150 mg/day	08/16/92	Unlimited	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Acute Therapy	151 mg to 300 mg/day	08/16/92	90 Days	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Ranitidine (Zantac) Maintenance Therapy	Less than or equal to 150 mg/day	08/16/92	Unlimited	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92
Acute Therapy	151 mg to 300 mg/day	08/16/92	90 Days	08/16/92	Proton Pump Inhibitors and Concurrent H2.	08/16/92

Miscellaneous Gastrointestinal Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Metoclopramide (Reglan)	Less than or equal to 60 mg/day	10/28/94	No Criteria	---	No Criteria	---
Misoprostol (Cytotec)	Less than or equal to 800 mcg/day	07/05/93	No Criteria	---	No Criteria	---
Omeprazole (Prilosec)	Less than or equal to 40 mg/day	07/05/93	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	8/28/1995
Sucralfate (Carafate)	Less than or equal to 4000 mg/day	07/05/93	No Criteria	---	No Criteria	---
Lansoprazole (Prevacid)	Less than or equal to 30 mg/day	08/28/95	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	8/28/1995
Pantoprazole (Protonix)	Less than or equal to 40 mg/day	10/08/01	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	10/08/01
Esomeprazole (Nexium)	Less than or equal to 40 mg/day	10/08/01	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	10/08/01
Rabeprazole (Aciphex)	Less than or equal to 20 mg/day	10/08/01	No Criteria	---	Proton Pump Inhibitors/ H2 Receptor Antagonists	10/08/01

Agent to Treat Irritable Bowel - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Daily Dose		Maximum Initial Dose		Duplicate Therapy	
	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Tegaserod maleate (Zelnorm)	12 mg	03/29/04	No Criteria	03/29/04	No Criteria	---

Antipsychotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Chlorpromazine (Thorazine)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Clozapine (Clozaril)	Less than or equal to 25 mg/day	01/16/95	Less than or equal to 100 mg/day	01/16/95	No Criteria	---
Fluphenazine (Prolixin)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---
Haloperidol (Haldol)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---
Loxapine (Loxitane)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 100 mg/day	01/16/95	No Criteria	---
Mesoridazine (Serentil)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 125 mg/day	01/16/95	No Criteria	---
Perphenazine (Trilafon)	Less than or equal to 8 mg/day	01/16/95	Less than or equal to 24 mg/day	01/16/95	No Criteria	---
Risperidone (Risperdal)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 6 mg/day	01/16/95	No Criteria	---
Thioridazine (Mellaril)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Thiothixene (Navane)	Less than or equal to 4 mg/day	01/16/95	Less than or equal to 20 mg/day	01/16/95	No Criteria	---
Trifluoperazine (Stelazine)	Less than or equal to 2 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---
Quetiapine (Seroquel)	Less than or equal to 50 mg/day	04/20/98	Less than or equal to 400 mg/day	04/22/98	No Criteria	---
Olanzapine (Zyprexa)	Less than or equal to 2.5 mg/day	08/18/97	Less than or equal to 10 mg/day	08/18/97	No Criteria	---
Ziprasidone (Geodon)	No Criteria	---	160 mg per day Oral 40 mg/day IM	08/16/03	No Criteria	---
Aripiprazole (Abilify)	No Criteria	---	15 mg/day	08/16/03	No Criteria	---

Antidepressants - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun
Amitriptyline (Elavil)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Amoxapine (Asendin)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 300 mg/day	01/16/95	No Criteria	---
Bupropion (Wellbutrin)	Less than or equal to 200 mg/day	01/16/95	Less than or equal to 450 mg/day	01/16/95	No Criteria	---
Citalopram (Celexa)	Less than or equal to 20 mg/day	05/15/99	Less than or equal to 40 mg/day	05/15/99	No Criteria	---
Clomipramine (Anafranil)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Desipramine (Norpramin)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Doxepin (Sinequan)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Fluoxetine (Prozac)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---
Imipramine (Tofranil)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Isocarboxazid (Marplan)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 50 mg/day	01/16/95	No Criteria	---
Maprotiline (Ludiomil)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Mirtazapine (Remeron)	Less than or equal to 15 mg/day	8/18/97	Less than or equal to 45 mg/day	8/18/1997	No Criteria	---
Nefazodone (Serzone)	No Criteria	---	Less than or equal to 600 mg/day	08/28/95	No Criteria	---
Nortriptyline (Pamelor)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 150 mg/day	01/16/95	No Criteria	---
Paroxetine (Paxil)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---
Phenelzine (Nardil)	Less than or equal to 45 mg/day	01/16/95	Less than or equal to 90 mg/day	01/16/95	No Criteria	---
Protriptyline (Vivactil)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---
Sertraline (Zoloft)	Less than or equal to 50 mg/day	01/16/95	Less than or equal to 200 mg/day	01/16/95	No Criteria	---
Tranlycypromine (Parnate)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---
Trazodone (Desyrel)	Less than or equal to 150 mg/day	01/16/95	Less than or equal to 400 mg/day	01/16/95	No Criteria	---
Trimipramine (Surmontil)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 250 mg/day	01/16/95	No Criteria	---
Venlafaxine (Effexor)	Less than or equal to 75 mg/day	01/16/95	Less than or equal to 225 mg/day	01/16/95	No Criteria	---
Paroxetine (Paxil CR)	Less than or equal to 12.5 mg/day	08/16/03	Less than or equal to 50 mg/day	08/16/03	No Criteria	---
Escitalopram (Lexapro)	Less than or equal to 10 mg/day	08/16/03	Less than or equal to 20 mg/day	08/16/03	No Criteria	---

Benzodiazepines/Miscellaneous Sedative/Hypnotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Estazolam (Prosom)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 2 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Flurazepam (Dalmane)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 30 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Quazepam (Doral)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 15 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Temazepam (Restoril)	Less than or equal to 7.5 mg/day	03/01/94	Less than or equal to 15 mg/day	03/01/94	240 mg/6 mos	03/01/94	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Triazolam (Halcion)	Less than or equal to .125 mg/day	01/31/92	Less than or equal to .25 mg/day	01/31/92	4 mg/6 mos	01/31/92	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Zolpidem (Ambien)	Less than or equal to 5 mg/day	01/16/95	Less than or equal to 10 mg/day	01/16/95	No Criteria	---	No Criteria	---
Zaelplon (Sonata)	No Criteria	---	No Criteria	---	No Criteria	---	No Criteria	---

Obsessive-Compulsive Disorder Agent - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Fluvoxamine (Luvox)	Less than or equal to 50 mg/day	08/28/95	Less than or equal to 300 mg/day	08/28/95	No Criteria	---	No Criteria	---

Benzodiazepines - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Alprazolam (Xanax)	Less than or equal to .75 mg/day	01/16/95	Less than or equal to 3 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Chlordiazepoxide (Librium)	Less than or equal to 20 mg/day	01/16/95	Less than or equal to 100 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Clonazepam (Klonopin)	Less than or equal to 1 mg/day	01/16/95	Less than or equal to 4 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Clorazepate (Tranxene)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Diazepam (Valium)	Less than or equal to 5 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Halazepam (Paxipam)	Less than or equal to 40 mg/day	01/16/95	Less than or equal to 40 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Lorazepam (Ativan)	Less than or equal to 2 mg/day	01/16/95	Less than or equal to 6 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Oxazepam (Serax)	Less than or equal to 30 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Prazepam (Centrax)	Less than or equal to 15 mg/day	01/16/95	Less than or equal to 60 mg/day	01/16/95	No Criteria	---	Concurrent Benzodiazepines and Misc Sed/Hypnotics	03/13/00
Alprazolam (Xanax XR)	Less than or equal to 0.5 mg/day	03/29/04	Less than or equal to 6 mg/day	03/29/04	Only for Panic Disorder			

Miscellaneous Sedative/Hypnotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Amobarbital (Amytal)	No Criteria	---	200 mg/day	01/19/98	Two weeks	04/20/98	No Criteria	---
Butobarbital (Butisol)	No Criteria	---	90 mg/day	01/19/98	Two weeks	04/20/98	No Criteria	---
Chloral Hydrate	No Criteria	---	1 gm/day	01/19/98	Two weeks	04/20/98	No Criteria	---
Pentobarbital (Nembutal)	No Criteria	---	100 mg/day	01/19/98	Two weeks	04/20/98	No Criteria	---
Ethchlorvynol (Placidyl)	No Criteria	---	500 mg/day	01/19/98	Two weeks	04/20/98	No Criteria	---
Secobarbital (Seconal)	No Criteria	---	100 mg/day	01/19/98	Two weeks	04/20/98	No Criteria	---
Amobarbital/Secobarbital (Tuinal)	No Criteria	---	50/50 mg/day	01/19/98	Two weeks	04/20/98	No Criteria	---

Anti-Obesity Agents - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Sibutramine (Meridia)	No Criteria	---	30 mg/day	07/26/99	Eight weeks	08/09/99	No Criteria	---
Phentermine HCL (Adipex-P)	No Criteria	---	37.5 mg/day	07/26/99	Twelve weeks	08/09/99	No Criteria	---
Phendimetrazine	No Criteria	---	105 mg/day	07/26/99	Twelve weeks	08/09/99	No Criteria	---
Fenfluramine (Pondimin)	No Criteria	---	120 mg/day	07/26/99	Twelve weeks	08/09/99	No Criteria	---
Diethylpropion (Tenuate)	No Criteria	---	100 mg/day	07/26/99	Twelve weeks	08/09/99	No Criteria	---
Mazindol (Mazanor, Sanorex)	No Criteria	---	3 mg/day	07/26/99	Twelve weeks	08/09/99	No Criteria	---
Orlistat (Xenical)	No Criteria	---	360 mg/day	07/26/99	Eight weeks	08/09/99	No Criteria	---

Bisphosphonates - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duration of Therapy		Duplicate Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Period	Date Begun	Class	Date Begun
Alendronate (Fosamax)	No Criteria	---	Less than or equal to 10 mg/day	08/19/03	No Criteria	---	No Criteria	---
Risedronate (Actonel)	No Criteria	---	Less than or equal to 5 mg/day	03/29/04	---	---	---	---

Skeletal Muscle Relaxants - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Carisoprodol (Somal)	No Criteria	---	Less than or equal to 1400 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Cholorzoxazane (Parafon Forte)	No Criteria	---	Less than or equal to 3000 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Cyclobenzaprine (Flexeril)	No Criteria	---	Less than or equal to 60 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Dantrolene (Dantrium)	No Criteria	---	Less than or equal to 400 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Metaxalone (Skelaxin)	No Criteria	---	Less than or equal to 3200 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Methocarbamol (Robaxin)	No Criteria	---	Less than or equal to 4500 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Orphenadrine Citrate (Norflex)	No Criteria	---	Less than or equal to 200 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Tizardine (Zanaflex)	No Criteria	---	Less than or equal to 36 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00
Baclofen (Lioresal)	No Criteria	---	Less than or equal to 80 mg/day	06/05/00	No Criteria	---	21 days out of 30	06/12/00

Cholinesterase Inhibitors - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Maximum Duration	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Donepezil (Aricept)	Less than or equal to 5 mg	05/15/99	Less than or equal to 10 mg per day	05/15/99	No Criteria	---	No Criteria	---
Tacrine (Cognex)	Less than or equal to 40 mg	05/15/99	Less than or equal to 150 mg per day	05/15/99	No Criteria	---	No Criteria	---
Rivastigmine (Exelon)	Less than or equal to 3 mg	05/17/02	Less than or equal to 12 mg per day	05/13/02	No Criteria	---	No Criteria	---
Galantamine (Reminyl)	Less than or equal to 8 mg	05/17/02	Less than or equal to 24 mg per day	05/13/02	No Criteria	---	No Criteria	---

Impotence Pill - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Maximum Duration	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Sildenafil Citrate (Viagra)	No Criteria	---	Less than or equal to 50 mg/day	06/01/98	No Criteria	---	8/30 days	01/04/99
Vardenafil (Levitra)	No Criteria	---	No Criteria	---	No Criteria	---	8/30 days	10/31/03

Antibiotics - Criteria Elements and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Maximum Duration	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Doxycycline (Periostat)	No Criteria	---	Less than or equal to 40 mg/day	05/13/02	No Criteria	---	9 months out of 12	05/13/02

Antihistamines - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Cetirizine (Zyrtec, Zyrtec-D)	No Criteria	---	Less than or equal to 10 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---
Desloratadine (Clarinet)	No Criteria	---	Less than or equal to 5 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---
Fexofenadine (Allegra, Allegra-D)	No Criteria	---	Less than or equal to 120 mg/day	08/16/03	Concurrent with other antihistamines	08/16/03	No Criteria	---
Fexofenadine (Allegra)	No Criteria	---	Less than or equal to 180 mg/day	08/16/03	No Criteria	---	No Criteria	---

Antimigraines - Criteria and Implementation Dates

Drug Name Generic (Brand)	Maximum Initial Dose		Maximum Daily Dose		Duplicate Therapy		Duration of Therapy	
	MG Per Day	Date Begun	MG Per Day	Date Begun	Class	Date Begun	Period	Date Begun
Zolmitriptan (Zomig, ZMT)	No Criteria	---	Less than or equal to 10 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	3 days out of every 30	08/16/03
Almotriptan (Axert)	No Criteria	---	Less than or equal to 25 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
Methysergide mealeate (Sansert)	No Criteria	---	Less than or equal to 2 bottles daily	08/16/03	Concurrent with other anti-migraines	08/16/03	150 days out of every 180	08/16/03
Naratriptan (Amerge)	Not Recommended for the Elderly							
Frovatriptan (Frova)	No Criteria	---	Less than or equal to 7.5 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
DH Enesylate (Migranal)	No Criteria	---	Less than or equal to 2 bottles daily	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
Rizatriptan (Maxalt, Maxalt MLT)	No Criteria	---	Less than or equal to 40 mg/day	08/16/03	Concurrent with other anti-migraines	08/16/03	4 days out of every 30	08/16/03
Eletriptan (Relpax)	No Criteria	---	Less than or equal to 40 mg/day	03/29/04	Concurrent with other anti-migraines	03/29/04	3 days out of every 30	03/29/04

MATRIX OF DRUG-DRUG INTERACTIONS

Incoming Claim	<i>Check for Drugs Already in History</i>																
	Propulsid	Monistat IV	Sporanox	Nizoral	TAO	Macrolides other than TAO	Non-Sedating Antihistamines	Serzone	Effexor	Luvox	MAO Inhibitors	Nitroglycerin	Viagra	Anti-arrhythmics Class 1A, III	Tricyclic Antidepressants	Antipsychotics	Vascor, Hismanal, Zagam
Propulsid		co-admin	co-admin	co-admin	co-admin									co-admin	co-admin	co-admin	co-admin
Monistat IV	co-admin																
Sporanox	co-admin						co-admin										
Nizoral	co-admin						co-admin										
TAO	co-admin						co-admin										
Macrolides other than TAO							co-admin										
Non-Sedating Antihistamines			co-admin	co-admin	co-admin	co-admin		co-admin		co-admin							
Serzone							co-admin				co-admin, 14 days						
Effexor											co-admin, 14 days						
Luvox							co-admin				co-admin, 14 days						
MAO Inhibitors								co-admin, 7 days	co-admin, 7 days	co-admin, 14 days							
Nitroglycerin													co-admin				
Viagra												co-admin					
Antiarrhythmics Class 1A, III	co-admin																
Tricyclic Antidepressants	co-admin																
Antipsychotics	co-admin																
Vascor, Hismanal, Zagam	co-admin																

